Strategy and Policy

Submitted by Maggie Petito on behalf of drugwatch international
14 April 2026 

Of late, numerous marijuana advocates state in the media that legalization for all marijuana is needed so that research can be done to determine marijuana’s effects. Recognition of who is advancing the argument indicates much about the quality of the argument -Maggie Petito

Washington Post article: by Sarah Klein – 14 April 2026:

As more states legalize recreational marijuana use, here’s what the research says about what cannabis is really doing to your brain.

Marijuana use seems to be more popular (or at least more openly talked about) than ever. Regardless of whether you’re on the gummy bandwagon, you might wonder how it really affects your brain after the buzz wears off.

About 15.4 percent of Americans older than 12 have used cannabis in the past month, according to 2024 data from the Substance Abuse and Mental Health Services Administration. That number has been increasing as new marijuana products hit the market and more states legalize its use, according to the Centers for Disease Control and Prevention.

Older adults — those 60 and older — are the fastest-growing group of cannabis users in the country. According to a 2022 study, adults over 60 who started using did so for medical reasons, including to treat pain and arthritis, sleep disturbances, anxiety and depression.

While more than three-quarters of those people found the cannabis either somewhat or very helpful, the question remains: What are the side effects? You may be particularly curious about brain effects, given concerns about cognitive decline. So what exactly does the research say?

Cannabis use is linked to worse working memory

This probably isn’t too surprising, but cannabis can affect your ability to retain information in the short term. This makes some intuitive sense to anyone who has tried it: “If you smoke cannabis, afterward, if you do a working memory test where you’re trying to maintain some piece of information, like a phone number or a short list of words, you’re less good at doing that while you’re acutely intoxicated,” said Joseph Schacht, associate professor of psychiatry and co-director of the Division of Addiction Science, Prevention and Treatment at the University of Colorado School of Medicine.

But lifetime use seems to have a similar effect. Consistent cannabis users tend to have lasting memory deficits compared with nonusers, he said. In a January 2025 study in JAMA Network Open, the largest of its kind, researchers looked at the effects of cannabis use on more than 1,000 adults ages 22 to 36 using brain imaging. Heavy lifetime users exhibited lower brain activity during a working memory task compared with nonusers after excluding recent users.

There isn’t much research on potential long-term memory effects, but it’s a growing area of study as more older adults use cannabis. “Essentially baby boomers who grew up using cannabis are [now] using it in older age but experiencing some of those effects on working memory,” Schacht said. Available research suggests no overarching association between cannabis use and cognitive decline or dementia risk, although larger and longer studies are needed on this topic.

It’s tied to changes in brain volume

Long-term cannabis use has also been associated with changes in brain volume. This is most pronounced in people who started using cannabis in adolescence, when the brain was still developing. “Cannabinoid exposure during that developmental window probably interferes with some of those normal brain development functions,” Schacht said.

Some research shows changes in the white matter of the brain in people who started using cannabis before the age of 16. White matter connects and facilitates communication among various regions of the brain. Younger users show more difficulty with cognitive tasks requiring executive function, such as inhibition control, linked to lower integrity of certain parts of white matter and higher behavioral impulsivity, said Staci Gruber, director of Marijuana Investigations for Neuroscientific Discovery at McLean Hospital in Belmont, Massachusetts, and associate professor of psychiatry at Harvard Medical School. Gruber is the study’s lead author.

In a 2026 meta-analysis of 77 studies in the journal Addiction, cannabis use was linked with reduced volume in the amygdala in particular, a region of the brain involved in processing and regulating emotions. But this study didn’t include information on when people started using the drug.

In adults ages 40 to 70 who began using cannabis after roughly 25 years of age, lifetime cannabis use is actually associated with greater brain volume, according to research published this year in the Journal of Studies on Alcohol and Drugs. That’s particularly true in areas of the brain with receptors for cannabinoids, the active compounds in cannabis that modulate things such as pain, mood and appetite. The study authors concluded this may be a sign of the “neuroprotective” benefits of cannabis in older adults, given that brain atrophy is common with age and is linked to cognitive decline and lower quality of life.

Those neuroprotective benefits could at least partly explain why cannabis use isn’t associated with dementia risk.

We need more data on how cannabis affects mood disorders

In a review in Lancet Psychiatry, researchers found no help or harm from specific cannabinoids with relation to a number of mood-related concerns, including anxiety and post-traumatic stress disorder. It also concluded there wasn’t enough data to study any potential effects on bipolar disorder or depression.

Gruber, however, noted that the study looked at either THC alone, CBD alone or a combination of THC and CBD, not the potential risks and benefits of the entire cannabis plant. (THC, or delta-9-tetrahydrocannabinol, is the psychoactive cannabinoid associated with the high caused by marijuana, while CBD, or cannabidiol, is a nonintoxicating cannabis compound.) “The idea that we would look primarily at single extracted compounds for things like anxiety is one that isn’t necessarily going to be as successful as when we look at multi-compound products,” she said. “The synergistic action of these things all together is significantly greater than the sum of its parts,” much like how sports teams are more successful with multiple players on the field.

Schacht notes that some people use cannabis as a way to mitigate symptoms without addressing the underlying cause. “As someone who has worked in addiction and substance use for a number of years, depression and anxiety are frequently reasons that people use a number of substances, such as cannabis, alcohol and nicotine,” he said. “Those drugs can be helpful in relieving those symptoms in the short term, but over the long term, I think it’s fairly clear that they are not helpful and, in some cases, actually exacerbate the problem that led people to turn to them in the first place.”

Using marijuana as a teenager or young adult is linked to a greater risk of some serious mental health problems. “People who start using cannabis when they are young and who have any kind of a family history of psychosis or severe mental illness are at risk for developing psychosis and severe mental illness themselves because of the cannabis use,” Schacht said. The greatest association with psychosis and other severe mental illnesses is also typically strongest in the heaviest cannabis users.

Ultimately, Gruber said, more studies are needed — both larger studies and those that focus on the entire cannabis plant.

And, yet, researching cannabis is challenging because it is categorized federally as a Schedule I drug, meaning that, according to the U.S. Drug Enforcement Administration, it has “no currently accepted medical use and a high potential for abuse.” The risk of abuse decreases as the schedule number gets higher. The government’s strict regulations on studying these substances limit research opportunities. “It would be so much easier if people could use those things in the laboratory, for example, but we can’t generally do that,” Schacht said.

That would also help researchers investigate whether the method of cannabis delivery matters. More research is needed to know whether smoking, vaping or oral administration make any difference in cognitive (or other) effects.

Age matters when it comes to problematic cannabis use

To many people, other Schedule I drugs such as heroin and LSD sound much more concerning. But research suggests that 22 percent to 30 percent of people who use cannabis have cannabis use disorder, a type of substance use problem.

The risk of developing cannabis use disorder is higher in people who start using marijuana in adolescence and use it frequently. “It doesn’t mean that every single person who uses cannabis at an early age is going to have a problem, but our work and the work of others demonstrates that earlier onset of recreational cannabis use, along with more frequent and higher magnitude of use, is usually associated with worse potential outcomes,” Gruber said.

To her, future research should focus on whether the potential therapeutic benefits of cannabis can be harnessed without increasing the risk of harm to improve upon current standards of care. It will take time for research to catch up to the increasing popularity of this plant, Gruber said, but that very popularity points to some benefit: “If people didn’t yield something from it, why would they keep using this?”

In the meantime, without more research, it can be challenging for some people to decide whether cannabis might benefit them. “The best thing we can hope for is good, sound, empirical data that helps to drive individuals’ decisions as opposed to hearing somebody say ‘That should never be used,’” Gruber said. If you’re concerned about a specific aspect of your brain health, such as dementia risk, and how cannabis may affect you, consider talking to your doctor before trying legal products.

Source: www.drugwatch.org

(A position statement by NDPA, as at April 2026)

By Peter Stoker, C. Eng., M.I.C.E. (Retd) – Director – National Drug Prevention Alliance

At various times new suggestions are made for policy and practice in responding to drug misuse, addictions, treatment, education and prevention. Whilst these suggestions may derive from genuinely constructive attempts to improve the condition of drug misusers, and of society at large, they can sometimes be exploited by those who advocate liberalising policy and practice.

Two earlier such well-known examples where this kind of exploitation has been seen are known under the terms ‘human rights’ and ‘harm reduction’. Both these initiatives have a genuinely valid place in policy and practice, but both have also been called into quite different tactical ploys by liberalisation ‘influencers’. Another such example has been the attempts to replace the terms ‘misuse’ or ‘abuse’ by the more neutral term ‘use’ – this illustrates how the power of words as can be deployed to influence particular policy/practice attitudes and goals.

More recently, these same influencers have widened their approach to address the subject of ‘stigma’. Moves in this field have even developed so far as to include the establishment of an Anti-Stigma Institute, under the auspices of the Addiction Policy Forum, a Washington DC-based nonprofit organisation.

Drug addiction can be seen as the extremity of drug misuse, the possible end state of a progressive behaviour which started with curiosity, then experimentation, then occasional use, through regular use to what becomes, for some, a compulsion to use. This end state can be seen to affect literally millions of people worldwide. At some stage in this progression, a person may become victim to what has been defined as SUDs – Substance Use Disorders; these disorders may include not only health consequences but also eventual dissociation by the user’s friends, partners, relatives, employers, social service providers, child care agencies, housing agencies and more. Many people perceive SUDs as a moral failing, not just a bad decision, and their reaction may well be influenced by this judgement call.

In the context of perceived stigma, a harrowing account of how thing can go badly wrong for those experiencing SUDs was published in ‘Filtermag.org’ by Patricia A Roos, a sociologist whose son Alex died from a drug overdose in May 2015. Her article, dated September 2025, was entitled ‘Stigma from Medical Providers Contributed to My Son’s Overdose’. (Ref 1) Here are a few of the points made in her article, paraphrased for brevity:

Alex had many ‘protection privileges’ – white, middle-class, educated supportive parents and friendship circle, never abused, and yet he took a downward path of behaviour, firstly through anorexia, then in addiction … he resided in many ERs etc, sometimes encountering medical providers who helped him, but many times not – instead of empathic support he experienced chastisement for ‘bad choices’ and ‘lack of willpower ’… ‘drug-seeking behaviour’ … ‘lack of engagement’ and ‘denial’. Stigmatisation powered his downward spiral … he was labelled, blamed … in effect written off. Roos observes that while stigma is present in multiple institutions, it must be said that its presence in medical care is especially pronounced, insidious and devastating. Roos goes on to comment that it is ‘perhaps not surprising that medical providers stigmatise, making moral judgements when they should be making prognoses and decisions based on science, relying on culturally-induced assumptions of personal responsibility instead of their scientific knowledge’.

Roos applauds the work of Erving Goffman, a renowned sociologist, author of many publications which address, inter alia, the subject of stigmatisation. Perhaps most relevant here is his 1963 book ‘Stigma – Notes on the Management of Spoiled Identity’. (Ref 2)

It should also be noted that towards the end of her article, Roos expresses support for ‘decriminalising  and regulating drugs’ and wider use of harm reduction initiatives. She also is scathing of the US Governments recent (2025) change of strategy and defunding, away from harm reduction, under the direction of Health and Human Services Secretary Robert F Kennedy Jr.

                                                       *        *       *       *

National bodies may strive to introduce order into stigmas around substance use disorder; for example, America’s NIDA (National Institute on Drug Abuse) have produced several papers around  this theme, one of which is entitled: ‘Addressing the Stigma that Surrounds Addiction’. (Ref 3)

On the other hand, critics of stigma can sometimes exhibit hastiness in dismissing all stigma as ‘bad’ – to go down this route would be to ignore that social stigma has always been a major factor in what controls and limits human behaviours, in the interest of society as a whole. As one observer put it “Stigmatisation is part of what makes humans social animals”.

In his 2025 book ‘What is it like to be an Addict?’ (Oxford University Press) (Ref 4), Owen Flanagan makes the key point that “… amongst the most important thing addicts say is that they are by no means blameless”.

As the review of Flanagan’s book concludes: “it is refreshing to read a book that refuses to dehumanise addicts by depriving them of responsibility or delegitimising the shame they feel for their actions”. In this context, it is worth reflecting on the fact that many drug misusers – including not a few addicts – achieve recovery and lasting sobriety without any help from anyone else – neither medical professionals nor AA groups play any part in the ability of these individuals to dig themselves out of the hole they were in.

In developing his thinking, Flanagan is sceptical of the tendency to medicalise all of life’s setbacks and sadnesses, and he goes on to make the constructive comment that dismissing the so-called ‘War on Drugs’ as a costly failure may be hasty – saying “… we can’t be sure that many addictions wouldn’t be worse in its absence”. Critics of prevention could do worse that contemplate on this observation.

And mention of prevention should remind us that addiction is only one part of the total experience of drug misuse – there are several phases of behaviour which come before addiction. It follows, therefore, that each of these phases may generate comments by those around the user – including what may seem to be just stigmatising comments – but are in fact a useful part of the self-recovering processes which enable individuals to recover.

Amongst those seeking to generate a more balanced view on stigma, an informal grouping of British specialists includes – amongst others – Professor Neil McKegany (Ref 5) – a prominent sociologist and leading researcher in the field of drug misuse, known for founding the Centre for Drug Misuse Research at the University of Glasgow in 1994; Deirdre Boyd, founder and head of DB Recovery Resources, which sustains ongoing working links with McLean Hospital, Massachusetts, and David Raynes, a Senior Adviser to the National Drug Prevention Alliance who was formerly a senior officer and drugs specialist with HM Customs and Excise (as it was known during his time).

Collating together some of the comments by these specialists on the subject of stigma …

McKeganey: “If one’s aim is to reduce prevalence of drug misuse, one needs to retain a view of drug use as a stigmatised activity” (by society as it stands) … “stigmatisation actually varies depending on the drug in question” – Cannabis, Cocaine, Heroin each attract different levels of stigma … “drug use can be stigmatised without the user being stigmatised i.e. moral judgement can stigmatise drug use but not the user”.

Boyd: “The greatest stigma is that which does not recognise addicts and their recovery … this takes recognition away from and is insulting to people who have altered their lives to stay that way and to give back to society.” … “Sadly, stigmatisation is often encountered with the medical profession itself”.(See later comments in this article, by Patricia S Roos) … “Stigma played a huge role in reducing tobacco use – adverts with children shaming parents who smoke, office workers expelled to smoke outdoors” … “stigma also pays a role in reducing alcohol use; images of drunken capering, of children abandoned, etc” (Recalling Hogarth’s 1751 image of ‘Beer Street’ and ‘Gin Lane’!)

Raynes: “Social stigma has for millennia been part of what controls and limits human behaviour.” … “This business of trying to remove social stigma from drug addiction and use, or from any antisocial behaviour, is in my view a trap, A very deliberate one … Don’t fall for it.”

                      *        *       *       *

In conclusion (for now) herein offered is an extended ‘quote’ from a paper written by an American doctor, Sally Satel. (Ref 6) This was published by John Hopkins University Press of Baltimore, as part of a larger paper entitled ‘Addiction Treatment Science and Policy for the Twenty First Century’ – and in it she nailed her colours firmly to the mast by entitling it ‘In Praise of Stigma’. Satel spoke on the value of constructive stigma as part of improving treatment effectiveness, but was roundly condemned for doing so. As she put it: “Clearly, I had committed heresy”.

Despite her much-voiced support for accessible, respectful and competent treatment, her support for stigma remained ‘a bridge too far’ for some. She resolutely commented “Why try to destigmatise irresponsibility that leads to ruptured families, ruined careers, and crime … we don’t have to neutralise the moral valence (valence meaning ‘capacity to classify’ e.g. ‘good-bad’) of addiction-fuelled behaviour to destigmatise the treatment process”.

She goes on to challenge some of the alleged benefits of eliminating stigma, as set forth by the National Institute on Drug Abuse (Ref 7) – as shown here following, in italics –  “… it will get more addicts into treatment/it will improve the availability of treatment/it will speed the development of medications” and “it will help addicts self-esteem”. A charitable evaluation of these allegations is that they seem to speak more from hope than from proven conviction.

Satel calls up McLean Hospital, Massachusetts, and in particular psychologist Gene Heyman, (Ref 8), who makes the powerful point that voluntary behaviour is mediated by the brain … motivation and self-control are acts of the brain. Recovery itself depends on willpower, and people have the capacity to transform themselves.

In the end, observes Satel, the de-stigmatisation campaign could be said to have its heart in the right place, but in her opinion its marksmanship is too sweeping, too uncontrolled, and thus tends to make things worse in its search for what could be better. As she says in closing her statement:

“Finally, even if we could somehow ‘untaint’ addiction, what would be the price? Stigmatisation is a normal part of human interaction, has a civilising effect on social life, and is often the basis of the antidrug messages we give our children … There is nothing unethical – and everything naturally and socially adaptive – about condemning the reckless and harmful behaviours that addicts commit. This need not negate our sympathy for them or our duty to provide care.”

       *        *       *       *

CONCLUSIONS:

This is a subject which will run and run, so it may be considered premature to attempt sweeping conclusions at this time. However, this writer offers the following as indicators of what might prove to be ‘route markers’ …

  • Stigma, when encountered, can be and should be assessed as either ‘constructive’ or ‘obstructive’ to interventions with drug misuse.
  • Stigma directed at the user is often obstructive to and unhelpful for progress.
  • Stigma directed at drugs and their effects on individuals and on society at large can be constructive in the right context, if applied sensitively.
  • Attempts by some to remove stigma in its entirety can often be identified as a tactic for unmerited liberalisation of drug strategy, policy and practice.

                                       *        *       *       *

REFERENCES:

  1. Roos, PA. ‘Stigma from Medical Providers Contributed to My Son’s Overdose’. Filtermag.org, 2015
  2. Goffman, E. ‘Stigma- Notes on the Management of Spoiled Identity’. Pelican, 1963
  3. NIDA – https://drugabuse.gov/about-nida/noras-blog/2020/04/addressing-stigma-surrounds-addiction)
  4. Flanagan, O. ‘What is it like to be an Addict?’. Oxford University Press, 2025
  5. McKeganey, N. ‘Controversies in Drugs Policy and Practice’. Palgrave Macmillan, 2011
  6. Satel, S. ‘In Praise of Stigma’. John Hopkins University Press, 2007.
  7. https://sallysatelmd.com/html/PraiseStigma2007.pdf – The text in this reference sets out the full statement by NIDA as to the benefits they saw at that time in ‘eliminating stigma’ – but in searching for the actual NIDA paper – entitled  ‘www.drugabuse.gov/about/welcome/aboutdrugabuse/stigma/‘ it was not found possible to access it.
  8. Heyman, GM. ‘Consumption Dependent Changes in Reward Value, a Framework for Understanding Addiction’. Elsevier, 2003

(ENDS)

 

by Christina Myer exec editor of The Parkersburg News and Sentinel – Mar 14, 2026

According to the Drug Policy Alliance, overdose deaths are decreasing most in places where harm reduction practices are at work.

Dasgupta is a scientist studying drug overdose deaths at the University of North Carolina, Chapel Hill.

Use-prevention efforts such as honest school-based awareness programs, prescription drug monitoring programs, improved access to affordable mental healthcare, even data collection efforts that help guide the conversation — it all helps.

For that matter, access to affordable healthcare in general — particularly in a state that relies so much on physical laborers who face the risk of injury and chronic physical pain daily — is essential. Even better if alternative means of pain management are encouraged rather than squashed.

But perhaps one of the least considered when there is so much lower-hanging fruit for politicians are the “deaths of despair,” and the role hopelessness and dismal economic prospects have played in this plague. Deep generational poverty, socio-cultural assumptions about both education/job training AND substance use, and the perpetual failure to bring any momentum to the expansion and diversification of our economy have been crippling.

As the abstract for one Marshall University study on “The opioid epidemic: Effects on recidivism in West Virginia,” put it, “the opioid epidemic was just a by-product of a much larger issue found in West Virginia.”

Now, tens of millions of dollars have been distributed across the state in the early stages of the West Virginia First Foundation’s mission of “Empowering West Virginians to prevent substance use disorder, support recovery, and save lives.”

According to Chairman Greg Duckworth, “These investments are not just funding grants, they are strengthening an ecosystem. We are supporting foster families, peer recovery networks, workforce pipelines, diversion strategies, wraparound youth services, and the long-term capacity needed to change outcomes for generations.”

Here’s hoping the goal is that one day the foundation will run out of money after having completed its mission and happily close up shop.

But until that day, no one can let what looks like success over the course of one year lull them into letting off the gas. We’re not even out of the driveway.

Source: https://www.newsandsentinel.com/opinion/local-columns/2026/03/editors-notes-harm-reduction-effort-working/

United Nations Office on Drugs and Crime

Vienna (Austria), 13 March 2026 — The 69th session of the Commission on Narcotic Drugs (CND) wrapped up today in Vienna after five days of deliberations on emerging drug trends, treaty implementation, governance issues and international cooperation. The session brought together 2078 participants, including representatives from 134 Member States, 20 intergovernmental organizations, nine United Nations entities and 198 non-governmental organizations, reflecting broad and high-level engagement, highlighting the Commission’s central role as the United Nations’ global policymaking platform on drug-related matters.

In his closing remarks, the Chair of the 69th session, H.E. Ambassador Andranik Hovhannisyan of Armenia, thanked Member States for their constructive engagement and reaffirmed the importance of multilateral cooperation in responding to complex and interconnected drug challenges.

The UNODC Acting Executive Director John Brandolino likewise highlighted the importance of dialogue and partnership, stressing that: “Preserving that spirit of openness, cooperation and compromise will be essential if we are to continue making progress.” He emphasized that, amid global uncertainty, the Commission remains a valuable and increasingly rare forum where diverse perspectives come together to advance collective responses to the world drug problem.

CND expert panel 

Under agenda item 5(e), the Commission advanced the establishment of the Expert Panel mandated by resolution 68/6, to prepare actionable recommendations to strengthen the implementation of international drug control treaties before the 2029 review. During its 69th session, the Commission filled the remaining seats allocated to the Eastern European Group and the Western European and Other States Group and appointed Natalie Yu- Lin Morris-Sharma from Singapore as Co-Chair by acclamation, completing the composition of the nineteen-member multidisciplinary panel of independent experts.

Substances placed under international control 

In carrying out its treaty-mandated functions, the Commission decided to place three substances under international control following recommendations from the World Health Organization. Two of the substances, both highly potent synthetic opioids (N-pyrrolidino isotonitazene and N-desethyl etonitazene), are linked to serious overdose risks, while MDMB-FUBINACA, a synthetic cannabinoid, is associated with severe adverse health effects.

Five resolutions adopted

The Commission adopted five resolutions aimed at strengthening international cooperation and promoting balanced, evidence-based approaches to drug policy.

The Commission adopted a resolution to reinforce the implementation of Article 13 of the 1988 Convention, which calls upon Member States to enhance regulatory and criminal justice efforts and to strengthen cooperation with the International Narcotics Control Board (INCB) and relevant partners in preventing  the diversion of equipment and related materials used for illicit drug production and manufacture, while ensuring their access and availability for medical and scientific purposes.

To combat the criminal exploitation of licit supply chains, the Commission adopted a resolution calling for stronger supply chain integrity measures — from “know your customer” practices to enhanced customs cooperation and real-time information sharing — to prevent traffickers from misusing licit supply chains for synthetic drug production and trafficking.

The Commission also adopted, through a resolution, an Appendix to complement the UN Guiding Principles on Alternative Development, promoting climate-sensitive, gender-responsive and community-driven strategies for sustainable transition away from illicit drug economies.

To stay ahead of evolving synthetic drug threats, the Commission adopted a resolution to improve early warning mechanisms, emphasizing the importance of data collection, enhanced monitoring, risk assessment and real-time information sharing in enabling faster public health and law enforcement responses to new psychoactive substances and precursors, including pre-precursors and designer precursors.

Finally, the Commission adopted a resolution that promotes integrated and coherent systems of scientific evidence-based drug-related public health responses — from prevention and treatment to recovery and improved access to and availability of controlled medicines — grounded in human rights, gender-responsiveness and coordinated cross-sector action.

Together, these outcomes reflect the Commission’s ongoing dedication to protecting health, developing a coordinated response to the synthetic drugs threat, and promoting viable licit economic alternatives to the illicit cultivation of drug crops and other drug-related activities.

Further information

The CND is the policymaking body of the United Nations, with primary responsibility for drug control and other drug-related matters. It is responsible for monitoring the world drug situation, developing evidence-based drug control strategies and recommending measures to address the world drug problem. 

Source: https://www.unodc.org/unodc/frontpage/2026/March/cnd-closing.html

from WRD News Team – November 5, 2025

A Response to Media Coverage of the Australian Capital Territory (ACT)’s  Drug Decriminalisation Anniversary

On 27 October 2025, the ABC published an article marking two years since ACT drug decriminalisation made the Australian Capital Territory the first Australian jurisdiction to remove criminal penalties for small amounts of illicit drugs. The piece featured advocates celebrating “meaningful harm reduction” and government officials claiming community support for treating drug use as a health issue. Health Minister Rachel Stephen-Smith stated the government was hearing from “the vast majority of the community” that they wanted drug use treated as a health issue, not a criminal one. Pill Testing Australia’s David Caldicott dismissed concerning statistics as “misconstruing correlation and causation.”

What the article downplayed, burying critical opposition voices and alarming data in the latter portions, was the stark reality: ACT drug decriminalisation is failing by nearly every measurable metric.

  1. The ACT Reality: Two Years of Deterioration

Since ACT drug decriminalisation was implemented in October 2023, the Australian Capital Territory has recorded:

  • Cocaine use up approximately 70%
  • Heroin use up 30%
  • Methamphetamine use up 40%
  • 16 suspected overdose deaths in 2025 alone
  • More than 1,100 drug-related emergency presentations in 2024-25
  • Drug-driving charges up more than 20%

Australian Federal Police Association president Alex Caruana stated bluntly: “The statistics are indicating that the ACT is now nation-leading when it comes to non-fatal overdoses. And our members have to be out there dealing with those non-fatal overdoses all the time… I think decriminalisation on the whole is something that hasn’t worked, and the data is indicating that very, very, very plainly it hasn’t worked.”

Yet media coverage continues to present ACT drug decriminalisation as a success story, echoing narratives built on selective statistics and misrepresented outcomes from Portugal’s controversial policy shift more than two decades ago.

  1. The Portugal Fallacy: Two Decades of Misrepresented Data

The foundation of the pro-decriminalisation movement, and the justification for ACT drug decriminalisation, rests heavily on a 2009 report commissioned by the libertarian Cato Institute and funded by the Marijuana Policy Project. This report, written by lawyer Glenn Greenwald after just three weeks in Portugal, has been cited thousands of times as definitive proof that decriminalisation works. Yet multiple independent analyses, including evaluations by the Obama White House Drug Control Policy office and Portuguese medical professionals, have exposed fundamental flaws in its methodology and conclusions.

Drug Use: The Inconvenient Truth

Contrary to claims of declining drug use, Portugal has experienced alarming increases across nearly every category since decriminalisation.

Overall Drug Consumption:

  • Between 2001 and 2007, overall drug consumption increased by 4.2% in absolute terms
  • Lifetime drug experimentation climbed from 7.8% to 12%
  • By 2017, drug use amongst those aged 15-64 was 59% higher than in 2001, a trend that would be considered catastrophic in any objective policy evaluation

Specific Substances (2001-2007):

  • Cannabis use amongst 15-34 year-olds jumped from 12.4% to 17%
  • Cocaine use more than doubled from 1.3% to 2.8%
  • Ecstasy use nearly doubled from 1.4% to 2.6%
  • Heroin use increased from 0.7% to 1.1%

Youth Drug Use: A Growing Crisis Amongst secondary school students, the age group society should most protect, drug use in 2011 was 36% higher than in 2001 and 76% higher than in 2006. These are not the markers of policy success.

The National Survey on the Use of Psychoactive Substances in the General Population, Portugal 2016/17, reported: “We have seen a rise in the prevalence of alcohol and tobacco consumption and of every illicit psychoactive substance between 2012-2016/17.”

The Death Toll: Rising Despite Claims Otherwise

Perhaps the most misleading aspect of the decriminalisation narrative concerns drug-related deaths. While the Cato report celebrated declining death rates, the complete picture tells a different story.

Drug-induced deaths did decrease initially from 369 in 1999 to 152 in 2003. However:

  • By 2007, deaths had climbed to 314, significantly higher than the 280 deaths recorded when decriminalisation began in 2001
  • By 2008, the figure reached 338 deaths
  • Using data from Portugal’s National Institute of Forensic Medicine, which employs more comprehensive testing methods, the toll represents roughly one death per day

Critically, the Obama White House analysis noted that roughly half of the decrease in heroin-related deaths occurred before decriminalisation was implemented, suggesting other factors were at play that had nothing to do with the policy change.

HIV/AIDS Crisis Amongst Drug Users

Portugal now holds the dubious distinction of having the highest rate of HIV/AIDS amongst injecting drug users in the European Union:

  • 85 new cases per million citizens in 2005, eight times the EU average
  • The number of new HIV/AIDS and Hepatitis C cases amongst Portuguese drug users is eight times the average found in other EU member states
  • Portugal remains the only EU country recording a recent increase in injecting drug-related AIDS cases
  • In 2005, Portugal recorded 703 newly diagnosed infections, followed at a distance by Estonia with 191 and Latvia with 108, a shameful 268% aggravation from the next worst case

This stands in stark contrast to the narrative of improved public health outcomes.

The Cocaine Crisis and Drug Trafficking

While advocates claim decriminalisation reduces drug trafficking, the evidence shows the opposite:

  • Cocaine seizures in Portugal increased sevenfold between 2001 and 2006
  • The country was rated the sixth highest globally for cocaine confiscations
  • In 2006, Portugal was responsible for 35% of all cocaine seizures in Europe
  • Drug-related homicides increased by 40% following decriminalisation, making Portugal the only European country with a significant increase in drug-related murders between 2001 and 2006

Public Perception: Citizens Report Growing Problems

Portuguese citizens themselves report growing concerns. A 2007 survey by the Centre for Studies and Opinion Polls at Portuguese Catholic University found:

  • 83.7% believed drug use had increased in the previous four years
  • 66.8% reported drugs were easily accessible in their neighbourhoods
  • 77.3% stated that drug-related crime had risen

The Drug Tourism Reality

The Cato report claimed drug tourism fears were unfounded, yet evidence from travellers and locals tells a different story. One 2015 visitor recounted: “Don’t go to Lisbon. I have just returned from a weekend in Lisbon. Consistent harassment from people selling drugs. I was approached 30-40 times over the weekend. Sitting outside drinking a coffee at lunchtime, must have been approached 5-6 times in one hour.”

Another account stated: “In the most touristy area of Lisbon, around the Praça do Comércio, the police tolerate drug dealers in Lisbon. That’s right. We walked past a man on the street who offered us marijuana whilst there was a police man standing only two metres from us. Nothing happened.”

The Medicinalisation Trap: Dependency Dressed as Treatment

A central pillar of Portugal’s approach has been the massive expansion of opioid substitution programmes, primarily methadone maintenance. By 2008, approximately 70% of Portuguese heroin users were enrolled in substitution programmes, representing roughly half of all problem opioid users in Europe.

While advocates present this as evidence of treatment success, critics raise profound questions about whether maintaining drug dependency through government-supplied opiates constitutes genuine treatment or merely a form of chemical social control. The European Monitoring Centre acknowledges that “questions are being asked about the long-term outcomes of those in care,” as many patients remain on methadone indefinitely with no path to abstinence.

One EMCDDA official noted: “Now that the epidemic is under control for the most part, people start asking questions. The question now is what is going to happen next? There is a part of the population who do not have the possibility of leaving the treatment.”

A New Yorker article captured the troubling reality of a Portuguese methadone patient: “I guess I should try to overcome my addiction. I know I should. But I’m not sure I can, and it isn’t really necessary. I am lucky to live in a society that has accepted the fact that drugs and addiction are part of life.”

  1. Oregon’s Reversal: When Reality Overtakes Ideology

Perhaps the most telling development occurred in 2024 when Oregon, which had implemented the most comprehensive drug decriminalisation measure in United States history in 2020, reversed course after devastating outcomes. State lawmakers repealed the decriminalisation laws, citing an overwhelmed health system and sharply rising drug-related crime.

Oregon’s experience demonstrated that decriminalisation, even when coupled with expanded treatment funding, cannot address the fundamental problems of drug addiction and trafficking. The swift reversal should serve as a warning to jurisdictions like the ACT that are only beginning to experience the full consequences of decriminalisation policies.

Conclusion: Confronting the Data

The media narrative around ACT drug decriminalisation relies on selective statistics, misleading timeframes, and anecdotal testimony that obscures measurable outcomes. When advocates dismiss dramatic increases in drug use, overdoses, and drug-related crime as “misconstruing correlation and causation,” they are asking us to ignore the evidence before our eyes.

The ACT’s experience after just two years mirrors Portugal’s longer trajectory: increased drug use across all categories, rising overdoses, growing public safety concerns, and a health system struggling to cope with the consequences. The Australian Federal Police Association’s assessment is blunt but accurate: “The data is indicating that very, very, very plainly it hasn’t worked.”

As jurisdictions worldwide reconsider decriminalisation policies, from Oregon’s outright reversal to growing concerns in Portugal itself, the question surrounding ACT drug decriminalisation is no longer whether it works. The data has answered that clearly. The question is whether policymakers and media will continue to prioritize ideology over evidence, and rhetoric over reality.

Source: Herschel Baker – Director Queensland, Drug Free Australia – https://drugfree.org.au/ 

Students with the Illinois Prevention Network at the Capitol on Wednesday, Feb. 25, 2026, pushing for bills aimed at drug regulation and reduction. (Courtesy of Kate Bell / Illinois Prevention Network)

by Georgia Epiphaniou, Jacques Abou-Rizk and Medill Illinois News Bureau, Capitol News Illinois


SPRINGFIELD — Youth advocates against substance abuse swarmed the Capitol this week, navigating their way into lawmakers’ offices, sharing their experiences in school and addressing what they viewed as gaps in Illinois’ drug and alcohol regulations.

Brought together by the Illinois Prevention Network – a coalition of organizations working to create safe, healthy and drug-free communities in Illinois – high schoolers canvassed the Capitol on Wednesday in support of bills aimed at reducing and regulating substance use throughout Illinois.

“Many kids, myself included, often feel as though we don’t have much power to do things and change things in the world,” Amber Diepenbrock, 14, of Wredling Middle School in St. Charles, said. “I’m here because I want to be able to represent kids my age more and talk about the problems I’m seeing in my own school.”

Kratom Regulation

Kratom is a plant that’s used as a stimulant and opioid substitute. Currently, it is only regulated by the 2014 Kratom Control Act, which makes it illegal for anyone under the age of 18 to purchase the substance. Five bills currently in House committees seek to amend or replace the act.

Kratom acts as a stimulant, but can also act as a cardiac or a respiratory depressant, similar to opioid. The drug is not Food and Drug Administration approved, with the organization warning consumers against its use because of the risk of serious adverse effects, including seizures, drug-induced liver injuries and substance-use disorder. In 2018, the Centers for Disease Control and Prevention found salmonella contamination in kratom products. The FDA said it is often used “to self-treat conditions such as pain, coughing, diarrhea, anxiety and depression, opioid use disorder, and opioid withdrawal.”

House Bill 1303 and House Bill 3127 seek to raise the age restriction to 21 and prohibit child-attractive products while imposing a 5% retail tax. House Bill 3215 would create a registration and labeling system for kratom products.

House Bill 3129 would add kratom’s active compounds as Schedule III controlled substances and repeal the existing Kratom Control Act. It would essentially ban the substance in Illinois with the exception of some medical uses. Another bill, House Bill 4930, would take the hardest line, prohibiting the distribution, manufacture and sale of kratom entirely unless they have been approved by the FDA. All five were referred to the House Rules Committee in March, 2025, meaning they all have a long way to go legislatively.

Senate Bill 1570, which is also awaiting a committee assignment, would effectively ban kratom for all individuals, regardless of age.

Rep. Bill Hauter, R-Morton, citing six kratom-related deaths in Tazewell County in 2023, said there is a need to regulate the drug, but he emphasized a complete ban would be more effective.

“Nobody really knows (how it works), so it has to be regulated,” Hauter, who is a physician, said. “More and more, municipalities are just saying to ban it completely. It’s so easily available, and it’s hard to regulate it, so they’re just banning it totally so nobody can have it unless they go to a municipality where they can buy it.”

Yana Malpani, a 17-year-old senior at Stevenson High School in Lincolnshire, Illinois, who is also president of its Catalyst substance prevention program, said that she has observed excessive use of both unregulated cannabis derivatives and kratom among teenagers.

“This is because it’s so accessible at gas stations, feed shops and convenience stores, anyone can technically go and purchase it without realizing,” Malpani said.

A lot of kratom products, such as candy and vapes, are marketed with bright colors, enticing teenagers to purchase them.

“Kratom and delta-8 are being marketed as products that look identical to candies,” Malpani said. “We aren’t able to tell if it is candy or not unless you really look at the fine print.”

Lowering the Legal Blood-Alcohol Content Limit

The group also pushed for House Bill 4333, which aims to lower the legal blood-alcohol content limit from 0.08 to 0.05 for DUIs. The bill is awaiting a hearing in the House Judiciary Committee.

Fifteen percent of alcohol-related deaths happen to drivers with a BAC less than 0.08, and crash risks are seven times higher for those testing at 0.05 than sober driving, according to a Boston Medical Center study.

“Right now, if your blood alcohol content is at 0.08, you’ll get a DUI,” Malpani said. “The problem is at 0.06, you become legally and physically impaired to drive. But right now, I can be at 0.06 and get behind the wheel.”

Utah experienced a 19.8% drop in fatal crashes in one year after lowering the BAC to 0.05 in 2018, according to the National Highway Traffic Safety Administration.

Youth Advocacy for Drug and Alcohol Abuse Prevention

Diepenbrock emphasized that although she and other students are unable to vote, their voice plays an important role in the push to regulate drug and alcohol use among youth. She said she’s seen students pass vapes and other substances around in her school and the impact it has on teenagers.

“When you actually try and look deeper into it, you can see the effects and how it impacts not only an adult, but also a child,” Diepenbrock said. “A child may not get their hands on a drug, but their parents may, and that can heavily impact them.”

Hauter said that it is important to include the youth in the drafting of such legislation to raise awareness for the effects of drug usage.

“I think it’s time that Illinois took this seriously,” Hauter said. “I can’t believe it’s taken this long, because, you know, this is one of those things that we need to address.”

How drug and alcohol-use policy affects teenagers is often left out of legislation, Malpani said, failing to address a major contributor to underage DUIs. In 2024, 245 drivers in Illinois under the age of 21 lost their license due to drug and alcohol use while driving, according to a report by the secretary of state’s office.

Illinois State Police report that drivers under age 21 represent 10% of licensed drivers but are involved in 17% of alcohol-related fatal crashes and that crashes are a leading cause of death for teens.

“I think a lot of times policy around substance-use prevention is drafted by adults who don’t have a full understanding of how the policy affects their teens and high schoolers,” Malpani said. “So right now, I think having youth draft the policy themselves is so much more beneficial because we know how it affects us.”

Georgia Epiphaniou and Jacques Abou-Rizk are graduate students in journalism with Northwestern University’s Medill School of Journalism, Media, Integrated Marketing Communications, and fellows in its Medill Illinois News Bureau working in partnership with Capitol News Illinois.

Capitol News Illinois is a nonprofit, nonpartisan news service that distributes state government coverage to hundreds of news outlets statewide. It is funded primarily by the Illinois Press Foundation and the Robert R. McCormick Foundation.

Source: https://news.wttw.com/2026/02/27/high-schoolers-flood-state-capitol-advocate-drug-abuse-prevention-bills

As Cartels Collapse, Prevention Rises:

From PR Newswire- SAN FRANCISCO – 3 March 2026
While the death of drug kingpin and cartel leader “El Mencho” makes headlines, the Foundation for a Drug-Free World scored a touchdown through the distribution of 1,000,000 The Truth About Drugs booklets during Super Bowl LX in the San Francisco Bay Area.  The Foundation said the figures are based on internal distribution records that have been independently audited.

Foundation for a Drug-Free World volunteers at Super Bowl LX in San Francisco

Recent reporting has highlighted the death of Mexican cartel figure Nemesio Oseguera Cervantes, known as “El Mencho.” BBC News reported he was killed in a confrontation with Mexican military forces in Tapalpa, Jalisco, on Feb. 22, 2026. El Mencho was Mexico’s most wanted cartel boss. He led the notorious Jalisco New Generation Cartel, which had become one of Mexico’s most powerful criminal organizations. While removing his name from the list of top fentanyl traffickers marks a victory, there are still 48.4 million people suffering from addiction in the United States—and some of them would do anything to get their next hit.

Addiction is not something a person can opt out of in a day. It holds its grip tightly and does not easily let go. “My goal in life wasn’t living… it was getting high,” says John, a recovering addict. “I kept saying to myself, I’m going to stop permanently after using one last time. It never happened.”

While not everyone can take down a cartel leader, everyone can take a stand against drugs through prevention. It is the key to stopping a young person from falling into addiction. Every addict started with a first hit. That is what the Foundation for a Drug-Free World works to prevent.

Through its educational materials, the Foundation provides factual information about drugs. The Truth About Drugs booklets do not simply tell someone to say no. They provide cold, raw data so individuals can make informed decisions. Each booklet describes what a specific drug is made of, what it does to the body and the mind, and its short- and long-term effects. It also includes testimonies from recovering addicts. By presenting factual information that speaks for itself, a person can decide never to take drugs.

In San Francisco, more people died from fentanyl in 2025 than the previous year. During Super Bowl LX, the Foundation launched a concentrated outreach effort, distributing one million The Truth About Drugs booklets across the San Francisco Bay Area. Some 350 volunteers rallied and gave out booklets to more than 6,800 shops for their customers in the days leading up to Super Bowl Sunday.

“I got out all my display boxes around El Cerrito today,” one volunteer says. “Dental offices, barber shops, insurance companies, nail and beauty shops, convenience stores, restaurants and a local medical college. Many of the places I placed the display boxes thanked me for volunteering for such a great cause.”

After losing 12 youth to fentanyl, a restaurant manager in Santa Clara welcomed The Truth About Fentanyl booklets. “I went to a barber shop and the guy accepted [the booklets],” another volunteer recounts. “He said he used to be a drug addict but maybe if he had known what drugs would do to his body, he would never have taken them.”

A woman who lost her son to a fentanyl overdose two years ago took a box of booklets to place at the front door of her church.

The Foundation for a Drug-Free World is a non-governmental drug education and prevention campaign. It holds Special Consultative Status with the United Nations Economic and Social Council (ECOSOC). The Foundation provides a secular  ‘Truth About Drugs’ program.

Source: https://www.wfmz.com/online_features/press_releases/as-cartels-collapse-prevention-rises-foundation-for-a-drug-free-world-distributes-one-million-truth/article_c4064957-561a-5361-9794-53d57f691b78.html

 

  • Yngvild Olsen and Sunny Patel –

Ms. B (identified by first initial of last name for privacy) had never told anyone about the sexual abuse she had suffered at the hands of her uncle as a young child. For years during her adolescence, the secret festered, driving her to run away from home, drop out of school, and begin drinking and taking opioids to numb the pain.

It wasn’t until she was sitting in a brightly lit room with other women at the clinic where she had started treatment for her opioid use disorder, surrounded by rainbow-colored positive affirmations, drinking a cup of hot coffee, and laughing at a joke the peer specialist had just told, that she felt safe enough to start telling her story.

Substance Abuse and Mental Health Services Administration (SAMHSA) grant funds had paid for the affirmation signs, the coffee, and the salary for the peer specialist. Ms. B was one of many women that year who benefitted from this care designed specifically to address the trauma that contributed to the development of their substance use disorders. And it was working.

Yet on January 13, that progress for Ms. B and many others was threatened. With no announcement or reasoning, the federal government abruptly cut $2 billion in already awarded grants to SAMHSA—an agency likely unfamiliar to most Americans, but one that undergirds and forms the safety net for the country’s behavioral health system. There was no warning for an agency already cut by $1 billion last year, hit with significant staff reductions, and poised to be subsumed under a new proposed entity, the Administration for a Healthy America, within the Department of Health and Human Services (HHS). Programs across the country were zeroed out overnight. Only after intense public outcry did the administration reverse course.

In early February, Congress passed bipartisan appropriations to preserve SAMHSA’s structure and funding, clearly signaling the little agency and its work is essential to the nation’s behavioral health system. This is welcome relief to the uncertainty just weeks ago. Adding to a recent focus on behavioral health, President Trump issued a related Executive Order, Addressing Addiction Through the Great American Recovery Initiative, on January 29. This order establishes a new interagency taskforce to provide recommendations and guidance for better coordination and alignment of relevant federal programs. On February 2, HHS Secretary Kennedy announced a new $100 million SAMHSA grant program, the Safety Through Recovery, Engagement, and Evidence-based Treatment and Supports, or STREETS Initiative, to fund outreach, mental health care, medical stabilization, crisis intervention, and linkages to housing for people experiencing homelessness and addiction.

These are welcome, if unclear, actions, and they come on the heels of the whiplash caused by mass grant cancellation and reversal—a terrifying stress test that exposed just how fragile America’s behavioral health infrastructure has become.

This is juxtaposed with recent data from the Centers for Disease Control and Prevention that demonstrated another remarkable and welcome increase in life expectancy in America on the heels of reductions in overdose mortality. However, much of the federal infrastructure that contributed to this progress was nearly dismantled overnight.

Confusion About Behavioral Health Care And The Role Of SAMHSA

What happened in mid-January reveals a deeper misunderstanding of how behavioral health care actually works in America, and why weakening SAMHSA puts lives at risk.

Despite progress, substance-related conditions, including accidents and unintentional injuries, and suicides remain among leading causes of death for people ages 25–64 in the United States. Millions of Americans continue to struggle with untreated or inadequately treated substance use disorders and mental illness. And communities everywhere—urban, rural, tribal—are grappling with shortages of trained providers, fragmented systems, and rising demand for services.

SAMHSA is the only federal public health agency whose sole mission is to address the full continuum of behavioral health needs—from prevention to treatment to supporting individuals in recovery. Its work does not replace direct clinical care. It often funds services that fall outside of traditional insurance models yet exist as glue in a system.

Take overdoses, for instance. SAMHSA funding has enabled states to saturate their communities with naloxone, a life-saving overdose reversal medication. SAMHSA investments have supported training for first responders and community organizations on how to recognize and respond to overdose. These investments are not abstract. They show up in emergency departments, resulting in fewer fatal overdoses, and in communities where people survive long enough because of SAMHSA funding to engage with treatment and sustain recovery.

As former career federal officials at SAMHSA and as physicians who continue to see patients, we’ve seen the agency’s work and impacts firsthand at the individual, family, and community levels. We’ve also seen how the programmatic expertise SAMHSA brings has helped other federal agencies make major systems level changes; examples include 1) the Drug Enforcement Administration’s regulatory flexibilities allowing for telehealth initiation of buprenorphine for the treatment of opioid use disorder, and 2) the Centers for Medicare & Medicaid Services promulgating a new billing code for peer support services in the 2024 Physician Fee Schedule. SAMHSA’s unique focus on the behavioral health needs of the country is what makes its role and work so special.

SAMHSA also recognizes that the work of saving lives and improving behavioral health wellbeing is done on the ground by trained and knowledgeable individuals. Few federal agencies other than SAMHSA fund the ongoing training and technical assistance needed to make sure the public health, public safety, and health care professionals serving people with, or at risk for, behavioral health conditions are up on the latest research and best practices. For example, grant programs such as the Addiction and Prevention Technology Transfer Centers, Center for Mental Health Implementation Support, and Opioid Response Network have provided cutting-edge support to thousands of public health and health care professionals, first responders and other public safety officials, state level professionals, and policymakers.

Many of these services and training/technical assistance grants were on the chopping block just a few weeks ago. Even though the cuts were ultimately restored, the whiplash furthered an unnerving sense of instability that began in spring 2025 with Secretary Kennedy’s announcement of a planned new Administration for a Healthy America that would comprise SAMHSA and several other HHS operating divisions. Collectively, these actions have undermined workforce morale, disrupted planning, and eroded trust in the federal government being a reliable partner. The grant funds were restored; the trust was not.

Looking Forward

The next question is what happens now that the fiscal year funding has passed.

Appropriations language alone does not ensure implementation. Take, for instance, the prior massive workforce reductions at the agency and the sudden $1 billion cut last year that required 23 states and the District of Columbia to file suit and obtain injunctions to continue the flow of funding. Most recently, on January 23, $5 billion in essential public health infrastructure funding by CDC to local health departments around the country was suddenly paused and then “unpaused” 24 hours later; these dollars were also appropriated by Congress. And a recent article in Health Affairs Forefront found that SAMHSA had spent only 34.6 percent of its FY 2025 budget allocation, based on a review of USAspending.gov accounts. 

Congress must exercise sustained oversight to ensure the administration fully executes on the will of Congress, that grants are reliably administered, and that the workforce and technical assistance infrastructure are rebuilt rather than quietly hollowed out. Such robust oversight and accountability functions have been lacking. Thus, it will be important for SAMHSA grantees, state behavioral health administrators, family members, and others with a vested interest to raise issues and concerns with their Congressional representatives regularly and urgently when there are future drastic changes to funding and programs. Ensuring that individuals, families, and communities impacted by substance use get the help they need is a bipartisan concern.

We also need hearings on what has happened, as well as Office of Inspector General and Government Accountability Office reports on the work SAMHSA and related agencies are doing and where they are falling short. We need active engagement with Congressional representatives where these dollars are awarded (and that’s every state and territory in the United States) to ensure that the money allocated is being disbursed by the government and reaching the communities it is intended to serve. The lesson of January is that sustained advocacy works, but vigilance is required to ensure follow-through on Congressional intent for appropriated funding.

SAMHSA may be little known to the general public, but its work touches millions of lives. Weakening it when the nation is finally turning the corner on the overdose crisis is a risk we cannot afford to take. Saving it once is not enough; ensuring its stability is the next test. Ultimately, the measure of our national commitment will be whether Congress secures long-term stability for SAMHSA.

Ms. B found her voice in a room funded by a government grant. We must ensure that those healing spaces continue to exist, the lights are still on, and the peer specialist is still employed when the next person walks through the door seeking help.

Authors’ Note:

Manatt Health works with a diverse group of clients, including states; state and federal policy makers and agencies; payers; health care providers and systems; foundations; associations; consumer organizations; and pharmaceutical, biotech, and device companies.

Dr. Olsen is a member of the American Society for Addiction Medicine (ASAM), serves on an ASAM Criteria Implementation Committee, and has a small clinical advisory role with them.

Source: https://www.healthaffairs.org/content/forefront/congress-has-preserved-substance-abuse-and-mental-health-services-administration-samhsa

MILAN, Feb. 19, 2026 /PRNewswire/

The Foundation for a Drug-Free World surpassed the milestone of 1,000,000 The Truth About Drugs booklets distributed across Italy during the Milano Cortina 2026 Winter Olympics to help combat drug abuse.

While society often seeks a quick fix in a pill, the world of professional athletes is different. “We should all be drug-free, especially in sports where it’s definitely dangerous to take drugs,” says a Belgian Olympian at Milano Cortina 2026 to a Drug-Free World volunteer. “Whatever you put your mind to, you can always make it,” he adds. “We do that best by being active every day.”

In 2025, reports found that one in four Gen Z Italians admitted to getting high regularly, while over 160,000 students aged 15 to 19 had used at least two illegal drugs. “These numbers are too high,” says Jessica Hochman, Executive Director of the Foundation for a Drug-Free World. “The best way to reduce them is through head-on prevention with real facts that make you give it serious thought before deciding to take a hit of a joint or snort cocaine at a party.”

And head-on, they did. While athletes broke records in alpine skiing, figure skating, luge and speed skating, the Foundation for a Drug-Free World scored big by distributing 1,000,000 The Truth About Drugs booklets across Italy in just a few weeks. Since January, over 400 volunteers saturated Italy’s boot with educational materials that explain what drugs are–without sugarcoating.

“They tell you that edibles are so concentrated with THC that they can lead you to paranoia, anxiety and sometimes psychotic episodes,” says Hochman. “They tell you that cocaine is one of the most dangerous drugs, capable of causing such addiction that someone might do anything to get it, even commit violent crimes.”

By giving the cold, raw facts, young people will think twice before experimenting with drugs.

“The most important part is knowledge and how bad it could be for your body,” says the Olympian. “I don’t think we learn about it enough in school. So we need other ways to get the information to children.”

Volunteers visited over 4,000 shops, providing boxes of The Truth About Drugs booklets to distribute to customers. Some shop owners, aware of the drug situation among youth, found hope that change is possible when they took booklets for their patrons.

“To all the kids out there, I think dreaming big is the first thing you should always keep in mind,” says the Olympian. “Eventually, you can maybe make it to your big dream like the Olympics. The best way to do that is by putting in the work and not by using any other ways to get there.”

The Foundation for a Drug-Free World is the largest nongovernmental drug education and prevention organization. Through a worldwide network of volunteers, millions of drug prevention booklets and educational materials have been distributed in over 180 countries. Thanks to the support of the Church of Scientology, these materials are made available free of charge to anyone wishing to take action to address the drug issue that affects everyone. For more information, visit www.drugfreeworld.org.

View original content to download multimedia:https://www.prnewswire.com/news-releases/foundation-for-a-drug-free-world-goes-for-the-gold-against-drugs-at-winter-olympics-302693258.html

SOURCE: Foundation for a Drug-Free World

Submitted by Dave Evans via Drug Watch International – 12 February 2026

If America’s pot problem is becoming so evident that even the legacy media is pumping the brakes, how bad is it?

By  Zach Jewell – DailyWire.com – Feb 11, 2026   

The New York Times editorial board expressed concern this week that the massive marijuana craze in America might have some major side effects — besides drowsiness and the munchies.

The Times editorial board, which dedicated a series of articles to pushing for marijuana legalization over 10 years ago, admitted on Monday that some of its arguments for legalized weed have been proven wrong after states began allowing recreational and medicinal marijuana use. It seems that many talking points from the pro-marijuana legalization side are falling apart as research uncovers some brutal truths about America’s pot craze.

“In our editorials, we described marijuana addiction and dependence as ‘relatively minor problems.’ Many advocates went further and claimed that marijuana was a harmless drug that might even bring net health benefits. They also said that legalization might not lead to greater use,” the Times editorial board wrote. “It is now clear that many of these predictions were wrong. Legalization has led to much more use. Surveys suggest that about 18 million people in the United States have used marijuana almost daily (or about five times a week) in recent years. That was up from around six million in 2012 and less than one million in 1992. More Americans now use marijuana daily than alcohol.”

Later, the editorial board added, “The unfortunate truth is that the loosening of marijuana policies — especially the decision to legalize pot without adequately regulating it — has led to worse outcomes than many Americans expected. It is time to acknowledge reality and change course.”

It’s rare for the Times to admit to so clearly pushing a narrative that turned out to be wrong. So, if America’s pot problem is becoming so evident that even the legacy media is pumping the brakes, how bad is it?

Addiction and other health issues stemming from marijuana use have spiked in the past decade as more states hopped on the pot bandwagon. As the Times pointed out, a large percentage of marijuana users aren’t just smoking a joint or two on the weekend; they’re consuming marijuana on a daily basis. According to research from Yale Medicine, a staggering 30% of cannabis users “meet the criteria for addiction.”

This heavy reliance on marijuana comes with multiple potential health risks, including cannabinoid hyperemesis syndrome, which gives users intense stomach pain and can cause vomiting. At least one recent study has also linked cannabis use to schizophrenia. The study, published in “Psychological Medicine,” found that up to 30% of schizophrenia cases in young men can be linked to cannabis use disorder.

A study conducted by UC San Diego School of Medicine and the New York University Grossman School of Medicine, meanwhile, found that employees who use cannabis regularly were more likely to miss work.

The advocacy group Smart Approaches to Marijuana has also pointed to research showing that driving fatalities involving marijuana skyrocketed between 2000 and 2018. Kevin Sabet, the president and CEO of Smart Approaches to Marijuana, told The Daily Wire that legalization leading to Increases in addiction was “absolutely predictable.”

Despite the promises of the legalizers, federal data show that (just as the Times notes) legalization drives use, including youth use increases,” Sabet said. “This is true in the national aggregate and in individual state data. It’s not rocket science: If you make a powerful addictive drug easier to access (and send the signal that it’s OK to use in the process), more people are going to use it. That is what I and many other people who were aware of the danger warned would happen and it is precisely what did happen.”

Now that nearly half the country has legalized marijuana in some or all forms, Sabet said the best path forward is for “states to focus on making sure that people, and above all young people, know how dangerous and destructive marijuana is: a permanent investment in infrastructure meant to promote prevention and awareness.”

“And it’s beyond important to remember here what the Times piece truly reveals,” he added. “Namely, that while people may disagree about policies and execution, they are now all agreed on the same set of facts. And those facts show beyond doubt that marijuana is dangerous, addictive, and creating havoc across America.”

The data pointing to some of these issues was available when the Times editorial board began publishing its series arguing for federal legalization. In a 2014 paper, researchers Hefei Wen, Jason M. Hockenberry, and Janet R. Cummings found that marijuana legalization led to an increase in marijuana abuse and dependence. The 2014 paper also found that as legalization surged, so did the rate at which adolescents experimented with the drug.

Ironically, the Times editorial board’s shift on marijuana coincides with the federal government in the process of reforming how it regulates the drug. In December, President Donald Trump signed an order to open the door to reclassifying marijuana as a Schedule III drug, meaning marijuana would be in the same category as drugs that have “a moderate to low potential for physical and psychological dependence.” For decades, the U.S. government has categorized marijuana as a Schedule I substance, which is defined as “no currently accepted medical use and a high potential for abuse.”

The U.S. government’s potential reclassification would not legalize marijuana at the federal level, but it could reduce the scale of marijuana-related offenses. As the president was considering the marijuana reclassification last year, nearly 50 organizations signed a letter urging Trump to keep marijuana classified as a Schedule I drug, arguing that marijuana “fits squarely” in the definition of a Schedule I drug, “a fact acknowledged in every scheduling review prior to 2023.”

Source: www.drugwatch.org

Submitted by Maggie Petito – drug-watch-international – 12 February 2026 

Opening remarks by Maggie Petito – DWI:

Subject: CuraLeaf

Here is more than a cautionary tale… Big Marijuana corporations and unproven medical treatments based on unproven claims?

“Ms McKenna said the psychiatrist who reviewed Mr Robinson’s case at Curaleaf and prescribed the medicinal cannabis was a children’s and adolescent psychiatrist and “had no consultant level experience in treating adult patients with Oliver’s complex presentation”. The coroner warned: “In my opinion there is a risk that future deaths will occur unless action is taken.” After the inquest, Alice Wood, of Farleys Solicitors, said: “There are real concerns here about the role of medicinal cannabis prescribers and their ethical duties. ‘First do no harm’ is a fundamental principle of medical ethics.

“Here, cannabis was prescribed to a vulnerable individual with known addictive behaviours, and there was a lack of consideration as to the impact on his mental health, and whether he could afford the cost of the private prescriptions. “The expert psychiatrist gave clear evidence that there is a lack of evidence in relation to the efficacy of medicinal cannabis in treating depression, and on the contrary there is evidence to suggest it can cause depression, or make depression worse.” A spokesman for Curaleaf said: “This is a truly tragic situation, and our thoughts remain with Mr Robinson’s family and everyone affected by his death.”

How often is this repeated? – Maggie Petito

TELEGRAPH, LONDON –  ARTICLE 

by Samuel Montgomery News Reporter The London Telegraph – 12 February 2026

Oliver Robinson, 34, died in Nov 2023 Credit: UGC/FAMILY/FARLEYS

A man with a psychiatric disorder killed himself after being prescribed cannabis, his family has claimed. Oliver Robinson, 34, was prescribed the drug through the private company, Curaleaf.

Catherine McKenna, the coroner for Manchester North, said the prescription for medicinal cannabis “acted as an obstacle” to him receiving appropriate psychiatric care.

At an inquest held at Rochdale coroner’s court, she ruled his death was by misadventure and found his actions were “undertaken as a means of communicating distress rather than with an intention to end his life”.

His family’s legal team said the ruling is thought to be the first time a prescription for medical cannabis had been found to have contributed to a death. They said there were “real concerns” about the role of medical cannabis prescribers and the drug’s efficacy for treating depression.

Under guidance from the British National Formulary, medicinal cannabis should not be prescribed to patients with a history of severe psychiatric disorders.

Mr Robinson, from Bury in Greater Manchester, was first given medicinal cannabis from May 2022 after a consultation with a psychiatrist at Curaleaf, one of the largest private cannabis clinics in the country.

He enrolled in a research study run by the London-based clinic in April that year for the “treatment of treatment-resistant depression”, where a psychiatrist relied on an “out-of-date” GP summary to issue the prescription, according to the coroner.

She had been unaware that Mr Robinson was receiving psychiatric treatment from the Priory for mental health issues thought to arise from cannabis dependency. When the clinic became aware of his “addictive tendencies”, they did not review his treatment plan, a prevention of future deaths report found.

The coroner said Mr Robinson was diagnosed with “recurrent depressive disorder and mental and behavioural disorder due to cannabinoid dependency” following an assessment by an NHS psychiatrist in April 2023. However, he continued to receive medical cannabis prescriptions until Nov 17 2023. Mr Robinson was found hanged at his home on Nov 24 2023.

Farleys Solicitors, which represented his family at the inquest, said the clinic knew Mr Robinson was also buying illicit street cannabis when he could not afford his prescription.

The coroner reported that the continuing prescription for medical cannabis “acted as an obstacle” to Mr Robinson “receiving appropriate psychiatric and addictions care”.

Alexander Robinson, Oliver’s brother, said his family had been through years of torment.

In a statement, he said: “My brother’s last year of his life was torture for him too. It is our belief that if he had not been prescribed cannabis, not only would he still be with us today, but a lot of this pain and suffering could have been avoided.

“We’re pleased that the coroner has found that this prescription probably contributed to his death.”

Coroner warns of future risks

The coroner wrote that Mr Robinson had a “background history of addictive tendencies which included excessive cannabis use” and had been under the care of a consultant psychiatrist at the Priory between Sept 2019 and Sept 2022.

Ms McKenna said the psychiatrist who reviewed Mr Robinson’s case at Curaleaf and prescribed the medicinal cannabis was a children’s and adolescent psychiatrist and “had no consultant level experience in treating adult patients with Oliver’s complex presentation”.

The coroner warned: “In my opinion there is a risk that future deaths will occur unless action is taken.”

After the inquest, Alice Wood, of Farleys Solicitors, said: “There are real concerns here about the role of medicinal cannabis prescribers and their ethical duties. ‘First do no harm’ is a fundamental principle of medical ethics.

“Here, cannabis was prescribed to a vulnerable individual with known addictive behaviours, and there was a lack of consideration as to the impact on his mental health, and whether he could afford the cost of the private prescriptions.

“The expert psychiatrist gave clear evidence that there is a lack of evidence in relation to the efficacy of medicinal cannabis in treating depression, and on the contrary there is evidence to suggest it can cause depression, or make depression worse.”

A spokesman for Curaleaf said: “This is a truly tragic situation, and our thoughts remain with Mr Robinson’s family and everyone affected by his death.

“We note the coroner’s conclusion of death by misadventure, and the recognition that this occurred in the context of multiple contributing factors. Cases involving mental health are complex and deeply distressing, and we respect the important role of the inquest in examining the circumstances surrounding Mr Robinson’s death.

“We will carefully consider any recommendations arising from the inquest and respond in line with the required process. Our priority remains providing responsible, clinically led care within established medical and regulatory frameworks.

“Out of respect for the family and patient confidentiality, it would not be right to comment further on the individual circumstances of this case. Our focus remains on supporting patients safely and responsibly.”

Source: www.drugwatch.org

by WRD News Team February 6, 2026          

 

Between 1980 and now, something fundamental has shifted in how we approach drugs, and understanding this transformation requires examining the historical record with clear eyes. Peter Stoker’s peer-reviewed paper, published in The Journal of Global Drug Policy and Practice in 2007, and very recently merged from a three-part in the Journal version into a single document, republished in the NDPA Website, traces the harm reduction history that changed everything, and his analysis, backed by over 250 references, makes for profoundly uncomfortable reading.

Back in 1980, America had just pulled off something remarkable in public health terms. Through coordinated prevention efforts involving parent groups and community organisations, drug use had dropped by 60%, with approximately thirteen million people stopping entirely. Parent groups had mobilised thousands of families around clear messaging that worked precisely because it was straightforward and uncompromising.

Today we’re told that same approach is not only outdated but fundamentally impossible to replicate. Prevention doesn’t work, the contemporary consensus insists, and the only realistic option is managing drug use rather than preventing it. Schools now teach children how to use drugs “more safely” instead of why they shouldn’t use them at all, representing a philosophical shift so profound that many who lived through both eras struggle to explain how it happened.

So what changed between then and now, and more importantly, how did such a dramatic reversal occur in barely more than a generation?

When Prevention Actually Worked

The 1970s were extraordinarily rough for American communities grappling with escalating drug use across virtually all demographic groups. By 1979, one in three teenagers had tried illegal drugs, whilst among high school seniors the figure approached an alarming two in three. Parents watched their children getting swept up in drug culture and recognised that something fundamental had to give.

Groups like the National Federation of Parents for Drug-Free Youth and PRIDE refused to accept this trajectory as inevitable or irreversible. They developed coordinated responses centred on three straightforward goals: stop kids starting, help users quit, and ensure treatment was available for those who genuinely needed it.

The results, documented across multiple independent studies, speak powerfully to the effectiveness of well-implemented prevention. Between 1980 and 1992, overall drug use fell 60%, representing one of the most successful public health interventions in modern American history. This wasn’t achieved through complex interventions or expensive pharmaceutical solutions, but through clear messaging and communities working together around shared values.

Then, almost imperceptibly at first but with gathering momentum, the tide began turning in a different direction entirely.

Liverpool’s Place in Harm Reduction History

Liverpool in the 1980s was struggling with profound challenges that had been building for years. The Toxteth riots of 1981 had left deep psychological and economic wounds, leaving the city angry, economically battered, and desperately searching for new answers to seemingly intractable problems.

A group of activists saw an opportunity to advance a radically different approach. Peter McDermott, now an editor at the International Journal on Drug Policy, later admitted with remarkable candour what they’d really been pursuing. The goal, in his own words, was to “signify a break with the philosophy that placed a premium on seeking to achieve abstinence,” and this moment would prove absolutely pivotal in harm reduction history.

What happened next is profoundly telling about the unintended consequences that emerge when ideology drives policy ahead of careful evaluation. Liverpool’s heroin users had historically smoked their drugs, a pattern that carried risks but avoided the particular harms of injection. After new programmes started handing out unlimited needles, the city shifted dramatically towards majority injecting use, and Hepatitis C rates climbed sharply during the same period.

A Liverpool mother whose two children battled heroin addiction told Stoker what she saw firsthand. Workers gave out needles “by the bag full,” and they even supplied known drug dealers who’d been promised they wouldn’t be arrested if caught carrying equipment.

The question nobody seemed willing to ask, or perhaps didn’t want to face honestly, was whether this represented genuine public health intervention or something else entirely.

Following the Money

George Soros, operating through various philanthropic entities under his control, had spent over $90 million by 1997 specifically pushing for fundamental changes in drug law and policy. Current estimates, based on tracking available records, put the cumulative total somewhere closer to $200 million invested over subsequent years in supporting liberalisation efforts.

That substantial financial backing funded major advocacy organisations including the Drug Policy Alliance, the Lindesmith Institute, and countless international conferences that shaped policy discourse globally. The money paid for glossy publications reaching policymakers, sustained media campaigns influencing public perception, and full-time lobbyists who could dedicate themselves entirely to advancing liberalisation agendas.

Prevention groups, by stark contrast, operated almost entirely on modest donations and small grants, and the financial mismatch was absolutely crushing in its practical effects on policy influence.

When you can afford international conferences bringing together hundreds of policymakers, employ professional PR firms that understand media dynamics, and fund sympathetic academic research whilst your opponents scrape by on volunteer hours, the playing field isn’t merely uneven. It’s tilted at such an extreme angle that meaningful competition becomes virtually impossible.

How Harm Reduction History Shaped Education

England and Wales had approximately 100 drug education coordinators serving 50 million people during the 1980s, which isn’t a particularly large number to convince if you’re attempting to shift fundamental policy direction. Focused advocacy groups recognised this vulnerability and exploited it systematically.

By the 1990s, British schools were incorporating materials suggesting “drug use is fun” and encouraging students to explore “the benefits of drug taking” without corresponding emphasis on risks. One widely distributed curriculum posed the question: “If adults drink alcohol why should I not take Ecstasy?” without providing any framework for evaluating the obvious differences in legal status, risk profiles, and social consequences.

Australia went considerably further, making these approaches mandatory components of school-based education across entire state systems.

The philosophical groundwork had been carefully laid over preceding decades through broader changes in educational theory. Carl Rogers had developed “values clarification” with the worthy intention of helping students discover values that would serve their development and communities. In practice, however, it morphed into something quite different, as external moral guidance came to be characterised as “anti-democratic” imposition. The new orthodoxy insisted that children should work out their own values largely independently, without what was dismissively termed “interference” from adults.

Rogers himself, watching how his concepts were being implemented and recognising troubling outcomes, later expressed profound reservations. He referred to what his work had enabled as “this damned thing” and questioned publicly whether he’d unwittingly initiated something “fundamentally mistaken.”

By the time Rogers voiced these concerns, however, the educational approaches his work inspired had already achieved such widespread implementation that reversing course would have required acknowledging systemic failure on a scale that bureaucracies rarely prove willing to contemplate.

What the Research Actually Shows

Needle exchange programmes consistently get presented as obvious public health victories, yet the accumulated research tells a considerably more complicated and often quite troubling story.

In Vancouver, HIV rates amongst participants jumped from 2% in 1988 to 23% in subsequent measurements. The city now holds the unfortunate distinction of Canada’s highest overdose death rate, and more than a quarter of participants continue sharing needles despite regular access to sterile equipment.

Montreal found participants had a 33% probability of HIV infection, whilst comparable non-participants showed only 13% probability, raising serious questions about whether participation might actually increase risk.

In India, baseline measurements before programme implementation showed HIV prevalence of 1%, Hepatitis B of 8%, and Hepatitis C of 17%. Following several years of operation, these figures had risen to 2%, 18%, and a truly alarming 66% respectively.

Analysis of 131 American programmes found that of nearly 20 million needles distributed, over 7 million were never returned, leading researchers to characterise many initiatives not as genuine exchanges but as distribution programmes.

Meanwhile, rigorous studies indicated that standard addiction treatment focused on reducing or stopping injection provided substantially superior protection against HIV and Hepatitis C compared to needle programmes operating without treatment components. This finding, however, doesn’t fit comfortably within the preferred narrative and consequently receives minimal attention.

Sweden’s Different Path

Sweden’s experience provides particularly instructive contrast. Following experimentation with permissive policies after World War II and evaluation revealing unfavourable outcomes, Sweden implemented comprehensive prevention-focused strategies as national policy.

The measurable results demonstrate what’s possible when commitment remains consistent over extended periods. Sweden maintains Europe’s lowest substance use rates across virtually all categories and age groups, a remarkable achievement sustained over several decades. Treatment centres operating both voluntary and court-mandated programmes achieve comparable success rates, suggesting quality matters more than admission pathway. Education systematically prioritises preventing initiation rather than teaching “safer” consumption methods.

The Swedish experience demonstrates conclusively that prevention can achieve substantial results when adequately resourced, systematically implemented, and sustained through consistent policy commitment over the time periods required for cultural change to take root.

The Power of Words

Language plays an extraordinarily significant role in shaping how different policy approaches are perceived by stakeholders, from policymakers to the general public. Certain terminology choices have proven remarkably influential precisely because the terms themselves carry implicit assumptions that bypass critical evaluation.

The term “soft drugs” implies substantially reduced harm potential, creating categorical distinctions that research doesn’t necessarily support. “Recreational use” frames consumption within normative leisure contexts, stripping away the reality that we’re discussing powerful psychoactive substances with genuine addiction potential. “Medical use,” when applied to smoking unprocessed plant material rather than tested pharmaceutical preparations, deliberately borrows credibility from established medical practice.

Perhaps the cleverest rhetorical trick has been characterising prevention as “prohibition,” a term that deliberately evokes 1920s American alcohol policy. The word triggers immediate images of gangsters and policy failure, despite substantial historical evidence that actual prohibition achieved measurable public health improvements.

Historical analysis by Robert Peterson demonstrates that prohibition outcomes contradicted common perceptions. Cirrhosis mortality decreased by over a third, alcohol-related psychosis declined markedly, and contrary to widespread belief, murder rates rose far more slowly during prohibition than before or after.

These facts receive minimal attention in contemporary discourse, strongly suggesting that terminology choices serve rhetorical rather than analytical functions, designed to trigger emotional responses rather than encourage careful evidence evaluation.

What Users Actually Want

Professor Neil McKeganey at Glasgow University’s Centre for Drug Misuse Research did something that should be standard practice but apparently represented something quite radical. He systematically surveyed substantial cohorts of drug-dependent individuals, directly asking what services they actually wanted.

The findings revealed patterns that fundamentally contradicted prevailing assumptions underlying current service delivery. The overwhelming majority didn’t request expanded needle programmes or indefinite methadone prescriptions. Instead, they expressed clear desire for clinical assistance in achieving complete cessation and sustained recovery, essentially asking for help to stop entirely rather than support for continued use under marginally safer conditions.

This peer-reviewed finding, published in respected journals and subjected to standard methodological scrutiny, contradicts the entire philosophical rationale underlying approaches focused on managing ongoing use. The research demonstrates that when you actually ask users what they want, they articulate goals aligning much more closely with prevention and treatment than with harm reduction philosophies. These findings, however, have received remarkably limited attention in subsequent policy development and funding decisions.

Europe’s Funding Games

The European Union formally maintains that drug policy falls outside its competence and remains under member state authority through subsidiarity principles. In practical operation, however, the EU exercises considerable influence through strategic funding decisions, policy recommendations carrying significant political weight, and coordination mechanisms shaping national development.

Former Swedish MEP MaLou Lindholm systematically documented troubling patterns in how these mechanisms operate. The European Cities on Drug Policy, representing approximately 30 cities favouring liberalisation, received substantial EU funding sustained over multiple years. Meanwhile, the European Cities Against Drugs, representing over 250 cities supporting UN conventions and prevention strategies, received outright rejections on multiple applications despite membership nearly ten times larger.

The Italian Radical Party, focused explicitly on drug liberalisation advocacy, maintains permanent office space within the EU Parliament building itself. The organisation utilises Parliament telecommunications, internet, and facilities, all taxpayer-funded, to lobby elected officials who often lack detailed policy knowledge.

Analysis suggests most elected representatives possess remarkably limited knowledge of harm reduction history and policy evidence, potentially increasing susceptibility to focused lobbying from well-resourced organisations that can afford professional staff dedicated entirely to influencing legislative processes. Most politicians know almost nothing substantive beyond simplified talking points provided by whichever advocacy groups reach them first.

The Evidence Double Standard

For decades, advocates attacked prevention for supposedly lacking sufficient evidence and failing to demonstrate effectiveness through rigorous evaluation. Demanding evidence-based policy certainly represents legitimate practice, and holding prevention to high standards is entirely appropriate.

What makes this problematic is the glaring double standard in how evidentiary demands get applied depending on which approach is under scrutiny. Anna Bradley, former Director of Britain’s Institute for the Study of Drug Dependence, acknowledged publicly in the late 1990s that “there is no research base for harm reduction,” essentially admitting that programmes promoted as evidence-based alternatives lacked the systematic evaluation their advocates demanded from prevention.

Stoker personally observed a 1988 presentation by Alan Parry, a Liverpool activist, who forcefully demanded rigorous proof from prevention programmes whilst simultaneously acknowledging his own programmes had no evaluation protocols due to “limited funding.” Assessment relied on subjective impressions that approaches appeared “working well.”

This differential standard continues characterising policy discourse in ways seriously undermining claims that contemporary drug policy is genuinely evidence-based. Prevention faces relentless demands for rigorous trials and demonstrated effectiveness, whilst approaches managing active use operate with substantially reduced scrutiny and minimal evaluation requirements.

Why Opposition Got Crushed

The massive resource differential created constraints so severe that fair debate on policy merits became virtually impossible. Well-funded liberalisation groups, backed by hundreds of millions, maintained capacity for activities prevention groups could barely imagine.

They organised international conferences attracting hundreds of participants, providing networking and coordinated messaging shaping global discourse. They afforded professional publication and distribution through established channels. They employed full-time staff and structured lobbying operations developing long-term policymaker relationships. They ran sustained media campaigns across multiple platforms. They funded research programmes and academic positions generating ostensibly independent scholarship supporting preferred directions.

Prevention organisations, operating primarily through volunteer contributions and modest grants, simply couldn’t compete effectively. When prevention advocates secured media attention, they frequently received characterisation as punitive and moralistic. Liberalisation advocates, meanwhile, benefited from portrayal as compassionate, evidence-based, and appropriately pragmatic.

These treatment patterns both reflected and substantially reinforced underlying disparities, creating self-reinforcing cycles where funding advantages translated into media advantages which further entrenched funding advantages through enhanced credibility.

The Cultural Shift Behind Harm Reduction History

Understanding harm reduction history comprehensively requires considering much broader cultural transformations occurring simultaneously. Substance use behaviours don’t occur in isolation but are substantially shaped by prevailing cultural environments and normative frameworks.

From the 1960s onwards, individual rights received progressively increasing prioritisation over community responsibility and collective wellbeing. Traditional authority figures experienced progressive reduction in societal influence. Non-judgementalism became increasingly elevated as paramount virtue, to the point where making moral distinctions between choices became culturally problematic.

Values-based education underwent substantial transformation towards pure individualism. Young people received consistent messaging that external moral guidance constituted “anti-democratic” imposition inappropriate in pluralistic societies. They were systematically encouraged to develop autonomous values without reference to adult perspectives or accumulated cultural wisdom.

Family structures underwent profound changes including dramatically increased divorce rates and single-parent households. Community bonds providing support networks and shared identity weakened substantially as people moved more frequently and participated less in traditional institutions. Materialistic values and immediate gratification became increasingly dominant. Self-focused outlooks progressively superseded concern for collective wellbeing.

Into this comprehensively transformed environment, creating what might be characterised as a moral vacuum, came messaging suggesting drug use represented merely another legitimate lifestyle choice. The message insisted it required professional management rather than moral evaluation or prevention efforts, fitting perfectly within broader currents elevating individual choice whilst dismissing traditional frameworks as outdated.

Drug policy didn’t change in isolation but was intimately connected to cultural shifts creating the environment where harm reduction history could unfold precisely as it did.

Where Things Stand

British drug education reflects substantial influence from approaches systematically prioritising managing use over preventing initiation. DrugScope, receiving up to £3 million annually in government funding, has consistently promoted these approaches whilst prevention perspectives receive substantially marginalised treatment in policy forums and funding decisions.

The Drug Education Forum and Drug Education Practitioners Forum, influential bodies shaping practice across thousands of schools, have been substantially influenced over extended periods by individuals known for publicly opposing prevention priority. Schools consequently receive official guidance tending systematically to undermine clear anti-drug messaging in favour of approaches focused on purported harm reduction.

Australia implemented similar approaches as mandatory national policy several years prior, whilst Canada systematically redirected substantial prevention funding towards programmes serving active users rather than preventing initiation. Across European jurisdictions, prevention organisations face persistent resource constraints whilst liberalisation advocacy receives substantial EU funding.

Nevertheless, recent developments suggest potential for significant reassessment. McKeganey’s research on user preferences created evident discomfort amongst groups claiming to represent user interests authentically. Sweden’s sustained success maintaining remarkably low rates through consistent prevention remains extremely difficult to dismiss. Some former advocates, speaking privately, have begun acknowledging limitations and disappointing outcomes of current approaches, though such admissions rarely translate into policy reversals.

What Harm Reduction History Teaches Us

Stoker’s analysis, drawing systematically on over 250 references spanning decades across numerous jurisdictions, establishes several key evidence-based conclusions deserving serious consideration.

Prevention demonstrates measurable effectiveness when adequately implemented and sustained over sufficient time periods. America’s dramatic 60% reduction during the 1980s provides powerful evidence that prevention works at population scale when communities mobilise around clear messaging. Sweden’s sustained low rates maintained consistently across decades offer additional compelling confirmation.

Current approaches focused predominantly on managing active use whilst neglecting prevention have produced disappointing outcomes across multiple domains. These approaches have demonstrably failed to align with stated user preferences, whom research indicates primarily desire complete cessation rather than indefinite management. They’ve failed families experiencing profound disruption from member addiction. They’ve failed communities experiencing elevated drug-related crime and social disorder.

The substantial financial advantage enjoyed by liberalisation organisations, sustained through foundation funding counted in hundreds of millions, requires explicit acknowledgement and strategic response if prevention voices are to receive fair hearing. Without comparable resources enabling professional operations and sustained engagement, prevention groups will continue facing persistent structural disadvantages.

Media treatment patterns systematically favouring liberalisation require critical examination and direct challenge. The assumption that liberalisation automatically represents compassionate pragmatism whilst prevention represents punitive moralising fundamentally lacks empirical foundation. Genuine compassion would logically prioritise preventing harmful initiation over managing consequences of initiated use.

Educational approaches require systematic reorientation towards messaging clearly communicating evidence-based realities: drugs present genuine health risks, initiation is demonstrably preventable, and young people deserve meaningful protection from exploitation and misguided frameworks normalising harmful behaviours.

Fundamentally, broader cultural renewal merits serious consideration. Shared values, despite contemporary dismissal as outdated, serve crucial protective functions. Community bonds provide essential support structures and accountability mechanisms. Clear guidance from caring adults serves essential protective functions during developmental periods when young people establish lifelong patterns.

Young people benefit substantially from learning that certain choices produce demonstrably better outcomes, not through judgementalism but from genuine concern for their wellbeing and ability to build lives worth living.

The Bottom Line

Stoker’s analysis reveals a well-funded, strategically sophisticated campaign that transformed drug policy over four decades. This transformation wasn’t driven by evidence or user preferences. Research shows users want help to quit, not indefinite management of continued use.

Instead, the shift was driven by ideological commitments backed by unprecedented funding from philanthropic sources, promoted through captured institutions, and facilitated by sympathetic media.

The consequences are troubling. Millions of lives have been negatively impacted by substance use that prevention might have forestalled. Families have been torn apart. Communities struggle with drug-related crime and social disorder. Billions have been allocated to approaches producing limited results whilst prevention remains underfunded.

But it’s not predetermined. Sweden proves prevention works when properly resourced. McKeganey’s research shows academic questioning is emerging. Parent organisations are growing.

The question is whether sufficient will exists to learn from harm reduction history’s lessons. Prevention produces results when adequately funded. Alternative approaches have proven expensive whilst producing disappointing outcomes, despite compassionate rhetoric.

The evidence points towards clear conclusions for anyone genuinely committed to reducing harm.

 

Source: www.wrdnews.org

 Two articles submitted by Maggie Petito – Drug Watch International – 03 February 2026

FIRST ARTICLE: 

Organised crime strikes gold in the Amazon region –  from Diálogo Americas – Southern Command – January 30, 2026             

Organized crime has become a dominant force in the Amazon region, especially in border towns, the Amazon Underworld platform, which specializes in cross-border crime, indicated in a recent report. The report highlights the alarming expansion of transnational criminal organizations (TCOs) into the Amazon’s fragile ecosystem, confirming the region is increasingly becoming a strategic refuge and operational hub for these groups.

According to the study, at least 67 percent of a total of 987 Amazonian municipalities across six major countries (Bolivia, Brazil, Colombia, Ecuador, Peru, and Venezuela) face the presence of criminal networks and armed groups. These TCOs are diverse and highly influential. They include major regional groups such as Brazil’s First Capital Command (PCC) and Red Command (CV); Colombia’s National Liberation Army (ELN) and dissidents from the Revolutionary Armed Forces of Colombia (FARC); Ecuador’s Los Lobos; and Venezuelan groups like the Cartel of the Suns (CdS) and the Tren de Aragua (TdA).

This expansion has devastating consequences for local communities and the environment. “The arrival or expansion of armed groups represents a turning point for many local communities that are seeing their natural environment destroyed,” notes the Amazon Underworld report. “Violence is reaching unprecedented levels, and young people are being drawn into activities such as gold mining and drug trafficking.”

The convergence of crime and environmental destruction

TCOs have dramatically escalated their activity by diversifying their illicit economies, creating a dangerous nexus between drug trafficking and environmental crime often referred to as “narco-mining” or “narco-deforestation.” Reports indicate that as much as 91 percent of forest loss in the Brazilian Amazon was linked to illegal activity orchestrated by well-structured criminal enterprises.

Illegal gold mining, in particular, has become one of the fastest-growing illicit economies in the Western Hemisphere, in some countries generating more revenue for organized crime than the drug trade itself. TCOs use the profits from cocaine smuggling to invest in mining operations, which in turn provides a method for laundering billions of dollars. This criminal convergence is acutely felt across Brazil’s Legal Amazon, where groups like the PCC and CV have rapidly expanded into environmental crimes, establishing a national scope of interconnected illicit economies that now challenge the Brazilian state across multiple regions. Over 4,000 illegal mining sites were identified across the Amazon region in 2023, underscoring the exponential growth of this market.

Tri-Border hotspots and the urban threat

The TCO crisis is particularly volatile in the Amazonian triple frontiers. In the Tri-Border Area of Brazil, Colombia, and Peru, Brazilian criminal groups have struck partnerships with Colombian guerrilla factions and Peruvian drug trafficking outfits to control the drug supply chain from coca cultivation in the Peruvian Amazon all the way to Atlantic ports. The expansion of the CV and the PCC has been rapid, with criminal gangs now operating in 344 out of 772 municipalities in the Brazilian Amazon (roughly 45 percent), according to a November 2025 report from the Brazilian Forum on Public Security.

The hundreds of rivers and clandestine airstrips scattered across the Amazon, originally used for the drug trade, are now also leveraged for the transport of illicit gold, facilitating the movement of contraband across borders to evade crackdowns. This competition for control has led to an explosion of violence. Large Amazonian cities such as Manaus and Belém, and even smaller towns like Tabatinga (Brazil) and Leticia (Colombia), have seen homicide rates surge as TCOs fight for criminal governance, establishing their own rules and exacting violent punishment for transgressions.

Targeting protected lands and Indigenous communities

The TCOs’ expansion poses a direct threat to the Amazon’s most protected areas. A significant portion of environmental crime hotspots, including illegal timber harvesting and mining, falls within designated Indigenous lands and Conservation Units. Indigenous communities are disproportionately affected, facing forcible displacement, mercury poisoning from mining, and violent recruitment of their youth into criminal ranks.

Reports indicate that these indigenous territories, which historically have been the most effective barriers against deforestation, are now on the verge of being breached by encroaching loggers, land grabbers, and racketeers.

The transnational challenge

While the TCO crisis spans the entire basin, certain regions have historically served as critical nerve centers — refuges and logistical support bases that facilitate TCOs’ regional expansion. For years, geographic complexities that lead to gaps in institutional oversight, as well as the presence of permissive environments have allowed criminal networks to use strategic ports for trafficking.

In these sectors, a sophisticated network of illicit actors managed to integrate illegal gold mining and drug transit into a singular financial engine. This system allows for the large-scale extraction of minerals, where criminal organizations often operate by exerting control over local populations and exacting “taxes” through these corridors. This created a self-sustaining cycle where the profits from one illicit market — such as cocaine — provided the liquid capital to expand into others, like gold and timber.

Basin-wide

The increasing sophistication of these illicit systems marks a critical phase in the Amazon’s history. Groups like the PCC and CV, whose power lies in their control over the “logistical veins” of the rainforest, have spent decades building their operations. By utilizing clandestine airstrips and an intricate network of rivers, these organizations move contraband across international boundaries, effectively treating the entire basin as a single, borderless theater of operations.

The convergence of TCOs and environmental destruction demands a unified, transnational strategy that treats the rainforest’s preservation as inseparable from regional security. By leveraging the comprehensive support of international partners with the firsthand operational knowledge of Amazonian nations, the region can move from being a sanctuary for crime to a stronghold for the rule of law. This integrated approach must do more than just disrupt crime; it must dismantle the systemic illicit economies that threaten the sovereign rights of the communities who call the forest home.

SECOND ARTICLE:

The Mining Arc: The Silent Operation that Sustains the Maduro Regime

Sabina Nicholls/Diálogo Americas – Southern Command – December 17, 2025

Gold has become the new lifeblood flowing through the veins of the Nicolás Maduro regime. With the oil industry collapsing and international sanctions restricting access to foreign currency, the Venezuelan regime has found in the extractive industry a critical alternative revenue stream and a mechanism for political control.

The Orinoco Mining Arc, a vast zone covering millions of hectares of the Amazon rainforest in southern Venezuela, has devolved into a battleground for armed groups, military factions, and criminal networks — all operating with the regime’s complicity.

“The Maduro regime demands a share of the revenues obtained in this area and acts as an arbiter in disputes between the organizations operating there,” Ryan C. Berg, director of the Americas Program and head of the Future of Venezuela Initiative at the Center for Strategic and International Studies (CSIS), told Diálogo.

Under the pretense of national development, the Mining Arc functions in practice as a network for the extraction and smuggling of illicit gold. This operation feeds international financial networks, circumvents sanctions, and guarantees a steady flow of foreign currency.

Having become the new financial lifeline of Chavismo, Venezuelan gold also acts as a powerful mechanism for political cohesion. Through this metal, the regime guarantees the loyalty of segments of the Venezuelan Armed Forces (FANB), enriches elites close to power, and sustains local structures linked to transnational criminal organizations, ultimately consolidating territorial control and reinforcing Maduro’s permanence in power.

Illegal mining with state complicity

In 2016, the Maduro regime established the Orinoco Mining Arc National Strategic Development Zone, a megaproject covering nearly 12 percent of Venezuelan territory, an area almost the size of Portugal. This region is rich in resources such as bauxite, coltan, industrial diamonds, and most crucially, gold.

The magnitude of this illicit economy was highlighted in a report by the Financial Accountability and Corporate Transparency (FACT) Coalition, which revealed that at least 86 percent of Venezuelan gold is produced illegally. Approximately 70 percent is subsequently smuggled, with an estimated illicit value of $4.4 billion in 2021. Though Venezuela accounts for only 5.6 percent of the Amazonian territory, it concentrates more than 30 percent of the illegal mining centers in the basin.

This scheme directly and indirectly benefits the Maduro regime. The semi-official mining sector, comprising state-owned companies such as Minerven and the Military Company for Mining, Oil, and Gas Industries (CAMIMPEG), sources minerals from illegal mines and exports them primarily to Turkey and the United Arab Emirates. Part of these profits flow directly into the regime’s coffers, according to the CSIS report, Illegal Mining in Venezuela: Death and Devastation in the Amazon and Orinoco Regions.

However, these operations represent only a fraction of the business. The majority of the gold leaves the country as contraband and is then formalized on the international market, with the regime and security forces securing a significant portion of the profits at every stage of the process.

The corruption machinery

The creation of the Mining Arc allowed the regime to deploy military units under the guise of protecting strategic areas and attracting investment. However, investigations reveal that this initiative serves to consolidate state control over mineral extraction and ensure the direct participation of military actors in the business.

A 2024 U.S. State Department report presented to Congress denounced the Mining Arc as a system of institutionalized corruption. Military personnel and officials have transformed access to the mines into a source of personal enrichment. This network of high-ranking military and regime officials led by Maduro himself, which facilitates large-scale illicit gold extraction and narcotrafficking, is widely known as the Cartel of the Suns.

“The Arc, home to numerous indigenous peoples, has become a center for mining and illicit gold smuggling. The extraction and sale of this mineral have become a lucrative financial scheme for some well-connected Venezuelans and members of the Bolivarian National Armed Forces,” the State Department document states.

The International Crisis Group (ICG), in its report, The Curse of Gold: Mining and Violence in Southern Venezuela, warns that the military deployment is part of a reconfiguration of territorial control. According to the study, many officers have evolved from mere security forces into direct economic actors. They allow illegal miners to operate in exchange for payments that can reach 20 percent of production or agreements to sell gold below market price. Some prominent generals in the area receive up to $800,000 a month in bribes, according to the ICG.

This dynamic reflects the Armed Forces’ increasingly central role in the political and economic fabric of Chavismo, a role reinforced after their decisive support for Maduro in the 2024 elections. “In a deeply polarized political landscape, these mechanisms allow the regime to ensure the loyalty of the Armed Forces,” Berg said.

Mining as political currency

Maduro has further used mining to consolidate the loyalty of political leaders. In November 2019, he announced that the 19 Chavista governors would each receive direct control of a gold mine, with the possibility of using the profits to bolster regional budgets, CSIS reported.

Even more alarming are allegations of state complicity and military permissiveness in the face of transnational criminal networks. According to the ICG, the FANB delegates control of mines to non-state armed groups, cementing a hybrid system involving the military, criminal organizations, and local authorities.

“The Maduro regime uses all means at its disposal to stay in power, and the current price of gold offers incentives to continue illegal mining in the infamous Mining Arc,” Berg said.

A mosaic of guerrillas and transnational crime

With the complicity of the state, southern Venezuela has been transformed into a mosaic of criminal actors who divide territory and gold profits in exchange for political loyalty to the regime.

According to the ICG, active cooperation exists between the FANB and the National Liberation Army (ELN), a Colombian guerrilla group historically linked to Chavismo. Both forces reportedly operate in coordination in areas of Yapacana and Canaima National Parks, imposing gold taxes, recruiting indigenous youth, and exercising social control through violence.

The ELN also allegedly controls the exploitation of a mine in San Martín de Turumbang, on the border with Guyana, a site reportedly ceded by the Venezuelan regime, according to InSight Crime. Simultaneously, the dissident FARC faction known as Segunda Marquetalia is disputing territory with the ELN, consolidating the presence of Colombian armed groups in southern Venezuela.

“The regime tries to arbitrate between the different groups wherever they operate, allowing those willing to pay kickbacks and collaborate with it to act, while persecuting and punishing those who refuse to do so,” Berg explained. According to him, the Venezuelan regime’s support for these guerrilla groups, designated terrorist organizations, “provides Maduro with security options in case his power is threatened, while generating income from illicit activities.”

Added to this network is the Venezuelan criminal organization Tren de Aragua (TdA), also designated a terrorist organization by several countries in the region. In Bolívar state, TdA acts as a mining syndicate, controlling operations in Las Claritas with protection from local and military authorities, InSight Crime reported. During the 2024 elections, the streets of Las Claritas were covered with pro-regime propaganda and images of the character “Super Bigote” (Super Moustache). This regime-created superhero cartoon based on Maduro became a visible symbol of the fusion between state propaganda and organized crime in a zone under the influence of terrorist organizations.

On the border with Brazil, the First Capital Command (PCC) has also extended its influence, operating in Yanomami territories and using air and river routes to extract Venezuelan gold. According to InSight Crime, this transnational smuggling circuit crosses Brazil, Guyana, and the Caribbean, financing armed structures, buying political loyalties, and propping up the regime in the face of international isolation.

Environmental crime and human cost

In addition to the expansion of organized crime, environmental devastation is advancing unchecked in southern Venezuela. The Mining Arc has become a hotbed of ecological destruction affecting the Venezuelan Amazon rainforest, one of the most biodiverse areas in the country. Illegal logging is giving way to mines, roads, and camps, while illicit operations are rapidly invading protected areas.

According to data cited by Infobae, by 2023 these operations had penetrated 27 of the 41 protected areas in the Venezuelan Amazon, and deforestation had skyrocketed by 170 percent annually. Between 2017 and 2020, more than 22,000 hectares were cleared in national parks such as Caura, Canaima, and Yapacana. Even Cerro Delgado Chalbaud, the source of the Orinoco River, was ravaged by Brazilian miners. Environmental monitoring infrastructure has virtually disappeared due to budget cuts and corruption, Infobae reported.

Added to the devastation is the massive use of mercury and other toxic chemicals that pollute rivers and soils, damaging human health, biodiversity, and Amazonian ecosystems. Data revealed by CSIS show that high levels of this element have been found in nearby rivers that supply drinking water to Colombia and Brazil and flow within Canaima National Park. Elevated levels of mercury have also been found in freshwater fish in the region, which are exported for consumption in Brazil, Guyana, and Trinidad and Tobago.

Criminal control also fuels human trafficking and sexual exploitation in mining camps, exacerbating the vulnerability of a region where Indigenous communities represent almost half of the population of Amazonas state. Agriculture has been displaced by mining, creating a dependence on illicit networks and causing high school dropout rates. Despite the apparent gold rush, poverty persists. In Bolívar, 82 percent of the population lived in extreme poverty in 2021, according to data from Crisis Group.

For Berg, “the Maduro regime is a full-fledged, devastating criminal regime that has empowered itself through relationships with criminal organizations in the heart of South America and poses a major challenge to regional and global order,” he concluded.

Source: www.drugwatch.org

Submitted by Maggie Petito – Drug watch International – 01 February 2026

By  Nav Rahi with Ben Simon in Toronto – AFP NEWS        Jan 31, 2026

Over 35 years as a drug user, Vancouver resident Garth Mullins said he’s had “hundreds and hundreds” of interactions with police, and long believed drug decriminalization was smart policy.

“I was first arrested for drug possession when I was 19, and it changes your life,” said Mullins, who is now in his 50s and was an early backer of Canadian province British Columbia’s decriminalization program that ended on Saturday.

“That time served inside can add up for a lot of people. They do a lifetime jolt in a series of three‑month bits,” he told AFP.

BC’s three-year experiment with drug decriminalization, which launched in 2023 and shielded people from arrest for possession of up to 2.5 grams of hard drugs, was ground-breaking for Canada.

Many praised it as a bold effort to ensure the intensifying addiction crisis devastating communities across the country was treated as a healthcare challenge, not a criminal justice issue.

But on January 14, BC’s Health Minister Josie Osborne announced the province would not be extending the program.

“The intention was clear: to make it easier for people struggling with addiction to reach out for help without fear of being criminalized,” Osborne said.

The program “has not delivered the results we hoped for,” she told reporters. For Mullins, the province’s desired results were never realistic.

The former heroin user, who currently takes methadone, is an activist and broadcaster who co‑founded the Vancouver Area Network of Drug Users (VANDU), which advised BC’s government on decriminalization.

At VANDU’s office in Vancouver’s Downtown Eastside neighborhood, home to many drug users, the walls are full of pictures honoring those who have died from overdose.

“The idea behind decriminalization was one simple thing: to stop all of us from going to jail again and again and again,” he said.

Breaking the cycle of arrests is crucial because criminal records make it more difficult to find work and housing, often perpetuating addiction, experts say.

But thinking decriminalization could help steer waves of users into rehab was misguided, and misinforming the public about the possible outcomes of the policy risked a backlash, Mullins said.

“For everybody out there, in society, sending fewer junkies to jail might not sound like a good thing to do.”

After the province announced the program’s expiration, Canadian media was filled with critics who said it had been mishandled.

Vancouver police chief Steven Rai said his force had been willing to support the plan, but “it quickly became evident that it just wasn’t working.”

Decriminalization “was not matched with sufficient investments in prevention, drug education, access to treatment, or support for appropriate enforcement,” he added.

Cheryl Forchuk, a mental health professor at Western University who has worked on addiction for five decades, said BC “never really fully implemented” decriminalization because the essential complementary programs — especially affordable housing supply — were never ramped up. “It was like they wanted to do something, but then really didn’t put the effort into it and then said, gee, it didn’t work,” she told AFP.

BC’s experience mirrors that in the US state of Oregon, which rolled back its pioneering drug decriminalization program in 2024 after a four-year trial.

Like in Oregon, BC’s program faced fierce criticism, with many saying public safety was threatened by a tolerance of open use.

A flashpoint moment in the western Canadian province was a 2024 incident where a person was filmed smoking what appeared to be a narcotic inside a Tim Hortons, the popular coffee shop chain frequented by families across the country.

Local politicians in Maple Ridge, BC, attributed the incident to a permissiveness about drugs ushered in by decriminalization. But for Mullins, the incident spoke to broader misconceptions about the intent of the policy.

Decriminalization did not allow for drug use inside a restaurant, and the person could have been arrested. Drug user advocates, he added, don’t want policy that makes the broader public feel threatened.

“We need something where everybody feels safe, right? If people who are walking with their kids don’t feel safe, that’s a problem for me,” he said. But, he added, security also matters to users for whom “the world feels very scary and unsafe.”

Source: www.drugwatch.org

 Working Group Meeting in Colorado Springs, Colorado

February 13, 2026

Washington – The U.S. Drug Enforcement Administration in coordination with federal partners and the People’s Republic of China convened the Bilateral Drug Intelligence Working Group (BDIWG) in Colorado Springs February 10 to 12, 2026.  This working group brought together law enforcement, prosecutors, customs, border security, public security, financial supervision, and technical experts to advance practical cooperation against the global threat of illicit synthetic drugs, including fentanyl, and the criminal networks that profit from them.

The shared, urgent, and life‑saving priority to stem fentanyl and other synthetic opioids has been emphasized by both President Trump and President Xi.  

The working group reviewed recent progress and agreed on concrete next steps to disrupt chemical supply chains, prevent diversion, and target illicit finance tied to transnational criminal organizations.  This included a look at drug trafficking trends in both countries, the impact of precursor chemicals on the drug supply, pill presses and related equipment, and the role of online advertising.   

DEA was joined by representatives from the Department of Justice, Department of Homeland Security, Department of the Treasury, and U.S. Customs and Border Protection along with counterparts from China’s Ministry of Public Security (MPS), China Customs, Supreme People’s Procuratorate, People’s Bank of China, and staff from key provincial police bureaus.

Recognizing the terrible human toll of synthetic drugs, in particular fentanyl, the United States and China are committed to working together, in line with the guidance from both countries’ leaders, to save lives, protect communities, and uphold the rule of law.

Source: DEA Public Affairs

Filed under: Strategy and Policy,USA :
by LEE Sanghyun – Maeil Business Newpaper(MK) – South Korea – 2025-12-28
If a person who habitually drives under the influence of alcohol acquires a license again, a conditional license system that requires the attachment of a “drunk driving prevention device” will take effect in October next year.

According to the “2026 Road Traffic Act” released by the National Police Agency on the 28th, people who have driven drunk twice or more within the past five years must install a DUI prevention device on their vehicle when they re-acquire their license after a two-year disqualification period.

The device prevents the vehicle from starting at all when alcohol is detected. The cost of installation is about 3 million won, and the police said they are in talks with the Korea Expressway Corporation to allow rental.

In addition, driving without installing preventive devices could result in up to a year in prison or a fine of up to 3 million won. It is also possible to revoke a driver’s license.

If another person is caught driving after avoiding alcohol detection by breathing instead, he or she will be sentenced to up to three years in prison or fined up to 30 million won.

According to the police, about 40% of drunk drivers have recidivism within five years. The police’s plan is to “block the source” as a device to prevent the possibility of such recidivism.

From next year, punishment for “drug driving” will also be strengthened. The move comes as the number of accidents while driving under the influence of psychotropic drugs such as propofol and zolpidem increases rapidly.

When drug driving is caught, it has been raised from “imprisonment of up to three years or a fine of up to 10 million won” to “imprisonment of up to five years or a fine of up to 20 million won.” A new provision has also been established that will result in “imprisonment of up to five years or a fine of up to 20 million won” for non-compliance with drug measurements.

The issuance of Type 1 licenses will also become stricter. Previously, if only the seven-year accident-free requirement was met, type 2 driver’s license holders could obtain type 1 licenses only by aptitude tests. Starting next year, you can get a type 1 license after an aptitude test only if you prove your actual driving experience with a certificate of auto insurance.

The standard for calculating the renewal period of a driver’s license will be changed from the existing annual unit (January 1st to December 31st) to six months for each individual’s birthday. The related system will also be adjusted so that trainees can legally train on the road to the places and courses they want without visiting the driver’s license academy in person.

Kim Ho-seung, director of the National Police Agency’s Living Safety Transportation Bureau, said, “We will strongly crack down on activities that threaten the lives of the people on the road and actively improve daily inconveniences.”

 

by  Mark S. Gold M.D. – Addiction Outlook – Posted  

 

The change was made despite lack of evidence of medicinal benefits.

  • President Trump directed federal agencies to expedite the process of reclassifying cannabis to Schedule III.
  • Now what? Many actions are needed, including new research and protection of adolescents.
  • Placebo-controlled, double-blind trials of pharmaceutical-grade cannabis constituents are needed.

The most consequential shift in cannabis policy in more than 50 years is now happening. A December 2025 executive order from President Trump has directed the federal government to down-schedule cannabis from Schedule I (illegal) to Schedule III (a lawful drug designation with a lower level of harm than Schedules I or II) . This is despite the alarming lack of research evidence for medicinal cannabis.

Rescheduling cannabis will provide significant tax advantages to the industry, allowing billions in previously banned business expense deductions that could hugely boost marketing efforts, research, or both. The executive order (EO) does not explicitly recognize cannabis as medicine. It also does not set national standards for cannabis labeling, dosages, or youth protection, all of which are essential.

Whether you view the EO as long overdue or ill-advised, the key questions now are how this change will be implemented, who will control the downstream effects of cannabis, and whether public health experts or lobbyists seeking to accelerate commercial momentum will define what happens next.

Currently, any cannabis warning labels are inconsistent across states, often minimal, and frequently omit critical risks, such as mental health effects, breastfeeding harms, and other dangers stemming from high-potency cannabis products.

5 Examples of Warning Labels 
5 Examples of Warning Labels – THIS NEEDS A BORDER AND ENLARGEMENT AND ‘PACKAG?? – H
Source: Dr Mark Gold

The executive order simultaneously instructs federal agencies—particularly the National Institutes of Health and the Food and Drug Administration—to expand, streamline, and lower barriers to cannabis/cannabinoid research.

Indeed, the now-history LSD-like Schedule I status of cannabis imposed hurdles to research. Nevertheless, considerable research has been done, even though a special license was necessary to use the drug in studies. However, rescheduling marijuana doesn’t guarantee adequate research funding, FDA approval for cannabis, THC, or CBD, or high-quality research.

What Drug Experts Say

Among the EO’s most vocal critics is Kevin Sabet, drug policy expert who served both Republican and Democratic administrations and now president of Smart Approaches to Marijuana, who sees the order as devoid of public health wisdom. Sabet warns that rescheduling signals medical endorsement despite cannabis’s association with significant health risks, especially for young users. Sabet highlights that the EO moves cannabis from Schedule I (not legal) to Schedule III (controlled but legal), although the medicinal effects of cannabis have never been FDA-proven or approved.

Harvard’s Kevin Hill, M.D., supports rescheduling for improving research facilitation, arguing that current cannabis use lacks clinical guidance. He emphasizes funding as crucial for quality research. Hill ‘s position is pragmatic: Lack of scientific certainty is not a reason to avoid research—it’s the reason research is needed.

Hill also places responsibility for research funding on states and industry. Legal cannabis markets generate billions in revenue, yet only a fraction is reinvested in rigorous research, prevention, or treatment. Ethical stewardship, he argues, demands that those profiting from cannabis bear responsibility for understanding its risks and benefits.

Thirty percent of cannabis users, including adolescents, develop a substance use disorder, according to Mt Sinai School of Medicine’s Dr. Yasmin Hurd. She emphasizes the importance of pairing research expansion with clear regulations to avoid exacerbating risks linked with cannabis.

A crucial area for future research is safe and effective dosing of THC (the intoxicant in cannabis) amid imminently rising sales of high-potency products. Large-scale, longitudinal studies tracking neurodevelopmental outcomes in relation to timing and potency of cannabis exposure are essential.

At the same time, policymakers face a proliferation of unregulated intoxicating cannabinoids sold outside state-licensed cannabis systems. Products such as delta-8 and other synthetic or semi-synthetic cannabinoids are widely available in gas stations and convenience stores, often with minimal oversight. These products disproportionately attract youth, undermining consumer safety. Closing loopholes has become a public-health necessity.

Recognizing the Rising Risks

Some media reports suggest the EO was pushed through despite vociferous objections highlighting the risks of cannabis use among adolescents and young adults. The link between early-age cannabis exposure and increased risk of schizophrenia, mood disorders, and long-term functional impairment is no longer speculative. The disorders carry lifelong healthcare, social, and economic costs. Yet current data are insufficient to guide prevention efforts. Without guidelines, prevention efforts will remain reactive and politically vulnerable. Nowhere are the stakes higher than among adolescents and young adults.

One of the nation’s leading scientists and long-time vocal opponents of legalizing cannabis, Yale’s Deepak D’Souza, M.D., has focused on the increasing amount of cannabis, its increased potency, frequency of use, and duration of effects, causing severe consequences in young people. Cannabis and some of its constituents produce acute impairments in memory, attention, executive function, impulsivity and risk-taking behaviour, and psychomotor coordination, critical for driving a car. Nora Volkow, M.D., director of the National Institute for Drug Abuse (NIDA) has underscored the need for balanced research, acknowledging both benefits and risks of cannabis.

Dose is another urgent research priority, since higher THC concentrations are associated with increased risks of psychosis, cannabis use disorder, cardiovascular events, and cognitive impairment. More isn’t always better. A post-rescheduling agenda should include an investigation into minimum effective doses, upper safety thresholds, and the feasibility of reducing THC concentrations while preserving potential therapeutic effects.

Since rescheduling will be interpreted as an implicit medical endorsement, regardless of official intent, a national, evidence-based prevention strategy is needed, modeled on successful tobacco-control frameworks Such a strategy needs to include school-based education, clinician training, parental guidance, and public-health messaging that’s scientifically grounded rather than moralistic/alarmist.

Federal consumer protection agencies need to become empowered to monitor misleading cannabis advertising.

Finally, the integrity of emerging research depends on maintaining a firewall between scientific inquiry and commercial influence. Industry participation in research isn’t inherently problematic, but it must be governed by transparency, independent oversight, and conflict-of-interest safeguards.

Acceptance Without Complacency

The December 2025 executive order is now a reality. There is likely to be a huge cash infusion without regulation, causing a commercialization boom in cannabis, with the potential to harm our youth more than ever. Industry needs to step up and fund academic research.

Youth protection and guardrails are indispensable. A good start would be warning labels, funding of prevention efforts directed toward teens and young adults, and increasing NIDA’s funding for cannabis/THC/CBD translational research .

If cannabis products remain legal and available, consumers need clear, standardized warnings reflecting the best available evidence on cannabis use disorder and psychosis risk; impaired driving; memory effects; and adolescent brain vulnerability. Public health warnings should not be optional, nor diluted by marketing language implying medical endorsement where none exists.

Source: https://www.psychologytoday.com/au/blog/addiction-outlook/202512/marijuana-rescheduling-is-now-real

From the French Connection to today’s criminal networks, drug trafficking in France has undergone profound transformations, evolving from centralized, predictable structures to decentralized, technologically advanced organizations. This article examines these changes and highlights the need for a comprehensive approach that combines targeted law enforcement, social prevention programs, financial monitoring, and international cooperation. By reflecting on historical experience, policymakers and law enforcement agencies can better understand modern trafficking methods, anticipate the adaptability of criminal networks, and enhance the overall effectiveness of strategies aimed at reducing the social, economic, and security impacts of drug-related crime

Introduction

Over the past decade, the illicit drug market in France has undergone unprecedented expansion, underscoring the magnitude of a phenomenon long underestimated by public authorities. A research note published in December 2025 by Christian Ben Lakhdar and Sophie Massin, professors at the University of Lille, estimates that the economic value of this market nearly tripled between 2010 and 2023, reaching approximately 7.9 billion U.S. dollars annually. This growth reflects not merely rising consumption levels but a profound restructuring of procurement dynamics: while cannabis remains dominant in terms of volume, cocaine has emerged as the most profitable substance, and synthetic drugs have experienced particularly rapid expansion. These trends point to the consolidation of criminal networks capable of optimizing pricing, purity, and distribution channels on an international scale. As a result, drug trafficking has become a major security and public health concern, extending well beyond the boundaries of conventional criminal activity. Understanding this contemporary landscape, however, requires a historical perspective, as today’s challenges are embedded in a longer continuum of State efforts to confront highly structured and adaptive criminal organizations in France.

The war on drugs in France has unfolded through multiple historical phases, each revealing shifts in criminal structures and governmental responses. During the 1960s and 1970s, a criminal network based in Marseille controlled the flow of heroin to the United States. This network, popularized globally by William Friedkin’s film The French Connection(1971), consisted of Corsican mobsters and Marseille traffickers operating clandestine laboratories where heroin was refined before being shipped by sea to New York and Boston . French authorities, cooperating closely with the U.S. Drug Enforcement Administration (DEA), relied on traditional intelligence methods: physical surveillance, infiltration, and monitoring of laboratories and transport routes. These operations identified key leaders, disrupted the trafficking network, and enabled the seizure of large heroin shipments. A notable example is the arrest of French TV presenter Jacques Angelvin in New York in 1962, resulting from a Franco-American joint investigation, which demonstrates how international collaboration facilitated the progressive dismantling of the French Connection while highlighting the interplay between domestic policing and transatlantic intelligence coordination.

Today, drug trafficking in France has become a pressing public health and security challenge, far more complex than in the 1960s. According to the French Monitoring Centre for Drugs and Drug Addiction, roughly 1.1 million people used cocaine at least once in 2023, while cannabis remained the most widely consumed illicit drug, with 5 million adults reporting use during the same year. Other substances, including heroin and synthetic drugs, circulate through ports, airports, and dense urban networks. Modern traffickers rely on encrypted communications and opaque financial flows to evade detection. Law enforcement agencies must sift through extensive data—from wiretaps and financial transfers to social media activity—to track the movement of drugs and identify key actors. Violence associated with trafficking is escalating, marked by targeted shootings, score-settling, and even acts of torture, underscoring the urgent need for multidimensional strategies to curb traffickers’ influence across France. The scale and sophistication of contemporary operations demand a response that combines physical, digital, and social interventions, illustrating that historical methods alone are insufficient for addressing modern organized crime.

A comparison between historical and contemporary criminal networks illuminates how organized crime has evolved and identifies levers for modern enforcement. The French Connection was dismantled due to its centralized structure and high visibility, but today’s networks require more sophisticated, adaptive approaches. Effective action now combines digital and field intelligence, targeted arrests, disruption of supply chains, financial tracking, and social initiatives to reduce traffickers’ appeal among vulnerable populations. International coordination is equally essential: France collaborates with Europol, Interpol, and other agencies to monitor drug and money flows across borders. Historical lessons provide a framework for evaluating the effectiveness of cooperation, infiltration, and criminal flow management, while also highlighting the necessity of adapting policing and judicial methods to technological innovation. By reconciling enforcement, prevention, and social protection, France aims to address current and future challenges in the war on drugs, reflecting the dynamic and multifaceted nature of modern trafficking networks.

France’s Narco Challenge

Over the past decade, France has faced a worrying surge in drug-related violence, affecting both the suburbs of major cities and medium-sized towns. According to the Ministry of the Interior, more than 110 tons of narcotics were seized in 2024, including 53 tons of cocaine—more than double the previous year’s haul (). Cannabis seizures exceeded 50 tons, alongside the destruction of nearly 700,000 plants. Meanwhile, 110 drug-related deaths and several hundred injuries were reported. Cities historically less affected, such as Clermont-Ferrand (150,000 inhabitants) and Avignon (92,000 inhabitants), were designated “reinforced security zones” following fatal shootings, while metropolitan hubs like Nantes saw over 1,100 drug-dealing hotspots dismantled between September 2022 and September 2023. Marseille, long a hub for drug trafficking, continues to experience deadly incidents, including the November 2025 murder of 20-year-old Mehdi Kessaci, apparently intended to intimidate his brother, an anti-drug activist. This event sparked widespread local protests, highlighting the persistence and territorial reach of criminal networks despite sustained law enforcement efforts. The scale and visibility of these operations underscore the pressing challenge posed by modern trafficking, both in terms of public safety and operational complexity.

The social and economic consequences of rising drug-related violence are profound. In neighborhoods of Marseille, Lyon, and Nantes, fear shapes daily life: residents restrict movement, shops close earlier or intermittently, and families hesitate to let children travel alone. Police presence, though increased through patrols and identity checks, is often seen as inadequate, fostering feelings of abandonment and vulnerability. In areas sometimes described as “no-go zones,” minors as young as 14 are recruited by traffickers for final distribution, surveillance, or territorial security, perpetuating cycles of violence and criminality. Public demonstrations, such as those following Mehdi Kessaci’s assassination, reflect dual social demands: for a more visible and efficient justice system capable of deterrence and for community support programs that reduce trafficking’s appeal among vulnerable youth. Authorities themselves acknowledge the limits of their power in these contexts. These dynamics illustrate that modern drug violence is not merely a law enforcement problem, but a deeply rooted social and economic issue, requiring coordinated interventions that address both criminal operations and the broader community environment.

Despite intensified policing, repression alone proves insufficient against criminal networks, whose sophistication surpasses the French Connection. Traffickers rely on undetectable smartphones, encrypted messaging, and cryptocurrencies to obscure financial flows, complicating investigations and prolonging operational timelines. “XXL clean-up” operations in spring 2024 resulted in thousands of arrests and the seizure of weapons, narcotics, and criminal assets, demonstrating short-term effectiveness but failing to curb trafficking long-term. Experts advocate a multidimensional strategy that combines targeted enforcement, digital surveillance, financial control, prevention measures, and social reintegration programs. This holistic approach draws lessons from historical dismantling but must adapt to modern realities: criminal networks are flexible, decentralized, and technologically sophisticated, making AI-driven analysis of big data critical. The contrast with the French Connection underscores both continuity and evolution: the principles of disruption remain valid, but operational methods must now account for mobility, cryptography, and the fluidity of modern criminal ecosystems.

Inside the French Connection

The French Connection, active primarily in the 1960s and 1970s, represents a historical model of organized crime built around a highly centralized supply chain. Groups based in Marseille controlled the production, refining, and export of heroin to the United States by importing morphine base from Turkey and the Middle East. Clandestine laboratories in the Marseille countryside transformed diacetylmorphine into highly pure heroin for U.S markets. The most notorious of these laboratories, the “Césari Lab,” linked to chemist Joseph Césari, was dismantled in March 1972 with nearly 100 kg of heroin seized. Cell leaders managed security, coordination, and transport, often relying on predictable routes: overland transfer to Marseille, concealment in shipments of fruit, textiles, or machinery, followed by maritime dispatch to the East Coast. While this organization enabled industrial efficiency, it also created vulnerability: fixed routes and concentrated production points made surveillance and interceptions easier, ultimately contributing to the network’s downfall. This paradox highlights the balance between operational efficiency and exposure in centralized criminal systems.

Authorities dismantled the French Connection through a three-pronged strategy. First, international cooperation with the U.S. DEA was significantly strengthened, ensuring continuous intelligence sharing on routes, laboratories, couriers, and financiers. This collaboration produced high-profile joint operations, including the January 1973 arrests of Jean-Baptiste Croce and Joseph Mari, key figures in Marseille’s heroin export to the United States. Second, French services applied classic intelligence techniques: surveillance, wiretapping, supply chain mapping, and meticulous monitoring of regional hubs. The investigations identified clandestine laboratories and intermediary networks. Third, targeted operations seized shipments, arrested chemists, and systematically dismantled production units, gradually weakening the network. These successive strikes revealed that what made the operation efficient also made it exploitable, demonstrating the inherent vulnerability of tightly centralized criminal structures.

These combined efforts exposed the internal weaknesses of a system the media depicted as sprawling. Dependence on fixed routes, the concentration of laboratories, and the public visibility of influential figures—including Marcel Francisci, a businessman and politician—facilitated intelligence work. By late 1973, these operations led President Richard Nixon to declare that Marseille heroin had effectively vanished from the American market. The French Connection provides a valuable framework for understanding contemporary criminal networks can be neutralized when flows, actors, and infrastructure are clearly identified, even without modern technology. Yet, comparing past and present highlights change: centralized, predictable structures have given way to fragmented and mobile networks using encrypted communications, digital services, and dispersed logistics. The enduring lesson is that law enforcement effectiveness depends on a combination of patient intelligence, international cooperation, and strategic adaptability—principles that remain essential for understanding today’s sophisticated criminal networks.

Modern Challenges in Narcotics Enforcement

Drug trafficking in France today relies on far more fragmented structures than those of the French Connection. Contemporary criminal networks operate through autonomous, interchangeable cells capable of functioning independently and dissolving rapidly under intense police pressure. This flexible design allows traffickers to simultaneously exploit multiple supply chains: cocaine is imported by container in Le Havre, cannabis resin transits via the Iberian Peninsula, heroin arrives from the Belgian Dutch border region, and synthetic drugs circulate within party circuits. Clandestine apartments, storage units, and logistical hubs outside city centers are used to split shipments into smaller loads, reducing the risk of interception. The mobility of these networks complicates the identification of operational bases: a single network may coordinate transactions from Paris, store merchandise in Brittany, and redistribute it in Lille neighborhoods. Furthermore, the systematic use of encrypted phones, VPNs, and ephemeral messaging services makes surveillance increasingly difficult. This operational fluidity creates a decentralized criminal environment without visible ringleaders, compelling investigators to combine traditional physical observation with digital intelligence and financial tracking to monitor complex networks efficiently.

The sophistication of modern trafficking is not unique to France. Criminal organizations worldwide are increasingly adopting advanced technologies to secure supply chains, reducing the role of human couriers. In July 2025, the Colombian Navy intercepted the first unmanned narco-submersible near Santa Marta, remotely controlled via satellite and capable of carrying up to 1.5 tons of cocaine. Still in testing, the vessel sailed several hundred kilometers offshore, demonstrating the integration of civilian technologies, including satellite connectivity for real-time navigation. Coordinated tracking between patrol vessels and aerial drones allowed authorities to monitor its trajectory before interception. This operation highlights a new form of trafficking in which removing the human factor—a criminal network’s primary vulnerability—creates a “black hole” for intelligence services. France, confronting mobile and interconnected traffickers, must combine physical surveillance, digital monitoring, and technological anticipation to maintain operational effectiveness, demonstrating the growing need for multidimensional approaches to narcotics enforcement.

France’s response centers on the Office Anti-Stupéfiants (OFAST), the French Anti-Narcotics Office created in 2020. OFAST coordinates police, gendarmerie, customs, and international counterparts, enabling rapid intelligence sharing on ports, transit routes, and financial flows. Between 2023 and 2024, OFAST conducted nearly 4,000 operations, including long-term infiltrations, high-risk container tracking, and analysis of encrypted smartphones seized during arrests. Local units focus on mapping criminal networks, tracing financial flows via cryptocurrencies, and identifying clandestine warehouses. Asset seizures totaled more than US$140 million in 2024, reflecting a strategy targeting the economic core of criminal organizations. By integrating human, digital, and financial expertise, France has developed a comprehensive approach to decentralized and mobile trafficking, illustrating that effective law enforcement now requires coordination across multiple domains rather than isolated interventions.

Long-term strategies aim not only to arrest traffickers but also to disrupt the structural and logistical foundations of criminal ecosystems. Operations target transit points, warehouses, money-laundering networks, and suppliers of encrypted equipment, while monitoring digital communications. Legal measures reinforce enforcement: the 2025 anti-drug trafficking law allows authorities to seize crypto assets, freeze assets linked to money laundering, and temporarily close premises. Complementary social programs aim to prevent recruitment in vulnerable neighborhoods, providing community mediation, educational support, and personalized guidance for at-risk youth. This holistic strategy demonstrates that combating modern trafficking requires simultaneous action across economic, digital, logistical, and social dimensions, limiting traffickers’ adaptability while restoring state control over affected territories.

By contrast, the United States focuses primarily on securing entry points and intercepting shipments before they reach national territory. In August 2025, Operation Pacific Viper, led by the U.S. Coast Guard, seized 34 tons of drugs, including cocaine and marijuana. The operation relied on intensive maritime patrols, surveillance of suspicious vessels, and coordination with the U.S. DEA and other federal agencies. Under the Donald Trump administration, the strategy prioritized upstream disruption, aiming to stop drug flows at the source rather than intervening in urban areas. This contrasts with the French approach, which combines intelligence gathering, field operations, financial tracking, and social interventions. The comparison highlights a central point: the effectiveness of anti-drug operations depends on adapting methods to the mobility, fragmentation, and technological sophistication of trafficking networks. Revisiting lessons from the French Connection demonstrates how precise identification of key players and routes allows disruption of centralized criminal networks, providing a valuable framework for contemporary enforcement strategies.

Continuity and Change in Narcotics Operations

Comparing the French Connection with today’s criminal networks reveals both enduring lessons and major structural shifts. Historically, the French Connection relied on a centralized, hierarchical organization with identifiable leaders and relatively fixed routes connecting laboratories, ports, and international markets. This visibility allowed targeted physical infiltrations and direct seizure of shipments, while communication remained limited to trusted messengers. Key principles—tracking flows, monitoring logistical hubs, and making targeted arrests—enabled authorities to disrupt the network for extended periods, demonstrating the importance of interagency coordination and precise intelligence. However, applying these methods directly to contemporary trafficking would be insufficient: the mobility, encryption, and decentralization of modern cells render the old model largely obsolete. Nevertheless, studying historical criminal networks remains invaluable for identifying the levers of action and disruption logic while cautioning against mechanically reproducing outdated practices in a vastly transformed technological and structural environment.

Modern trafficking operates through decentralized, autonomous networks functioning across multiple routes and territories. Leaders are no longer visible, cells can dissolve quickly, and financial flows move through shell companies or electronic wallets, evading conventional oversight. As Pamela F. Izaguirre noted regarding Mexico, the high-profile arrest of a cartel leader did not change the overall dynamics of criminal organizations, which continued to adapt and reconfigure themselves. Today’s criminal networks display even greater plasticity, forcing law enforcement to integrate traditional methods with advanced tools: physical surveillance and targeted interventions remain essential but must be complemented by cyber-surveillance, big data analytics, and financial tracing. The contrast with the French Connection is striking: predictability and centralization no longer simplify police operations. Contemporary strategies demand a combination of field operations, digital intelligence, and real-time international coordination to counter constantly evolving criminal structures.

Nevertheless, some principles persist: accurate intelligence, interagency cooperation, and sustained effort remain the foundation of effective enforcement. For instance, a 2025 joint operation between France and Spain, involving surveillance, electronic monitoring, searches, interceptions, and real-time intelligence sharing, led to the arrest of 24 network members, including leaders, and the seizure of more than 150 kg of drugs. This demonstrates that classic investigative methods—carefully adapted—retain relevance, while international coordination ensures rapid information exchange, harmonization of procedures, and mobilization of specialized teams. The evolution of trafficking also highlights the need to link coercive and social strategies. Unlike the export-focused, relatively invisible French Connection, today’s criminal networks operate within cities and suburbs, spreading violence and insecurity. A balanced approach combining law enforcement, technological innovation, and social intervention is therefore essential to restore territorial control and reduce traffickers’ adaptive capacity.

Conclusion

Almost every week, French media report drug-related violence, from gang shootouts and score-settling accompanied by torture to tense neighborhoods. In early December 2025, north of Paris, a fight between two gangs of traffickers erupted in a kindergarten playground, terrifying three-year-olds. The war on drugs has become a pressing reality at the heart of national debate, as President Emmanuel Macron concludes his term amid public confusion and limited popular support for his policies. Contemporary trafficking networks—decentralized, mobile, and technologically sophisticated—no longer follow the traditional models of the French Connection, rendering targeted arrests insufficient. French authorities now rely on advanced investigations, international cooperation, and digital monitoring. Europol, Interpol, and cross-border agencies enable near-instantaneous sharing of information on drug flows, financial transactions, and encrypted communications. Specialized units analyze this intelligence to trace supply chains, identify key players, and map trafficking hotspots. Revisiting historical practices demonstrates that lessons from the French Connection remain relevant, emphasizing the enduring value of combining patient intelligence, strategic coordination, and technological adaptation to combat modern, adaptive criminal networks effectively.

The social, legislative, and technological dimensions are equally critical for a sustained response, requiring strategies that go beyond immediate enforcement. Neighborhoods plagued by violence demand comprehensive prevention, educational support, community engagement, and targeted programs to limit the pool of potential recruits for dealers and lookouts—efforts supported by social organizations, local authorities, and political actors across the spectrum. Concurrently, French authorities are leveraging AI, predictive analytics, and financial tracking tools while reinforcing legislation on cryptocurrencies and money laundering to disrupt fluid and technologically sophisticated criminal networks. Logistical monitoring, mapping of hotspots, and coordinated international cooperation further strengthen these efforts. Beyond law enforcement, these measures aim to restore state authority, rebuild public trust, and address the structural vulnerabilities exploited by traffickers. Rising public demand for harsher repression risks polarizing society, yet solidarity and strategic foresight remain essential, particularly as Europe faces mounting geopolitical pressures, including the imperial ambitions of Vladimir Putin, demonstrating the inextricable link between domestic security and international stability.

Source: https://smallwarsjournal.com/2025/12/24/frances-war-on-drugs/


Opening Statement by NDPA:

This essay by Gillis-Smith is published here not through any support of its content, but as an example of the published works in this area of the drugs policy/practice field at large. Readers must draw their own conclusions as to its validity and value.

by Paul Gillis-Smith – program lead on psychedelics and spirituality,  Harvard Law School – November 30, 2025

“psychedelics golden age” of access, research, and culture. A significant reason is their assumption that psychedelics were easy to get because few laws criminalized their possession or sale prior to the Comprehensive Drug Abuse Prevention and Control Act of 1970. But that story leaves out the legal predecessors to the Controlled Substances Act, specifically the Food, Drug, and Cosmetic Act (FDCA) of 1938. 

This essay corrects the false notion of a legal psychedelic “free-for-all” through the story of Lisa Bieberman, an LSD enthusiast and Harvard Square denizen of the 1960s. I draw upon archival research at the Peter Stafford Papers at Columbia University for Bieberman’s bimonthly publication, the Psychedelic Information Center Bulletin, and the Cambridge Public Library Archives for Bieberman’s never-published memoir manuscript, To Mark A Spot: A Psychedelic Pilgrimage. Bieberman was prosecuted under the FDCA, which gave the FDA authority to regulate food, drugs, medical devices, and cosmetics. According to a story in the Harvard Crimson, she was the first person in New England prosecuted for an LSD violation under the FDCA, for illegally shipping LSD through the mail. 

Bieberman was a Radcliffe graduate (’63) who encountered psychedelics through Timothy Leary and Richard Alpert, two faculty in Harvard’s Department of Social Relations, just as their time at Harvard screeched to a halt. Upon her graduation, she worked for Leary and Alpert’s para-academic organization, the International Federation for Internal Freedom, which Bieberman describes in her memoir as continuing Leary and Alpert’s research, starting a pharmaceutical lab, and launching a combination clinic-utopian colony (71-72). She kept their Cambridge headquarters afloat while Leary, Alpert, and company flew off to Mexico, the Caribbean, and eventually upstate New York. 

Bieberman started the Psychedelic Information Center (PIC) in Harvard Square in 1965, releasing a bimonthly bulletin where she reported on changing drug laws, sold mushroom grow guides, publicized new psychedelic churches, and attempted to correct myths, like whether smoked banana peels are a psychedelic (they aren’t).

IMAGE: Psychedelic Information Center Bulletin 3; December 1965; Peter G. Stafford papers; Box 29 Folder “Psychedelic Information Center Bulletin (Cambridge, Mass.)”; Rare Book and Manuscript Library, Columbia University Library

In 1965, in the third installment of her PIC Bulletin, Bieberman provided an open offer for LSD for Christmas: “Santa Claus has a batch of LSD, but the law won’t let him carry it across state lines in his little red sleigh.” Based on the offer, it is clear she was aware of her limitations per the FDCA. Nevertheless, based on information in her memoir, she mailed LSD to a handful of out-of-state requests (242). Bieberman reports that on March 18, 1966, she received a letter from the FDA that threatened prosecution for shipments of LSD across state lines to Kansas, Missouri, and California with improper labeling (under FDCA, (502)(e)(1)(A)(i), per the FDA Papers, 35). She had sent sugar cubes to a student in Kansas who had apparently publicized his acquisition a bit too loudly; and Bieberman alleged that the FDA caught wind of him (242-243). She was arraigned in the summer of 1966 and pleaded not guilty. The day after her arraignment, Bieberman left Boston for UC Berkeley’s LSD Conference. 

In mid-November of 1966, Bieberman at last had her day in court — three days, in fact. According to her memoir, she found her lawyer inept —Bieberman felt she had done far more research on her case than her lawyer could ever be convinced of doing (295-297). The judge found her guilty of violating the Food, Drug, and Cosmetic Act: four counts of mailing LSD without proper labeling. She was sentenced to a year of probation. 

While the state’s sentence was light, the extralegal consequences were worse. After her sentencing, Bieberman reported that she was urged by her department at Brandeis University, where she had just begun a PhD in Psychology, to resign (299). Because of her drug conviction, the Massachusetts Registry of Motor Vehicles refused to renew her driver’s license.

Bieberman’s run-in with the law did not dissuade her from psychedelic advocacy. Two months after her sentencing, she published Session Games People Play: A Manual for the Use of LSD. In her Bulletin in April 1967, she devoted several paragraphs to the confused state of the law regarding psychedelic research and how researchers can obtain and manufacture their own LSD. She implores her readers to pick up the Drug Abuse and Control Amendments (1965) for themselves, as “too few people read the law books, and (contrary to popular belief) they are really not hard to read.” 

Bieberman’s case demonstrates that the FDA would prosecute cases involving psychedelics in the ’60s, counter to the common conception that all activities involving psychedelics were legally unrestricted until the Controlled Substances Act. In fact, this was a known risk, as Bieberman notes in her Christmas coupon, and in her frequent admonitions against secrecy and paranoia among psychedelic enthusiasts. 

In an essay for The Boston Globe Magazine in 1968, Bieberman insisted that paranoia and underground activities cannot be the winning strategy – nor were religious arguments likely to be compelling if they were disingenuous: “Most psychedelic groups up till now have kept their activities nine-tenths submerged; when they get in trouble they scream religious persecution. But I do not think our courts will ultimately choose to persecute religion, where it proves itself genuine and conscientious.” While Bieberman did not take up a legal defense on the grounds of religion for her use and advocacy of LSD, she did become a devout Quaker. In an essay titled “Phanerothyme: A Western Approach to the Religious Use of Psychochemicals,” Bieberman offered a model of using psychedelics in a Quaker style. Rather than offering legal protection, Bieberman’s religious approach to LSD was intended to support the lessons that a psychedelic experience “has to teach, to support one’s companions in their search, and to put the insights gained into practice in living.”  

This post is part of a digital symposium titled The PULSE of Psychedelics, Law, and Spirituality. 

About the author – Paul Gillis-Smith

  • Paul Gillis-Smith is a program lead on psychedelics and spirituality, as part of the Transcendence and Transformation Initiative at the Center for the Study of World Religions. He is an alum of Harvard Divinity School (M.Div ’24), where he focused on the history of psychiatry as it relates to psychedelic medicine and chaplaincy.

Source: https://petrieflom.law.harvard.edu/2025/11/30/lsd-gospel-christmas-tidings-and-the-fda-during-the-psychedelic-sixties/

Opening statement by NDPA:

NDPA has mixed feelings about Harm Reduction – in one form, aiming to minimise harm in users while they consider cessation of drug use, it is something which NDPA supports, but in another form it is a ‘closet legalisation ploy’ – promoting the notion that drug use is valid and one should only seek to reduce the harm users experience – and NDPA clearly does not support this form. With this caveat, this article is included as an opinion piece for reading.

by Ricardo Fuertes, EATG member and representative at the EU Civil Society Forum on Drugs – December 17, 2025

Earlier this month, Mr Fuertes participated in the Civil Society Forum on Drugs as a representative of EATG. The discussions offered important insights into the current direction of EU drug policy and the conditions under which civil society organisations are operating.

The New EU Drugs Strategy: An Unbalanced Approach and the Downgrading of Harm Reduction

The European Commission presented the new EU Drugs Strategy. From the perspective of many civil society organisations, the Strategy is notably unbalanced. While prevention, treatment, and social integration are clearly highlighted and structured as core pillars, harm reduction is treated differently. Rather than being recognised as a distinct and essential pillar, it is dispersed across the document, diluted in its language, and separated from the other approaches.

At the same time, the Strategy is highly detailed when it comes to security-related themes, threats, and supply reduction. Considerable attention is given to law enforcement and control measures, while approaches grounded in public health and human rights receive comparatively less emphasis. Decriminalisation and the legal regulation of drugs are entirely absent from the framework. In addition, the Strategy lacks a defined timeframe or end date, raising concerns about accountability and evaluation. It is also not accompanied by a dedicated budget or a comprehensive action plan beyond an Action Plan against drug trafficking.

These concerns have been explicited in a joint letter coordinated by the International Drug Policy Consortium and signed by a wide number of organisations, including EATG, as a tool to encourage negotiation with Member States.

Systemic Barriers and Excluded Populations

Discussions throughout the Forum highlighted the need to better address systemic barriers affecting vulnerable populations. While HIV and viral hepatitis are mentioned within the EU Drugs Strategy, this is done in broad terms, without clearly identifying who is being left behind and why.

From EATG’s perspective, undocumented migrants must be explicitly included in prevention and treatment efforts. Legal precarity, fear of detection, and administrative barriers continue to exclude many undocumented migrants from access to drug services, HIV prevention, and care for viral hepatitis. A generic commitment to identifying systemic barriers is not sufficient; concrete measures are needed to ensure that prevention and treatment are accessible to all, regardless of migration status.

Civil Society Participation Under Pressure

A noticeable decline in participation at this year’s Forum was also observed. This reflects the increasingly difficult conditions under which many civil society organisations are operating across Europe. Participants reported funding cuts, staff reductions and layoffs, as well as decisions to limit participation in international meetings. These pressures are forcing organisations to reduce activities and service provision, with harm reduction particularly affected.

Across the Forum, there was a shared sense that civil society space is narrowing and that critical voices are at risk of being marginalised.

As debates around the EU Drugs Strategy continue, EATG will continue to underline the importance of protecting civil society space, restoring harm reduction as a central pillar of drug policy, and ensuring that prevention and treatment genuinely reach the most marginalised, including undocumented migrants. A balanced, public health- and rights-based approach is not an abstract principle; it requires concrete actions, political commitment, and sustained investment.

           Photo: Delegates at the Civil Society Forum on Drugs – December 17, 2025

Source:  https://www.eatg.org/blogs/the-new-eu-drugs-strategy-an-unbalanced-approach-and-the-downgrading-of-harm-reduction/

by Wall Street Journal   The Editorial Board        Dec. 19, 2025

Forwarded by Maggie Petito, DWI – 20 Dec 2025

Rescheduling pot sends the wrong message to vulnerable young brains.

Joe Biden sought to wave away student debt to attract young people. Now President Trump is making a play for the bro vote by relaxing federal regulations on marijuana. Can’t afford to buy a home? Don’t worry, dude. Puff away your economic anxieties in mom and dad’s basement.

Mr. Trump’s move on Thursday to reschedule marijuana runs counter to his Administration’s goals on public health, the economy and culture. Mr. Trump said his order “doesn’t legalize marijuana in any way, shape, or form, and in no way sanctions its use as a recreational drug.”

Yes, and no. Reclassifying marijuana under the Controlled Substances Act doesn’t legalize the drug under federal law. But it does let marijuana sellers deduct expenses from their taxes like other companies. It also sends the signal to young people that marijuana isn’t all that harmful, despite mounting evidence that it is. ***

Marijuana is currently a Schedule I drug, meaning it has “no currently accepted medical use and a high potential for abuse.” Mr. Trump aims to change it to Schedule III—akin to anabolic steroids—indicating that it has some legitimate medical uses and “a moderate to low potential for physical and psychological dependence.”

Yet a recent review of 15 years of research found the evidence of marijuana’s medical benefits to be weak or inconclusive. “The evidence does not support the use of cannabis or cannabinoids at this point for most of the indications that folks are using it for,” said the study’s lead author Michael Hsu.

Far stronger evidence points to its potential harm. Mr. Trump may not realize that weed today is four to five times more potent than in the 1990s. The drug’s dangers and risks of dependency increase with potency. The Centers for Disease Control and Prevention (CDC) estimates that about three in 10 people who use marijuana will develop an addiction.

A study this year found that 40% of car drivers who died in accidents in an Ohio county tested positive for THC, the psychoactive ingredient in marijuana. Marijuana advocates claim weed is no worse than alcohol. They ignore that cannabis has longer-term impact than alcohol, especially among the young.

As the CDC says, “cannabis use directly affects the parts of the brain responsible for memory, learning, attention, decision-making, coordination, emotion, and reaction time.” Medical imaging of adolescent brains shows structural changes in areas involved in impulse control and decision-making.

It can cause psychotic symptoms, especially at higher potency. A bag of cannabis gummies can cause a bad trip for some users. The CDC this summer reported that at least 85 people who frequented a Wisconsin restaurant that had mistakenly used THC-infused oil in pizza dough experienced symptoms of cannabis intoxication. Nearly half of those who got sick suffered paranoia and a quarter hallucinated. The number of cannabis-related incidents reported to poison-control centers has surged 23-fold since 2009, mostly among teens and children.

As we reported last week, young pot users are showing up with rising frequency at emergency rooms with uncontrolled vomiting and psychotic symptoms. One study this year found young users had a sixfold higher risk of heart attacks and fourfold greater of strokes. Yet the same Administration that targets Tylenol—which has proven benefits and minimal risks—now says marijuana is fine.

The cannabis lobby claims rescheduling will allow more research on the drug, but the industry can run trials on marijuana now. It simply has no incentive to do so because it can sell its products in most states without Food and Drug Administration approval. ***

So why ease regulation on pot? Occam’s razor says Mr. Trump wants to shore up support among young voters. On Thursday he volunteered that rescheduling polls well.

Is he sure? Ballot measures to legalize the drug for recreational use failed in South and North Dakota, Arkansas and Florida in recent years. Voters in Maine and Massachusetts have launched referenda campaigns to repeal legalization. Pot smoking is a leading reason employers reject job applicants after drug tests.

We’re not for punishing casual pot smokers. But sending a message to teens and 20-year-olds that marijuana is harmless is a recipe for more damaged brains and human tragedy.

COMMENTARY FOLLOWS ON THE ABOVE WSJ ARTICLE, PUBLISHED IN A VIDEO, FEATURING TWO COMMENTATORS – MS FINLEY AND MS STRASSEL

The Wall Street Journal’s Editorial Board, in today’s edition, astutely notates the contra-indicators of lives under the cloud of marijuana.

“Now President Trump is making a play for the bro vote by relaxing federal regulations on marijuana. Can’t afford to buy a home? Don’t worry, dude. Puff away your economic anxieties in mom and dad’s basement.

Mr. Trump’s move on Thursday to reschedule marijuana runs counter to his Administration’s goals on public health, the economy and culture. Mr. Trump said his order “doesn’t legalize marijuana in any way, shape, or form, and in no way sanctions its use as a recreational drug.”

Yes, and no. Reclassifying marijuana under the Controlled Substances Act doesn’t legalize the drug under federal law. But it does let marijuana sellers deduct expenses from their taxes like other companies. It also sends the signal to young people that marijuana isn’t all that harmful, despite mounting evidence that it is… Mr. Trump may not realize that weed today is four to five times more potent than in the 1990s… So why ease regulation on pot? Occam’s razor says Mr. Trump wants to shore up support among young voters. On Thursday he volunteered that rescheduling polls well. Is he sure? Ballot measures to legalize the drug for recreational use failed in South and North Dakota, Arkansas and Florida in recent years. Voters in Maine and Massachusetts have launched referenda campaigns to repeal legalization. Pot smoking is a leading reason employers reject job applicants after drug tests. We’re not for punishing casual pot smokers. But sending a message to teens and 20-year-olds that marijuana is harmless is a recipe for more damaged brains and human tragedy.”

Ms. Finley states that the new EO benefits the marijuana conglomerates/rackets to be treated as if a bona fide “legitimate” pharmaceutical company….at @ 2:40

She says the EO’s position, as claimed, needs the change to ease research….which she claims as “hooey.”

The “high risk for abuse” and addiction/dependency is a fact of marijuana.

Ms. Strassel notes that Marijuana’s potency is 4 to 5 xx more potent. The psychoactive ingredient of marijuana “soaks into the brain” impacting coordination, memory, reduces impulse control, causes psychotic behaviors…and so on.

Over 17 million Americans use marijuana daily.

The arguments deliver more than enough factors to reconsider the benefits of the new EO on reclassifying marijuana, much of which ignores medical and psychiatric crises as well as public safety.

Ms. Finley claims that marijuana regulation is quite faulty, mostly a `trust but verify’ non-regulatory structure passing off marijuana as an experiment.

I believe this Executive Order was issued based on flawed justifications which could benefit the marijuana and attendant other rackets but not human health. Personally, I do not hold that America’s Veterans are furthered with marijuana addiction.

Ms. Strassel, whose professional track record indicates her preference for President Trump’s on-the-job behaviors, cites Trump’s Oval Office comments as if he is speaking out of both sides of his mouth.

Strassel states that the EO does not alter the standing but “directs.” She claims that many lawsuits will soon follow. Marijuana is a non-FDA approved drug.

MAHA = Make America High Again is now a slogan by some. Strassel notes that the claimed 82% public approval for re-classifying is suspicious with untested public health consequences.

Ms. Strassel claims “sending a message” is underway with recreational drugs exploding. Getting the warnings before the public is missing as public approval for de-classifying proceeds.

SOURCE: www.drugwatch.org

Virus-free.www.avast.com

Opening Statement by DEA Administrator Terrance Cole – December 15, 2025:

DESIGNATING FENTANYL AS A WEAPON OF MASS DESTRUCTION

By the authority vested in me as President by the Constitution and the laws of the United States of America, it is hereby ordered:

Section 1.  Purpose and Policy.  Illicit fentanyl is closer to a chemical weapon than a narcotic.  Two milligrams, an almost undetectable trace amount equivalent to 10 to 15 grains of table salt, constitutes a lethal dose.  Hundreds of thousands of Americans have died from fentanyl overdoses.

The manufacture and distribution of fentanyl, primarily performed by organized criminal networks, threatens our national security and fuels lawlessness in our hemisphere and at our borders.  The production and sale of fentanyl by Foreign Terrorist Organizations and cartels fund these entities’ operations — which include assassinations, terrorist acts, and insurgencies around the world — and allow these entities to erode our domestic security and the well-being of our Nation.  The two cartels that are predominantly responsible for the distribution of fentanyl in the United States engage in armed conflict over territory and to protect their operations, resulting in large-scale violence and death that go beyond the immediate threat of fentanyl itself.  Further, the potential for fentanyl to be weaponized for concentrated, large-scale terror attacks by organized adversaries is a serious threat to the United States.  

As President of the United States, my highest duty is the defense of the country and its citizens.  Accordingly, I hereby designate illicit fentanyl and its core precursor chemicals as Weapons of Mass Destruction (WMD).

Sec. 2.  Implementation.  The heads of relevant executive departments and agencies (agencies) shall take appropriate action to implement this order and eliminate the threat of illicit fentanyl and its core precursor chemicals to the United States.  This includes the following actions:

(a)  the Attorney General shall immediately pursue investigations and prosecutions into fentanyl trafficking, including through criminal charges as appropriate, sentencing enhancements, and sentencing variances;

(b)  the Secretary of State and the Secretary of the Treasury shall pursue appropriate actions against relevant assets and financial institutions in accordance with applicable law for those involved in or supporting the manufacture, distribution, and sale of illicit fentanyl and its core precursor chemicals;

(c)  the Secretary of War and the Attorney General shall determine whether the threats posed by illicit fentanyl and its impact on the United States warrant the provision of resources from the Department of War to the Department of Justice to aid in the enforcement of title 18 of the United States Code, as consistent with 10 U.S.C. 282;

(d)  the Secretary of War, in consultation with the Secretary of Homeland Security, shall update all directives regarding the Armed Forces’ response to chemical incidents in the homeland to include the threat of illicit fentanyl; and

(e)  to ensure the United States uses the full array of appropriate counter-fentanyl tools, the Secretary of Homeland Security, as consistent with applicable law and in coordination with the heads of relevant agencies, as appropriate, shall identify threat networks related to fentanyl smuggling using WMD- and nonproliferation-related threat intelligence to support the full spectrum of counter-fentanyl operations.

Sec. 3.  Definitions.  (a)  “Illicit fentanyl” means fentanyl that is manufactured, distributed, or dispensed, or possessed with intent to manufacture, distribute, or dispense in violation of section 401 and 406 of the Controlled Substances Act (21 U.S.C. 841, 846). 

(b)  “Core precursor chemicals” means the core chemicals that create illicit fentanyl and its analogues, such as Piperidone or other Piperidone-based substances.

Sec. 4.  General Provisions.  (a)  Nothing in this order shall be construed to impair or otherwise affect:

(i)   the authority granted by law to an executive department or agency, or the head thereof; or

(ii)  the functions of the Director of the Office of Management and Budget relating to budgetary, administrative, or legislative proposals.

(b)  This order shall be implemented consistent with applicable law and subject to the availability of appropriations.

(c)  This order is not intended to, and does not, create any right or benefit, substantive or procedural, enforceable at law or in equity by any party against the United States, its departments, agencies, or entities, its officers, employees, or agents, or any other person.

(d)  The costs for publication of this order shall be borne by the Department of Justice.

                              DONALD J. TRUMP

THE WHITE HOUSE,

    December 15, 2025.

Source: https://www.dea.gov/documents/2025/2025-12/2025-12-15/fentanyl-designated-weapon-mass-destruction

Kevin Sabet’s message is getting through. Credit: Getty
by Sohrab Ahmari – US editor of UnHerd  – 29 Nov 2025 

In June 2014, Maureen Dowd published a column that has since acquired legendary status in drug-policy circles. In it, the New York Times writer recounted her experience trying a marijuana candy bar on a visit to Denver not long after Colorado legalized pot. After a calm first hour, the drug plunged her into a personal hell: panting, shudders, confusion, deep paranoia. Eventually: “I became convinced that I had died, and no one was telling me.”
Social media gently mocked Dowd when her column first appeared: silly Boomer, she didn’t dose it right — couldn’t handle the ride. Momentum for legalization was gathering back then, driven by the anti-antidrug Left, the free-market Right, and lobbyists and entrepreneurs who could just hear the cha-ching sounding from the next big vice industry. Twenty-three states plus the District of Columbia would follow in Colorado’s footsteps in the decade that followed.
The picture of weed shared by many older Americans, drawn from their own college years, helped ease the path of legalization. Weed, the mellow drug. The Cheech-and-Chong drug. The Grateful-Dead-road-trip drug. The munchies drug. The drug that, if anything, makes you overly cautious behind the wheel. Dowd thought of marijuana along similar lines — that is, until she tried the legalized stuff for herself and nearly lost her ever-loving mind. 
Since then, weed potency has only intensified, with some concentrates reaching near-pure levels of THC, the plant’s primary psychoactive compound. Only now are policy makers and opinion elites reckoning with what Big Weed has wrought: “turning a drug that used to be 5% THC, and made people pass out for a few hours and eat Cheetos, into one that triggers psycho killers,” as Kevin Sabet, a former drug adviser in successive Democratic and GOP administrations, tells me.
Sabet admits that such talk can make him sound like Reefer Madness, the classic anti-weed propaganda film from 1936. “But if you look at almost every single mass shooting in this country, there are many common denominators, and one of them is a substance. And it’s not alcohol, and it’s not meth, and it’s not fentanyl. So you can guess what it is. It’s marijuana.”  
Take Robert Westman, the 23-year-old who murdered two children and wounded 30 people in a gun rampage at a Minnesota Catholic school in August. In his diaries, Westman, who both used weed and worked at a dispensary, blamed the drug for his violent tendencies. “Gender and weed fucked up my head,” he wrote. “I wish I never tried experimenting with either. Don’t let your kids smoke weed or change gender until they are, like, 17.” 
A 2025 study, published in the East Asian Archives of Psychiatry, found a definite and growing link between US mass-shooting perpetrators and the use, possession, and distribution of cannabis. Moreover, the researchers found that younger mass killers are more likely to be involved with marijuana. They concluded that the drug is particularly harmful to “subgroups of individuals” prone to such violent eruptions.
Even if they don’t go full Columbine, young people who regularly use today’s high-potency varieties are at elevated risk for psychosis, per a 2019 study published in Lancet Psychiatry. King’s College London, home to the lead author, sums up the grim finding: “In cities where high-potency cannabis is widely available, such as London and Amsterdam, . . . a significant proportion of new cases of psychosis are associated with daily cannabis use.”
Things have gotten so bad that The Guardian, which once pooh-poohed concerns about weed, now regularly runs warnings about its adverse effects on health (it doubles the risk of heart death, to mention just one recent finding). Most recently, the paper took readers inside a pioneering London clinic specially dedicated to addressing cannabis psychosis. It’s a crisis that goes far beyond a typical “bad trip,” shattering minds and leading many users to take their own lives.
“We are dealing with a fundamentally different drug,” says Sabet, “that has been genetically modified and bred by a powerful industry that we are now sanctioning and encouraging, and allowing to contribute to inaugurations.. . . The fact that we are allowing this, to me, that’s immoral.” Despite bipartisan opposition from a pro-weed lobby led by the likes of John Boehner, the former Republican House speaker, Sabet’s calls for limits have begun to break through.
Most notably, Sabet has led the campaign urging President Trump not to remove marijuana from Schedule I, the most serious category in the federal government’s scheme for classifying drugs. As he wrote in a widely read UnHerd essay, reclassification wouldn’t mean federal legalization. But it would grant the drug a false federal “imprimatur of being safer,” thus allowing Big Weed to enjoy tax deductions from which they are currently barred. 
So far, Sabet’s campaign seems to have stayed Trump’s hand, even as the president has floated the idea of Medicaid coverage of marijuana products as a stress and pain balm for seniors. “This [reclassification] isn’t a priority for the president,” Sabet tells me. “But on the other hand, there are some lobbyists and maybe friends of his son-in-law and others in the business” who would benefit from rescheduling and its associated tax benefits, meaning Sabet’s work is far from over.
Kevin Sabet came to the drug problem from an unusual personal angle. Born in the Midwest to a Bahai family that left Iran before the 1979 Islamic Revolution, he remembers a childhood in which he didn’t know anyone who so much as drank. (The Bahai religion, which is persecuted by Iran’s ruling Islamists, preaches the unity of all faiths — and total abstinence). When he moved to Orange County as a teenager, his perspective was radically different from that of his peers. And what he saw of addiction encouraged him to fight it. 
As an undergrad at the University of California, Berkeley, in the mid-’90s, he says, “I saw the influence of the [drug] culture. I saw marijuana shops before that was even a thing.” Then the rave culture arrived, giving rise to what he describes as a “mini-epidemic” associated with the hallucinogen ecstasy, also known as MDMA. As a student, he’d go to clubs and hand out postcards showing scans of drug-addled brains on one side, and a call-for-help number on the other.
His activism won him some attention in the press — and then a phone call from Barry McCaffrey, the retired US Army general then serving as President Bill Clinton’s drug czar. “I thought the call was fake,” Sabet recalls. But it wasn’t. Gen. McCaffrey was offering him a job as a speechwriter. Sabet accepted and moved to Washington before heading to Oxford to earn a master’s degree in social policy.
“Weed potency has only intensified, with some concentrates reaching near-pure levels of THC.” 
After 9/11, many of Sabet’s friends went off to Afghanistan in defense of the homeland, and he felt guilty writing papers at “Oxford, of all places, a comfortable place.” As it happens, the White House called again — this time, the George W. Bush administration with an offer to hire him as a senior speech writer on drug policy. “ ‘We want you to serve your country,’ ” he remembers the caller saying. “ ‘We know you’re not a Republican, but we also know you’re not a Democrat, and that’s fine with us.’ ” (His politics, as far as I can tell, are: whatever will stop this scourge.)
Yet another White House stint came during the Obama administration, which tapped him as senior drug-policy adviser (by then he’d finished his master’s and a doctorate at Oxford). It was around that time, the 2010s, that marijuana legalization went from a pothead’s dream to a serious business and political enterprise. Weed, the legalizers said, is harmless. Sabet disagreed, and he published a book, Reefer Sanity, to push back against the complacent mythology.
The book, in turn, led to his founding of a restrictionist advocacy group, Smart Approaches to Marijuana, or SAM, today the most visible drug-policy organization in Washington (a telling indicator of the growing concern about Big Weed).
But why the focus on marijuana? Why not the likes of fentanyl or heroin? Marijuana, Sabet answers, “is the most dangerous drug in my mind because it’s the most misunderstood.” There was a time when one could “experiment” with pot as part of the transition to adult responsibility and success. “The marijuana of today is doing the opposite,” he says, potentially derailing a person for life. “It’s causing violence, it’s causing erratic people to lose any sense of reality.”
And it’s addictive, a truth that Americans are still reluctant to accept. Sabet recalls speaking to a large group about the addiction angle, only for a member of the audience to tell him during the Q&A portion: “I use it every day, Kevin, and I’m qualified to tell you it’s not addictive.” 
The numbers say otherwise. As the Associated Press reported on Tuesday, regular use of marijuana has now outpaced drinking, with 18 million Americans reporting daily use, up from fewer than 1 million in the 1990s. In tandem, there has been an explosion in diagnoses of cannabis-use disorder — an insatiable craving for the drug that leaves people incapable of fulfilling ordinary responsibilities; 1 in 3 pot users suffers from it, with symptoms classified from mild to severe.
But aren’t alcohol and tobacco just as destructive? Why not call for a new Prohibition and extend it to cigarettes for good measure? 
“The reason I would say that Prohibition wasn’t sustainable as a policy in America is because alcohol has been so ingrained in Western civilization, since before the time of the Old Testament.” Then, too, alcohol is associated with human sociality, and for most people, the substance and its effects leave the body after 24 hours. Not so with weed, which lingers for much longer and at a cellular level. Sabet thus dismisses the argument that we shouldn’t restrict marijuana until alcohol is under control: “That’s like saying my headlights are broken, and just to be consistent, I’m going to break my tail lights, too.”
As for smoking: “Ninety percent of the people who built the Brooklyn Bridge were smokers. They were smoking at the time they built the Brooklyn Bridge. They could function. Maybe it even made them concentrate better,” Sabet says. The cigarette — unlike tobacco itself — “is a relatively new invention.” 
Lung-cancer deaths before the 1920s were almost unheard of. Only with the rise of a cigarette industry did the smoking crisis appear. And that, he says, is also what’s happening with legalized, industrial weed, a product hawked by growers chasing ever higher THC yields — mental health be damned. Moreover, as cigarette smoking rates decline, Big Tobacco is looking to enter the weed market, Sabet says.
So what to do now, beyond restriction (a cause that’s already lost in half of US states)? At the root of the drug crisis, Sabet thinks, is a “moral and spiritual breakdown.” Drugs, he suggests, offer too-easy answers to the search for meaning; or else they palliate the pain associated with modern life. Even so, Western societies can erect guardrails, for example by hindering the spread of weed advertising to ever-younger audiences. 
As for those already trapped, Sabet sees a role for behavioral incentive systems, such as programs that offer cash rewards for addicts who don’t use — or ones in which they face a choice between doing time or going to rehab. 
“I’m calling for a new effort on drugs,” he says, aware of the odium attached to the War on Drugs. “I don’t love the war analogy because wars have defined ends, or they should. And this will never stop. We will never stop having to stop drug use among young generations. . . . I embrace aiming for a drug-free society, even if it’s not possible. We’ve never had a violence-free society, but that doesn’t mean that we don’t want to aim for that.” 
Source : https://archive.is/DrvMY#selection-480.0-487.55

by Jared Culligan – Program Manager, Safety –

From 2019 to 2023, the National Highway Traffic Safety Administration (NHTSA) recorded more than 4,931 deaths in drunk driving traffic crashes during the month of December. In addition, a study by NHTSA found more than 54% of injured drivers had some amount of alcohol or drugs in their system at the time of the incident.

While this month focuses primarily on reducing impaired driving on the road, it’s also crucial to extend this conversation to safety in the workplace and how drunk and drug impaired driving can impact the construction industry.

What can your organization do to prevent drunk and drug impaired driving incidents?

  • Perform random and post-incident drug testing and have a recovery-ready workplace to engage and support employees in stopping substance misuse whenever possible.
  • Provide education and training materials on the effects of certain substances.

NAHB has several Video Toolbox Talks, available in English and Spanish, that cover drunk and drug impaired driving and its underlying causes. Please be sure to check out our content and help spread awareness as we approach the holidays:

In addition, several government establishments are promoting materials during this time of year. Check out their available resources here:

If you know of anybody that needs immediate help, please reach out to the 988 Suicide and Crisis Lifeline or SAMHSA’s National Helpline, 1-800-662-HELP (4357).

by Erin E. Bonar, Ph.D et al. – News Release Michigan Medicine – University of Michigan

Among people over 50 who use cannabis, those most likely to drive after partaking are men, people who use daily, and those who use THC-containing products for mental health reasons

With cannabis-related vehicle crashes on the rise, a new study suggests that prevention campaigns shouldn’t focus just on young people.

In fact, 20% of people over 50 who use cannabis products reported that at least once in the past year, they had driven within two hours of using the drug.

That means they likely got on the road while the THC in cannabis still impaired their reaction times, attention and other abilities that are important to driving safely.

The findings, from a University of Michigan team led by addiction psychologist Erin E. Bonar, Ph.D., are published in the journal Drug and Alcohol Dependence. The data behind the study come from the National Poll on Healthy Aging, based at the U-M Institute for Healthcare Policy and Innovation.

Bonar and the poll team published an initial analysis in late 2024, but the new paper dives deeper into the data.

“So much of the effort to reduce ‘driving while high’ through awareness campaigns has focused on young people, but our findings show this is a cross-generational issue,” said Bonar, a professor of psychiatry at the U-M Medical School. “Targeting messages at those middle age and older adults with the highest risk of post-use driving could also include message about the options for addressing the health issues that they may be trying to self-treat with cannabis.”

Those most likely to drive after using cannabis

Adults age 50 and over who use cannabis products daily or nearly daily were three times as likely to say they had driven soon after using, compared with those who only use cannabis rarely, the study finds.

Those who use cannabis for mental health reasons were twice as likely to say they’d driven after using it, compared with those who didn’t list mental health among their reasons for choosing to use cannabis.

And men over 50 who use cannabis were 72% more likely to drive after using THC-containing products, compared with women in the same age group who use cannabis.

In all, the poll showed that 21% of people age 50 and up had used a cannabis product at least once in the last year, including 27% of those aged 50 to 64 and 17% of those aged 65 and up.

Of the 729 respondents over 50 who said they had used cannabis in the past year, 27% said they use it daily or almost daily, while 43% had used it only once or twice. The rest were divided between those who use monthly (14%) and weekly (16%).

Beyond the riskiest groups

While the study results suggest some groups of people over 50 who could especially benefit from targeted preventive messaging about the risks of driving after using cannabis, broad-based messaging appears to be needed, Bonar says.

In all, 65% of the people in the survey who said they use cannabis were between the ages of 50 and 64, with the rest over 65. But there was no difference between the age groups in likelihood of post-cannabis-use driving.

There were also no differences in post-use driving by age, race, ethnicity, income, history of loneliness, or caregiver status.

Those who live in states where recreational cannabis has been legalized were no more likely to drive after using the drug than those living in other states.

In addition to mental health, the poll asked about other reasons that adults over 50 might use cannabis, including several related to health. In all, 52% of people over 50 who use cannabis cited a mental health or mood-related motive for using cannabis, and 67% cited a sleep-related motive.

There was no difference in whether participants drove after cannabis use based on using it for pain, other medical reasons or sleep-related reasons, once the researchers adjusted the data. However, there was some signal that those who use it for sleep reasons may be more likely to drive after using.

This suggests a need to help adults age 50 and up understand that there are options for treating these conditions that have much more evidence behind them than cannabis, said Bonar. It also highlights the need for more robust research on which health conditions cannabis might address most effectively.

Age-specific messaging

Bonar and her co-authors also note that driving guidelines for people over age 50 who choose to use cannabis should also consider the effects of aging on cognitive and motor abilities, and the potential for interactions between cannabis and the prescription drugs that these adults are more likely to take.  

Helping adults over 50 who choose to use cannabis understand the potential impacts of today’s more potent cannabis, compared with the forms available in their younger years, is also important, says Bonar.

And when advising people over 50 about reducing driving risks related to their cannabis use, she said, health care providers and public health agencies may want to focus on strategies like using cannabis at times when they’re unlikely to need to drive, such as before bedtime, and the importance of planning ahead for safe transportation via a designated driver or ride share service.

Bonar is a member of IHPI and of the U-M Addiction Center, the U-M Injury Prevention Center and the U-M Eisenberg Family Depression Center.

In addition to the new paper on cannabis use and driving among people over 50, the National Poll on Healthy Aging recently issued a report on driving behaviors among people age 65 and over. Find it at https://michmed.org/w4Ayn

Bonar and colleagues also recently published an Injury Prevention Center report on the impact of recreational cannabis legalization in Michigan, including data on motor vehicle crashes and fatalities linked to cannabis.

In addition to Bonar, the study’s authors are Lianlian Lei, Matthias Kirch, Kristen P. Hassett, Erica Solway, Dianne C. Singer, Sydney N. Strunk, J. Scott Roberts, Preeti N. Malani, and NPHA director Jeffrey T. Kullgren.

Citation: Driving after cannabis consumption among US adults ages 50 years and older: A short communication, Drug and Alcohol Dependence, DOI:10.1016/j.drugalcdep.2025.112985, https://authors.elsevier.com/a/1mCG51LiD3LPLZ

Source: https://www.eurekalert.org/news-releases/1109142

News Article by US News ReporterDec 01, 2025

There is “insufficient” evidence supporting the use of cannabis or cannabinoids for most medical purposes, a new review has concluded.

“We reviewed the totality of the evidence—over a thousand studies with emphasis on randomized trials, meta-analyses, and systematic reviews,” Dr Kevin Hill, one of the review authors, and director of addiction psychiatry at Beth Israel Deaconess Medical Center, and a professor of psychiatry at Harvard University, told Newsweek.

He said that “beyond the FDA-approved indications, the evidence for cannabis and cannabinoids as a medical treatment is limited.”

The review was published online in the peer-reviewed medical journal JAMA Network on November 26.

Why It Matters

There has been increasing use of cannabis and cannabinoids for medical treatment in recent years. It has gained popularity among cancer patients, for managing nausea, pain and reduced appetite, and it is favored among patients with chronic pain for its analgesic properties.

However, its use medically has gathered some concern, as while certain patients may experience benefits, some medical professionals have said that there is not enough research to determine if the positives outweigh any future negatives.

After the Senate passed its funding package to end the U.S. government shutdown, which included a measure that will lead to the banning of many THC products, the issue of cannabis use has been in the spotlight.

What The Review Found

The review found that 27 percent of adults from the U.S. and Canada have used cannabis for medical purposes, while 10.5 percent of Americans report using cannabidiol (CBD) for therapeutic purposes.

“Cannabis and cannabinoids like CBD have a broad range of effects, so, with so many people suffering from medical problems, it is not hard to see why they might consider cannabis and cannabinoids as treatments,” Hill said.

However, he said that “the evidence is not strong” for their use medically.

While doctors may “consider cannabis and cannabinoids as third-line treatments in various clinical scenarios,” Hill said, “the lack of evidence coupled with significant risks means that, most often, the risks outweigh the benefits.”

The review found that almost a third of adult users of medical cannabis go on to develop a cannabis use disorder—a complex condition that is a type of substance use disorder, where a patient can experience a problematic pattern of cannabis use that causes them distress or impairs their life.

It also found that daily inhaled cannabis use compared to nondaily use was associated with higher risks of coronary heart disease, heart attack, and stroke,

“The adverse effects of cannabis upon one’s physical health are becoming more well-defined,” Hill said.

He said that the purpose of this review was to provide clinicians and patients with “better information with which to have sensible, evidence-based conversations,” conversations about medical treatment which he said should take place between doctors and patients, and “not between budtenders and customers in dispensaries.”

What Other Experts Think

Jonathan Caulkins, a professor of operations research and public policy at Carnegie Mellon University, who was not involved in the review, told Newsweek that while there is “high-quality evidence supporting certain very specific medical uses,” most medical use is “predicated on much less evidentiary basis, and below what is expected for FDA approval.”

He said that what is “important” about this review is that it helps “counter the messaging from cannabis treatment advocates, who promote the good news, and the hopes, without balance or caution.”

“The actual situation is nuanced, and more gets written that pushes for an overly optimistic view of cannabis’ medical value,” he said.

Yasmin Hurd, chair of translational neuroscience and the director of the Addiction Institute at Mount Sinai, also told Newsweek that the findings are “notable” because it “confirms what has been previously published from other reviews and consensus reports like those from the National Academies, noting that there is insufficient evidence for the use of cannabis to treat most medical conditions.”

While the authors have “done a very comprehensive and in my view very useful review of this topic,” Dr Igor Grant, a professor of psychiatry and director of the HIV Neurobehavioral Research Program and Center for Medicinal Cannabis Research, at the University of California, San Diego, told Newsweek, “it is clear from the way the article is written that the authors have significant concerns about the use of medicinal cannabis, and as such have tended to emphasize many of the negatives, including potential side effects.”

He said that this “does not mean that the side effects are not there, nor does it negate the fact that evidence for efficacy of medicinal cannabis is weak in many areas. But there does seem to be a definite slant.”

He also said that while this review highlights cardiovascular risks, other research has also shown there is “actually no statistically reliable evidence to suggest that cannabis users suffer more cardiovascular risk, including no effect on hypertension, myocardial infarction, and presence of coronary atherosclerosis.”

What People Are Saying

Caulkins told Newsweek: “We customarily expect medicinal drugs to be produced in a way that guarantees consistency from dose to dose. Every pill in a bottle of pills that is prescribed by a physician, manufactured by a pharmaceutical company and distributed by a licensed pharmacy should have essentially the exact same dose. With the exception of the FDA-approved and regulated cannabinoids (which account for a tiny share of all consumption that is described or understood to be “medical cannabis”), there is not that same quality control for medical cannabis.”

He added: “Cannabis smoke contains known carcinogens. Sometimes good medical practice exposes patients to carcinogenic risk, notably radiation treatment does. But we do that carefully and knowingly, because the risk of untreated cancer is greater than the risk that radiation therapy will create new cancer. But given that in many cases the upside benefit of medical cannabis is not well established, it is striking how cavalier the system is with respect to known carcinogens present in cannabis smoke. For most categories of consumer products, the presence of known carcinogens is sufficient to have that product taken off the shelves, even if there are not epidemiological studies documenting effects on cancer rates at the population level. For whatever reason or reasons, we collectively seem surprisingly unconcerned about that risk regarding smoked cannabis, medical or non-medical.”

Hurd told Newsweek: “There remain numerous concerns about cannabis for medical use since there is so little known about whether it works, what particular conditions it might be helpful to treat and what dose and dosing regime for clinicians to recommend. In addition, there are also concerns that individuals will use ‘medicinal cannabis’ obtained from sources where the contents are not verified and cannabis with high THC concentration has well known significant side effects. Cannabis should be used with caution in medical settings. As such, like many medicines, especially where there is very limited information available, it is best to start low dose and go slow. Also, cannabis should not be the first line therapy and instead used only for conditions where conventional therapies have failed.”

She added: “It is important that the public also begins to better understand that cannabis is a very complex plant with hundreds of chemicals whereas ‘medicine’ is normally a product that has specific, well studied components. Also, cannabis is different from specific cannabinoids, like cannabidiol (CBD), which has FDA approval for the treatment of certain epilepsy conditions.”

Grant told Newsweek: “While I agree that physicians who are counseling patients about potential use of cannabis for various indications need to both warn patients about lack of evidence in many cases, the possibility of side effects, and certainly evaluate a patient in the event they have major psychiatric or substance use disorder, there are, as they note protocols for doing this, and in some ways, assuring safety. I believe also that the risk of people who use medicinal cannabis, who are often people who are older with various kinds of chronic conditions, is rather low that they will systematically increase their use to the point of developing a cannabis use disorder. Cannabis use disorder is real, and a concern, but very unlikely to be a problem in the clinical setting. The article tends at times to conflate recreational and medicinal use: that’s a bit like using data from opioid addiction to comment on appropriate use of opioids in a clinical setting.”

Source: https://www.newsweek.com/does-cannabis-actually-have-medical-benefits-11118810

December 03, 2025

|

Houston –The U.S. Drug Enforcement Administration is intensifying its fight against the deadly threat of synthetic opioids with the launch of Fentanyl Free America, a comprehensive enforcement initiative and public awareness campaign aimed at reducing both the supply and demand for fentanyl. This effort underscores DEA’s unwavering commitment to protecting American lives and communities from the devastating impacts of fentanyl, which claimed nearly 50,000 lives last year according to the Centers for Disease Control and Prevention (CDC). 

Through intensified enforcement operations and heightened intelligence, DEA is applying unprecedented pressure on the global fentanyl supply chain, forcing narco-terrorists, like the Sinaloa Cartel and CJNG Cartel, to change their business practices. This has led to encouraging signs of progress. DEA laboratory testing indicates 29% of fentanyl pills analyzed during fiscal year (FY) 2025 contained a potentially lethal dose, a significant drop from 76% of pills tested just two years prior in FY 2023. Additionally, fentanyl powder purity decreased to 10.3%, down from 19.5% during the same time period. These reductions in potency and purity correlate with a decline in synthetic opioid deaths to levels not seen since April 2020. 

As of December 1, 2025, DEA has seized more than 45 million fentanyl pills, and more than 9,320 pounds of fentanyl powder, removing an estimated 347 million potentially deadly doses of fentanyl from our communities. DEA intelligence indicates a shift in cartel operations, with increased trafficking of fentanyl powder and domestic production of fentanyl pills. The seizure of more than two dozen pill press machines in October further highlights this trend.

The DEA Houston Field Division was one of 23 domestic field divisions and seven foreign divisions that initiated Operation Fentanyl Free America in October. During a period of a month, this targeted enforcement effort resulted in the seizure of:

  • 350 Counterfeit pills 

    • which is equivalent to 103 deadly doses 

  • 149 pounds fentanyl powder

  • 3154 pounds methamphetamine

  • 30 pounds of cocaine

  • 36 firearms

  • $249,285 U.S. currency

“Operation Fentanyl Free America seizures in October highlighted the ongoing threat of fentanyl. Despite the steady decline in overdoses in most of the South Texas,” said Special Agent in Charge of the Houston Field Division Jonathan C. Pullen. Fentanyl is still an imminent threat, and we can’t afford to look the other way. We will continue to get this poison off the streets, ensuring safer communities for generations to come” 

The threat of poly-drug organizations; cartels that traffic a portfolio of drugs opposed to a single substance became even more apparent during Operation Fentanyl Free America.  Aside from producing less potent fentanyl, the cartels have increasingly diversified their operations in an attempt to minimize their risks and maximize profits, an evolution driven by opportunity and greed.

DEA remains at the forefront of the fight to disrupt trafficking networks and strengthen the government’s response to this epidemic.  Fentanyl Free America represents DEA’s heightened focus on enforcement, education, public awareness, and strategic partnerships. The goal of the campaign is clear: eliminate the fentanyl supply fueling the nation’s deadliest drug crisis. Since 2021, synthetic opioids have claimed nearly 325,000 American lives. 

The Fentanyl Free America campaign also emphasizes the importance of public engagement.  DEA encourages everyone from community leaders, clergy, educators, parents, physicians, pharmacists, and law enforcement to take an active role in raising awareness by protecting others through education; preventing fentanyl poisonings by understanding the dangers; and supporting those impacted.  Free resources including posters, radio advertising, billboards, and social media resources are available at dea.gov/fentanylfree.  

DEA’s efforts are part of a larger whole-of-government strategy to dismantle transnational criminal organizations and protect U.S. communities from fentanyl.  

SOURCE: https://www.dea.gov/press-releases/2025/12/03/dea-launches-fentanyl-free-america-initiative-combat-synthetic-drug-3

HRH has good intentions, but her view is dehumanising and damaging

The Princess of Wales has called for an end to the ‘stigma’ of addiction 
Credit:Paul Grover/Daily Telegraph/PA Wire/PA Images

The Princess of Wales is patron of The Forward Trust, a charity devoted to assisting addicts to remain abstinent from their drug of addiction. She has just spoken out forcefully against the view that addiction is weakness of will or any kind of moral problem.

“Addiction is not a choice or a personal failing,” she said, implying thereby that it was a medical condition like any other, such as Parkinson’s disease or multiple sclerosis. She said that “people’s experience of addiction in still shaped by fear, shame and judgment, and that this ought to change”.

I am sure that HRH meant well, and that she feels genuine sympathy for addicts; but unfortunately, her view is simple, unsophisticated, dehumanising and empirically false.

It is dehumanising because, by denying that addiction is a choice, it deprives addicts of their agency both in theory and to a certain extent in practice. If, after all, you persuade someone that he does not make a choice in doing something, you also persuade him that choice cannot prevent him from doing it. He is not a human being like you and me, but a helpless feather on the wind of circumstance.

This turns him into an object, not a subject, both to himself and others. Such a view is implicitly degrading, demeaning and far from compassionate. It implies the need for an apparatus of care to look after him, much as one would look after an animal in a menagerie, with kindness but not with much respect.

Take the case of the injecting heroin addict and think what he has to do and learn to become such an addict. He has to learn where to obtain heroin and how to prepare it. He has to learn to disregard its unpleasant side effects. He has to overcome a natural aversion to pushing a needle into himself. This is not something that just happens to him.

Moreover, not only do most addicts take the drug for some time before becoming physically addicted to it, but they are fully aware in advance of the consequences of taking the drug long-term. Addicts are not “hooked” by heroin, as they often put it; rather, they hook heroin.

It is untrue that addicts require a professional apparatus to overcome their addiction. Millions of people have given up smoking, though nicotine is addictive. During the Vietnam War, thousands of American soldiers addicted themselves to heroin and gave up, with almost no assistance, one they returned home.

In 1980, Porter and Jick pointed out that people treated with strong painkillers as in-patients in hospital did not go on to become addicts once they left hospital. This was unfortunately interpreted to mean that such drugs were not addictive; but, on the contrary, it shows that addiction, in the sense of continuing addictive behaviour, is not straightforwardly a physiological condition.

At the root of the Princess’s misapprehension is the post-religious or secular view that if a person is the author of his own downfall, he is due no sympathy or compassion. It is a highly puritanical view, and since we do not want to be puritans, we make the problem a medical one instead. But since we are all sinners and the authors of our own downfall, at least in some respect or other, this also has the corollary that sympathy or compassion is due to no one when he needs it.

The Princess appears to think that if you say to an addict that he has behaved, and continues to behave, foolishly and badly, you are necessarily saying to him, “Go away, darken my doors no more”. She seems to think that the truth, far from setting people free, will imprison them until someone comes along with a technical key to unlock them.

Of course, some addicts benefit from assistance, but not for the reasons the Princess supposes. Medication may reduce their physical sufferings, and if we take once more the example of injecting heroin addicts, we discover that they may well have so destroyed their relations with everyone – their families and friends – that there is no one to whom to turn if they desire to change their ways. They thus need a helping hand, but this is not the same as removing fear or stigma (a very necessary, though not sufficient, aid to civilised life). Though she did not mean them to be so, the Princess’s words were not so much demoralising, as amoralising.

Source: https://www.telegraph.co.uk/gift/51db8fdbd5d80cb6

Filed under: Strategy and Policy,UK :

  • Emerging drugs, which include designer drugs and new psychoactive substances, are substances that have appeared or become more popular in the drug market in recent years.
  • Emerging drugs have unpredictable health effects. They may be as powerful or more powerful than existing drugs, and may be fatal.
  • Because drug markets change quickly, NIDA supports the National Drug Early Warning System (NDEWS), which tracks emerging substances. NIDA also advances the science on emerging drugs by supporting research on their use and on their health effects.

Source: https://nida.nih.gov/research-topics/emerging-drug-trends

 

The European Union Drugs Agency (EUDA) today launched the new EUDA Health and Security Threat Assessment System (ETAS), designed to strengthen Europe’s preparedness for serious and emerging drug-related threats and to support coordinated responses. Foreseen under the EUDA regulation, the service was unveiled at the meeting of the Heads of Reitox national focal points (NFPs), taking place this week in Lisbon, bringing together representatives from across Europe.

ETAS will help EU Member States identify, assess and respond to drug-related health and security threats linked to drug markets, illicit substances and changing patterns of use. The system provides structured, evidence-based assessments to support timely decisions on mitigation, early preparedness and strategic responses at national and EU level.

As a core component of the EUDA’s wider preparedness framework, ETAS operates in close coordination with the European Drug Alert System (EDAS), the EU Early Warning System on new psychoactive substances and the Network of forensic and toxicological laboratories. Together, these services combine early warning, rapid alerts and in-depth assessments, reinforcing Europe’s capacity to detect and respond to fast-evolving drug-related risks.

Threat assessments can be triggered by requests from an EU Member State or the European Commission or when signals from the EUDA’s monitoring, alert and early warning systems indicate that a coordinated response may be needed. Member State requests are submitted via the EUDA Management Board member or through the national focal point. The NFPs act as key contact points for ETAS and contribute throughout the assessment process.

Drawing on data from health, law enforcement and laboratory sources, as well as expert input from national authorities, ETAS delivers practical options for action, tailored to different threats.

The first assessments under the new system are focusing on highly potent synthetic opioids and the availability and harms of crack cocaine in the EU. These are being carried out in close cooperation with the countries concerned. A pilot threat assessment, published in June 2025, examined the evolving presence and impact of highly potent synthetic opioids (particularly ‘nitazenes’ and carfentanil) in the Baltic States.

These early cases illustrate how the new system will support Member States and EU institutions in turning evidence into concrete measures on the ground, contributing to a safer and more resilient Europe.

EUDA and national focal points discuss new partnership framework

A central issue at this week’s meeting is the ‘Reitox Alliance’, a new partnership framework between the EUDA and the NFPs. Building on decades of shared experience, the alliance aims to strengthen cooperation, enhance preparedness and ensure a coordinated European response to emerging drug-related challenges.

The new operating framework, set for adoption by the Management Board next month, will replace the previous Reitox operating framework, functioning since 2003. The alliance aligns the network’s activities with the EUDA’s updated mandate and promotes mutual support, capacity building and innovation among Member States.

The meeting will also focus on policy and institutional updates, scientific projects, national reporting, communication activities and planning for 2026. Topics include cannabis policy, prisons and international cooperation.

This is the last Reitox meeting under the current Executive Director, Alexis Goosdeel whose mandate ends on 31 December this year. Speaking at the event, Mr Goosdeel said: ‘The new Reitox Alliance will mark a significant step forward in how we work together as a European network, and will give us a stronger, more coordinated platform for tackling the complex drug challenges we face. ETAS is just one example of how this renewed partnership can translate shared expertise into concrete, operational services that help Member States anticipate threats and act quickly. As I conclude my mandate, I am proud of what we have achieved together and confident that this enhanced cooperation will support Europe’s preparedness for years to come.’

Source: https://www.euda.europa.eu/news/2025/new-threat-assessment-system-launched-strengthen-eu-response-drug-related-threats_en

 

exp-customer-logo  TAMPA BAY TIMES
OPINION PIECE :

Patrik Ward is an economics student and member of the Adam Smith Society at the University of Tampa.

Abigail R. Hall is a senior fellow at the Independent Institute in Oakland, Calif., and an associate professor of economics at the University of Tampa.

What looks like an anti-drug measure may, in practice, be a show of power.
The recent U.S. strikes on alleged Venezuelan drug-traffickers in the Caribbean were framed as a necessary measure against transnational crime. Beyond their questionable legality, these measures risk deepening the very markets they seek to destroy. In attempting to sink traffickers at sea, the U.S. may have buoyed the economics of the drug trade.

In late October, U.S. naval forces carried out multiple strikes against vessels in the Caribbean suspected of transporting drugs linked to Venezuelan criminal networks. According to U.S. officials, the strikes sought to disrupt smuggling routes and weaken cartels. Venezuelan officials condemned the attacks as a violation of sovereignty.

Although U.S. leaders defended them as part of a broader campaign against narcotics trafficking, the timing and targets suggest a broader strategic move. Venezuela’s government remains deeply corrupt and internationally isolated, making it an easy symbol for demonstrating U.S. strength in the region. What looks like an anti-drug measure may, in practice, be a show of power—a bid to assert influence and signal strength, rather than a coordinated effort to reduce trafficking.

On a baseline level, a tougher stance on trafficking sounds like a beneficial policy. If the United States government raises the “punishment” for trafficking (i.e., killing traffickers on the open sea), smugglers may reconsider their choice.

However, illicit markets don’t mirror textbook logic. They adapt. By raising the risks, these strikes may have also raised the rewards, inflating prices, shifting routes and enriching the most dangerous agents.

This dynamic, common in financial markets, is often referred to as the “risk premium” — higher expected punishment leads traffickers to demand higher prices to compensate for the danger.

In the short run, some suppliers in the drug trade may exit the market. But those who stay are those most willing to take extreme risks or who already have the means to absorb them. In this case, cartels with deep pockets and little concern for collateral damage. Enforcement ends up selecting the most violent, not the most vulnerable.

As enforcement intensifies in one region, illegal activity doesn’t disappear — it relocates. This “balloon effect” means that squeezing the supposed drug trade in Venezuelan waters may simply push it toward alternative routes through Central America, the Caribbean or the West Coast. This doesn’t reduce the flow of drugs, but the geography of violence and corruption shifts, destabilizing communities far from the original target.

The economic effects don’t end there. As risk and costs climb, drug producers face incentives to cut corners and stretch profits by diluting drug purity. This generally takes the form of mixing cheaper — and often deadlier — additives like fentanyl. What begins as a “security measure abroad” can quickly spiral into a public-health crisis at home as domestic demand persists, and drug supply grows more potent and unpredictable.

These mechanisms reveal that when policy targets symptoms rather than the underlying causes or incentives, markets evolve faster than enforcement can adapt. The United States has spent decades trying to outgun an industry whose demand base is resilient and concentrated domestically. The real question isn’t whether to combat trafficking — it’s how. Every dollar spent on maritime strikes is a dollar not spent on reducing domestic demand, expanding treatment capacity or fostering economic alternatives in producer countries.

So, what can we do differently?

If the goal is to weaken trafficking networks, policymakers would do better to strike the cartels economically, not their boats. Forty years of interdictions — from the Caribbean to Plan Colombia — show that cutting supply routes rarely cuts supply. Research suggests that every dollar spent on treatment and prevention reduces drug consumption up to five times more than enforcement and interdiction spending.

Real deterrence starts at home. Expanding access to treatment, addressing poverty and mental health crises and targeting the financial pipelines that launder cartel profits strike demand and incentives directly. Cooperation with Latin American governments can then make enforcement smarter, not louder. The point isn’t to dominate the Caribbean — it’s to make drug trafficking a losing business model.

A purely militarized approach treats illicit markets as a law enforcement problem when it’s fundamentally an economic one. The logic of the market doesn’t vanish at sea — it simply resurfaces somewhere else.

Source: https://www.tampabay.com

301 deaths. 301 names, ages, faces removed. 301 families, communities, homes (or home equivalents) emptied. 

In 2023, there were 301 opioid-related overdose deaths in Alameda County. Standing alone, that figure isn’t alarming to those of us reading behind “safe” walls on our expensive devices. 

Nothing exposes us to the truth more than cold numbers. This data-driven meta-analysis will show there is far more to concern about the complexities that eventually result in the plague of opioids claiming those 301, and thousands more, lives.

The acceleration of the Alameda County crisis

Those 301 Alameda County lives claimed by opioids in 2023 represent a 60% increase  from 2022. Alameda County experienced the worst increase of all Bay Area counties in opioid overdose deaths from 2018-2021; Alameda’s rates tripled over this time while neighboring (Courtesy Alameda County)

There is an apparent inequity within the county. African-Americans’ fatal overdose rates are triple  that of the county average, and the homeless comprise 30% of all overdose deaths. 

(Courtesy Alameda County)

The teen paradox: Less use, more deaths

The focus is on teens, right? That would make sense. After all, teen substance use excluding cannabis is DOWN, compared to the 20.9% of high school juniors in 2002, the 8% figure of 2022 represents major improvement. 

Despite this, death rates are not improving. In fact, teen overdose deaths doubled in the eight short months between August 2019 and March 2020. As of 2022, 22 teens were dying WEEKLY from drug overdose in the United States. And overdoses are now the third leading cause of death for the youth, after guns and cars.

Fentanyl changed it all.

Now, over 75% of teen overdose victims’ lives are claimed by fentanyl. There was nearly a 300% INCREASE in fentanyl deaths aged 15-19 from 2018 to 2021. 

The problem isn’t necessarily addiction. It’s contamination. 

84% of teen overdose deaths are unintentional, and around a quarter of teen overdose deaths involve fake prescriptions. Fatal drugs like fentanyl spread through adult markets due to their potency and make their way to teens by accident. Most teens do not even get hooked onto the drugs that kill them.

Treatment inequality and solutions

Teen treatment right now is almost a scandal. While 42% of adults aged 45+ receive medications for opioid use disorder within three months of diagnosis, only 5% of teens do. Out of every five teens with substance use disorder, only one gets treatment.

Regardless of everything, prevention programs are still a solution. Project Towards No Drug Abuse (Project TND) has shown a 25% reduction in hard drug use. Medication-Assisted Treatment (MAT) reduces overdose deaths by 70-80%. Endless life-saving rescues by naloxone have been documented by near-death survivors. 

It is not that there are no solutions. Ironically, teens are the ones with the least access to drugs. We know what works, and Alameda County cares for its people. The change to prevent teen opioid overdose deaths must originate in expanding access and awareness to the systems proven to save lives.

Source: https://www.pleasantonweekly.com/alameda-county/2025/11/17/the-data-driven-paradox-of-prevention/


This article was written as part of a program to educate youth and others about Alameda County’s opioid crisis, prevention and treatment options. The program is funded by the Alameda County Behavioral Health Department and the grant is administered by Three Valleys Community Foundation.

The Government’s new mandate to carry out random oral-fluid roadside drug testing marks a milestone in New Zealand’s road safety policy

Under recently passed laws, police can now stop any driver, at any time, to screen with an oral swab for four illicit substances: THC (cannabis), cocaine, methamphetamine and MDMA (ecstasy).

Police will begin the rollout in Wellington in December, with nationwide coverage expected by mid next year.

Drivers will face an initial roadside swab taking a few minutes; a positive result triggers a second test. If confirmed, the driver will face an immediate 12-hour driving ban and have their initial sample sent to a lab for evidential testing.

With nearly a third of all road deaths involving an impairing drug, moves like this are clearly aimed at a serious problem.

Efforts by the previous Labour-led government stalled because no commercially available oral-fluid device met the evidentiary standards required at the roadside.

The government now appears to have what it needs to begin roadside testing. But it remains unclear whether this policy will achieve its goal of preventing truly impaired driving.

The science behind cannabis and driving

The research on cannabis and driving impairment is mixed. Many studies show an associative rather than causal link: people who use cannabis more often tend to report more crashes, but not whether those crashes happened while they were impaired.

Unlike alcohol – where blood-alcohol concentration closely tracks impairment – no such relationship exists for THC. Cannabis is fat-soluble, so traces linger in the body and appear in saliva long after any intoxicating effect has passed, making saliva testing a relatively poor proxy for impairment.

For the other targeted drugs – the stimulants methamphetamine, cocaine and MDMA – the connection to driving impairment is also unclear. At lower doses, stimulants can even improve certain motor skills. The risks are instead tied to perceptual shifts or lapses in attention, which a saliva test cannot detect.

Because cocaine and meth remain illegal globally, it is difficult to conduct the controlled studies needed to link presence and impairment.

The policy’s focus on just four illicit drugs also raises questions of scope. In practice, these are among the easiest and most visible substances to target: the low-hanging fruit.

Yet impairment from prescription medications such as sedatives or painkillers is far more common and remains largely self-policed.

Responsibility falls to individuals and their doctors to decide when it is safe to drive – a much bigger problem than many realise.

Police expect to conduct about 50,000 tests a year – around 136 a day nationwide – compared with more than four million alcohol breath tests annually.

While that’s a modest number, the introduction of roadside breath testing in the 1980s proved transformative. Alcohol consumption, which had been rising for decades, peaked around 1980 and then began to fall after the combined impact of breath testing and public awareness campaigns.

Whether the new drug-testing programme can produce a similar deterrent effect – without that level of visibility or education – remains to be seen.

Even if it does, the overall impact may be small. Drug use and drug-driving are far less common than alcohol use ever was, so the scope for large behavioural change is limited.

The problem of lingering traces

Another pressing question is what happens when the test detects traces of cannabis long after impairment has passed. THC can remain detectable in regular users for up to 72 hours, even though its intoxicating effects last only a few.

That means a medicinal cannabis patient who took a prescribed dose the night before – or a habitual user with high baseline levels – could therefore test positive while driving safely.

Although the law provides for a medical defence, there is still no clear procedure for proving a prescription at the roadside. Few people carry that documentation, and it’s uncertain whether digital GP records would be accepted.

In practice, some law-abiding drivers will inevitably be caught up in the process simply because of residual traces that pose no safety risk. Conversely, an inexperienced cannabis user may feel heavily impaired yet return a low reading.

This uncertainty reflects a deeper flaw in the system. When the previous government first designed the policy, it intended to test for impairment.

Because no devices could meet the evidentiary standard, the law was amended to test only for presence.

Perhaps the resulting regime’s relatively low-level penalties – such as a $200 fine and 50 demerit points for the confirmation of one “qualifying” substance – will help it withstand legal scrutiny, but they also highlight its scientific limitations.

Other jurisdictions have taken a different path. Many have returned to behavioural assessments of impairment – the traditional field-sobriety approach of observing coordination, balance and attention.

In the United States, for instance, officers often rely on such behavioural indicators because the law there still centres on proving a driver was impaired, not simply that they had used a substance.

In the end, a test that measures presence rather than impairment risks confusing detection with prevention – and may do little to make New Zealand’s roads any safer.

Author: Joseph Boden, Professor of Psychology, Director of the Christchurch Health and Development Study, University of Otago

Source: https://www.1news.co.nz/2025/11/17/will-drug-testing-drivers-really-make-nz-roads-safer/

From: Drug Free America Foundation – 11 November 2025 19:28

          

New research from the Journal of Adolescent Health reveals critical insights about how cannabis legalization affects youth behavior, and why local policies matter more than ever. The study, led by researchers at the Public Health Institute, Kaiser Permanente and University of California, examined cannabis use among over 377,000 California high school juniors before and after the state legalized recreational cannabis retail in 2018.

The findings highlight an alarming trend: Frequent cannabis use among teens increased significantly after legalization, particularly in communities that permitted retail storefronts and delivery.

What the Research Shows:

  • Teen cannabis use increased significantly following legalization (except in areas that permitted only medical delivery of cannabis products).
  • Frequent use, defined as 20 or more days a month, grew the most, reversing a previous downwards trend and continued to increase through 2020.
  • Communities that banned retail cannabis sales entirely, consistently had lower rates of youth use, both before and after legalization.
  • Local policies made an impact. Jurisdictions that allowed storefront or delivery sales saw a significantly higher rate of use among high school juniors.

 Why Does This Matter for Prevention?

  • Teen Vulnerability– The teenage brain is still developing until the mid-twenties, making it especially sensitive to substances like THC. Early cannabis use has been linked to problems with memory, mental health disorders and increased risk of addiction.
  • Frequent use– Using marijuana on 20 or more days per month is a serious concern for teens. Regular or heavy use greatly increases the risk of dependency and the development of cannabis use disorder, potentially disrupting academic, social, and emotional growth.
  • Increased exposure– Legalization brings broader marketing, normalized use and greater access, especially when retail stores and delivery services are allowed in local neighborhoods/communities.

Recommendations for Communities:

  • Adapt or maintain retail bans to limit access and reduce normalization of use.
  • Restrict cannabis marketing, particularly near schools or on digital platforms frequently visited by young people.
  • Support local prevention coalitions to help educate families and youth about the real risks of early cannabis use.
  • Have open conversations with teens.

The Bottom Line:

Legalization does not mean safety. As this study demonstrates, when cannabis becomes more visible and accessible, youth use follows. Communities that stand firm with restrictive policies and invest in prevention can make a real difference in protecting their teens.

Source: Drug Free America Foundation | 333 3rd Ave N Suite 200 | St. Petersburg, FL 33701 US

by La Derecha Diario –  Editorial Team    17/10/2025     

Submitted by Maggie Petito, DWI – 20 October 2025

Opening remark by Maggie Petito:

This article is out of Argentina. The Cartel de los Soles has morphed, as many Latin cartels do, into differing allegiances and profit streams, it remains a fact that drug running corrupts.

Who is ‘El Pollo’ Carvajal: the Chavista spy who confessed to having financed the Kirchners with drug trafficking money

Hugo Carvajal confessed before the United States justice system that Hugo Chávez allocated millions of dollars from drug trafficking to support left-wing governments

    Hugo Armando “El Pollo” Carvajal, former chief of military intelligence for the Hugo Chávez regime, became a key figure for the U.S. justice system. Extradited from Spain in 2023, Carvajal faces charges of drug trafficking and narco-terrorism in the United States. In exchange for a reduced sentence, he decided to cooperate with the DEA and the Department of Justice, revealing how Chavismo used the state oil company PDVSA to finance left-wing movements throughout the region.

On June 25, Carvajal pleaded guilty to four drug trafficking-related offenses before Judge Alvin K. Hellerstein in the Southern District Court of New York. There, he admitted his membership in the Cartel de los Soles, a criminal organization embedded in the Venezuelan Armed Forces and considered terrorist by Washington. He also acknowledged having collaborated with Colombian guerrillas and supervised the shipment of tons of cocaine to North America.

Carvajal’s confession not only exposed the structure of Chavista drug trafficking, but also its international political financing network. In court statements and documents leaked to European media, the former spy claimed that Chavismo illegally financed left-wing movements for at least fifteen years, channeling money to allied leaders and parties in Latin America and Europe.

According to his testimony, among the main recipients of funds were Néstor Kirchner in Argentina, Lula da Silva in Brazil, Evo Morales in Bolivia, Gustavo Petro in Colombia, Fernando Lugo in Paraguay, and the Podemos party in Spain, as well as the Five Star Movement in Italy. “All of them were recipients of money sent by the Venezuelan Government,” the former military officer stated before the court.

Carvajal explained that the Bolivarian regime operated through diplomatic pouches and official flights to move the funds, coordinated by Tareck El Aissami, then Minister of the Interior, with the direct approval of Nicolás Maduro, who at that time was foreign minister. He stated that the same method was used to send money to the Kirchners.

In his most explosive testimony, Carvajal claimed that Hugo Chávez financed Cristina Fernández de Kirchner’s 2007 presidential campaign with 21 million dollars. The money allegedly arrived in Buenos Aires on 21 diplomatic flights, organized when Jorge Taiana—currently Fuerza Patria’s candidate—was Argentine foreign minister and a key figure in the political alliance between Caracas and Buenos Aires.

“The Venezuelan Government has illegally financed left-wing political movements around the world for at least 15 years,” Carvajal reiterated in a document submitted to the U.S. judge, also committing to provide unpublished documentation that would prove the route of those funds. The revelation shook both the international judicial sphere and Argentine politics, once again putting Chavista influence over Kirchnerism under scrutiny.

Who is Hugo Armando Carvajal?

Born in Puerto La Cruz in 1960, Carvajal was one of Hugo Chávez’s most trusted men. He reached the rank of major general in the Bolivarian Army, and for years led the General Directorate of Military Counterintelligence (DGCIM), where he controlled the regime’s secret operations. In 2008, he was sanctioned by the Office of Foreign Assets Control (OFAC) of the United States for his role in cocaine trafficking and his cooperation with the FARC. Since then, his name has appeared on the Clinton List, which identifies officials linked to drug trafficking and terrorism.

His political career took him to the Venezuelan Parliament as a PSUV deputy, but over time he distanced himself from Maduro and denounced internal corruption and the regime’s authoritarian drift. After breaking ranks, he fled the country and ended up detained in Spain, where he remained a fugitive until his extradition.

Today, on U.S. soil, Carvajal seeks to reduce his sentence—estimated at about 20 years—by offering evidence of how Chavismo bought political loyalties with drug trafficking money.

His testimony, which combines espionage, cocaine, and political corruption, could open a new judicial chapter in Latin America, exposing the illicit financing network that connected the Venezuelan narco-dictatorship with Kirchnerism and other left-wing governments.

Source: www.drugwatch.org

Why is the International Convention for the Suppression of Acts of Nuclear Terrorism (ICSANT) important for Small Island Developing States (SIDS)? Millions of radioactive sources are being transported and used worldwide for medical, agricultural and industrial purposes, and SIDS are not an exception. For instance, in virtually every country in the world there are radioactive sources being used for cancer treatment.

As recently stated by H. E. Ambassador Ron O. Pinder, Permanent Representative of The Bahamas to the International Atomic Energy Agency, the country is finalizing national legislation to ensure that all nuclear or radiological materials within the country’s territory are managed safely and securely. In this regard, adherence to ICSANT would help underpin these efforts.
During the Diplomatic Week 2025 “Delivering Security, Opportunity, and Justice through Diplomacy”, held on 19-23 October 2025 in Nassau, The Bahamas, UNODC discussed the Bahamas’ adherence to ICSANT, including how the Convention improves national, regional and international security. The Office also highlighted the role of ICSANT in detecting and identifying smuggled radioactive material and otherwise deterring terrorists and other criminals from using these substances. The event was opened by the Prime Minister the Honourable Philip EB Davis. It gathered over 200 delegates representing Bahamian ministers and diplomats as well as ambassadors from other countries and officials from international and regional organizations.
Ms. María Lorenzo Sobrado, Head of the Chemical, Biological, Radiological and Nuclear (CBRN) Terrorism Prevention Programme within UNODC’s Terrorism Prevention Branch spoke at the first high-level plenary session on “Emerging security threats: The Bahamas perspective”, which also featured the Honourable Wayne Munroe, KC, MP, Minister of National Security, representatives of the Royal Bahamas Police Force, the Royal Bahamas Defence Force and the Haiti Gang Suppression Force (formerly the Haiti Multinational Security Support Mission). In particular, Ms. Lorenzo Sobrado illustrated through concrete examples that the threat of terrorist and other criminal use of nuclear and other radioactive material is real for all States, not only for those ones with nuclear power programmes. She also emphasized that all States, including The Bahamas, need to establish robust and sustainable legal frameworks to counter this threat. ICSANT, to which The Bahamas is not yet party, is an essential tool at the country’s disposal to strengthen its criminal justice system and effectively prevent and combat malicious acts involving nuclear and other radioactive material.
Mr. Artem Lazarev, Programme Officer of UNODC’s CBRN Terrorism Prevention Programme, conducted a side-event on ICSANT. Through a fictional case study, he further raised awareness of relevant national stakeholders of The Bahamas on the main provisions of the Convention, benefits for the country of being party to it, and available technical and legislative assistance of UNODC.

The UNODC staff also conducted high‑level bilateral meetings on ICSANT with the following national officials: the Honourable Wayne Munroe, KC, MP, Minister of National Security; Mr. Jamahl Strachan, MP, Parliamentary Secretary, Ministry of Foreign Affairs; Her Excellency Ms. Jerusa Ali, Director General, Ministry of Foreign Affairs; and Mr. Ryan Sands, Legal Counsel, Civil Aviation Authority of The Bahamas. Among other things, the UNODC staff provided an overview of UNODC’s ICSANT‑related tools and the tailored technical and legislative assistance that the Office can offer to The Bahamas with regard to the country’s adherence to, and implementation of, ICSANT.

The country visit was conducted under a project funded by the Government of Canada.
Source: https://www.unodc.org/unodc/en/terrorism/latest-news/2025_unodc-promotes-the-international-convention-for-the-suppression-of-acts-of-nuclear-terrorism-at-the-annual-diplomatic-week-in-the-bahamas.html

Kate Dubinski · CBC News ·

Faced with teens drinking alcohol and using drugs at higher rates than others in the province, a local health unit will try to reverse the trend by using a system first developed in Iceland.

The Icelandic Prevention Model will be adapted to reflect local data and community needs, officials with Southwestern Public Health told CBC News.

“Local health status data is clear: reported use of alcohol, cannabis, tobacco, and other substances among youth is higher here than in Ontario,” said Peter Heywood, director of healthy communities at the health unit, which covers St. Thomas, Woodstock, and Oxford and Elgin counties.

More than one in three young people in that region reported using alcohol, cannabis and smoking a full cigarette for the first time in Grade 9, according to public health data, and more than half of young people reported drinking alcohol in the previous year, about 10 per cent higher than the Ontario average.

High school students will be asked to take a survey from Nov. 24 to Dec. 5, asking about substance use. They’ll be asked about their experiences in school, their communication with parents and siblings, their friendships, what they do in their spare time, how they see their mental health and what substances they use and how they perceive that use.

The results will be analysed and will guide how officials apply the Icelandic model locally, said Jessica Austin, a health promotor with Southwestern Public Health.

“The Icelandic Prevention Model was developed in Iceland by social scientists in the 90s (who) looked at factors that influence youth substance use to inform their community that had high substance rates on where they could focus their efforts to lower those rates,” Austin said.

Iceland’s teenagers used drugs and alcohol at the highest rates in Europe. Now, their rates are among the lowest.

Approach adopted worldwide

The approach has been adopted in communities around the world, including some in Canada. It focuses on prevention rather than targeting specific behaviours. Using the local data, the health unit works with community agencies, recreational facilities, faith groups, police officers, and school boards to give teens a sense of belonging.

“We know substance use is a complex issue and it requires a complex solution,” Austin said. “We’ve done a lot of work using provincial data, but now we will be able to work more effectively with the local data, to come together and get into the root causes.”

It typically takes a few years for change to happen, she added.

“I think everybody gets excited when we see the Icelandic graph sitting at one per cent for smoking rates and six per cent for alcohol-use rates, when we are sitting in the nearly 50 per cent alcohol-use rates for our youth,” Austin said.

“We would love to get down to that under the 10 per cent marker. In the short term, we want to at least get to the provincial rate.”

Source: https://www.cbc.ca/news/canada/london/icelandic-prevention-model-southwestern-public-health-9.6971289

 

Canada is betting on the Icelandic Prevention Model to reduce youth drug use.
But does it fit Canada’s opioid crisis and diverse communities?

Since 2020, Canada has been piloting a new strategy to prevent youth from using drugs and alcohol.

The strategy is based on a highly successful model pioneered in Iceland in the 1990s — one that helped cut Iceland’s youth substance use from among Europe’s highest to the lowest.

But in Canada, the effectiveness of the Icelandic model remains unproven — and some experts say Canada needs a strategy that is better targeted to Canada’s own culture.

“The [Icelandic Prevention Model] was originally developed to address alcohol and tobacco use in Iceland in the 1990s,” Leslie Buckley, chief of addictions at the Centre for Addiction and Mental Health (CAMH), told Canadian Affairs in an email.

“It was not designed with opioids or mental health in mind and doesn’t appear to incorporate trauma-informed practices,” she said.

The Icelandic model

The Icelandic Prevention Model aims to deter youth substance use by treating “society as the patient.” 

The model is implemented through entire communities by a range of organizations, including town councils, schools, health providers, youth organizations and parent groups. 

Its aim is to strengthen the social conditions that affect youth substance use, such as peer pressure, parental influence, extracurriculars and community ties. For example, parents are encouraged to have their children at home in the evenings.

In Iceland, the strategy has yielded impressive results.

Between 1998 and 2013, the share of 15 to 16-year-olds who reported getting drunk in the past 30 days fell from 42 per cent to five per cent. Daily smoking dropped from 23 per cent to one per cent, and lifetime cannabis use fell from 17 per cent to six per cent.

But its founders stress that the model must always be adapted to a country’s own culture. 

“We don’t tell people what to do, but we provide this framework, and always it has to be culturally adapted,” said Jon Sigfusson, chairman of Planet Youth, the organization that created the Icelandic Prevention Model. 

“What works in Iceland doesn’t work in Canada or anywhere else.” 

In an email to Canadian Affairs, Planet Youth emphasized the importance of understanding the unique dynamics of the community in which the strategy is being rolled out. 

“The key strategies include building a strong coalition that works in the community for the community, using survey data that looks into risk and protective factors and specific community challenges, guiding decision-making based on data,” Planet Youth’s email said.

‘The entire community’

In Canada, the Icelandic Prevention Model was first piloted in 2020 among Grade 10 students in Lanark County, Ont.

Today, it is being piloted in seven communities across the country, including in Cape Breton, N.S., Mississauga, Ont., and the Grand Erie region of Ontario.

Canada’s adoption of the Icelandic Prevention Model marks a major shift from Canada’s pre-2020 approach to substance use prevention, which relied on short-term, targeted education campaigns to help youth recognize and resist peer pressure.

“The ‘just say no to drugs’ approach does not work and has been proven ineffective time and time again,” said Sefin Stefura, project manager of the Icelandic Prevention Model in Cape Breton.

Buckley, of CAMH, says the Icelandic Prevention Model’s focus on the entire community is one of its strengths.

“One positive aspect of the Icelandic Model is that it involves an entire community — and bringing people together to work on a common goal,” she said in her email.

At the same time, experts caution that the Icelandic Prevention Model — which was first implemented in the 1990s — was not designed to address the complex challenges Canadian youth face today.

The model needs rigorous evaluation in Canada due to its “different population, different sociocultural landscape, and differing substance[s],” Buckley said.

“We cannot highlight enough the importance of evaluation in the early pilots,” she said.

No silver bullet

A recent consultation by the Canadian Centre on Substance Use and Addiction found that Canadian youth want mental health support, peer-led education and non-judgmental tools for coping with stress and trauma.

“Youth often start using substances for social reasons — to fit in and socialize more effortlessly — but often continue because they are using it to cope with stress, mental health challenges or pain,” the report says. 

Cape Breton is adapting its strategy to ensure all research and interventions put mental health, accessibility and lived experience at the forefront, says project manager Stefura. The community also plans to create a youth congress to co-lead decisions with schools and municipal leaders.

“There is really no way to separate [trauma and mental health] from primary prevention,” she said.

In Ontario’s Grand Erie region, health promoters Lina Hassen and Josh Daley say they view the Icelandic Prevention Model as a valuable framework — but only when part of a larger approach.

“We don’t pretend or believe that this is a silver bullet,” said Daley. “We know it’s a complex issue, so it’s going to have a complex solution, and we think this is complementary to what’s going on.”

“We have a local drug and alcohol strategy,” Hassen added. 

“We are recognizing the need to embed mental health components — such as training for schools and community leaders on trauma-informed care — and aligning the model with local mental health resources.”

Dagmar Morgan-Sinclair, the executive director of the team implementing the Icelandic Prevention Model in Mississauga, says the model complements, but should not replace, other targeted substance use prevention programs.

PreVenture

In Canada, one such program is PreVenture. As Canadian Affairs previously reported, PreVenture is an evidence-based Canadian program used primarily in schools and universities that helps youth identify and mitigate behavioural traits that can correlate with substance use disorders.

“Our strategy is a ‘yes, and’ to some of these individualized-focused programs,” said Morgan-Sinclair. “This is something that works in tandem.”

Buckley agrees that the Icelandic Prevention Model’s broad, community-based approach should be paired with targeted programs like PreVenture, which have been proven to work in the Canadian context.

“Health Canada says the [Icelandic] program allows for local adaptation — but most of the funded communities are in smaller or rural areas, and don’t include places with the highest rates of youth drug use like Vancouver or Toronto,” she said. 

Canada’s efforts to reduce youth substance use have, so far, been modest. Health Canada, for example, committed just $20 million to the Icelandic Prevention Model over five years, while the opioid crisis is estimated to cost the country about $40 billion a year. 

“We have not invested in primary prevention as much as we should,” said Buckley. 

“We need to consider, invest in and test these upstream prevention practices in Canada,” Buckley said.

Source: https://www.canadianaffairs.news/2025/10/19/canada-follows-icelands-lead-on-drug-prevention/

by John Suarez (612) 367-6845/ Janisset Rivero (786) 208-6056  –   Center for a Free Cuba, September 29th, 2025, Washington, DC. 

The Havana regime’s historical ties to drug trafficking and its role as an intermediary and coordinator in the hemisphere for drug trafficking into the United States have been presented in the report “Cuba: Precursor of the Cartel of the Suns. Drug Trafficking in the Hands of the State,” compiled by the Ibero-American Alliance for Global Security, the Cuba in Transition Association, and the Center for a Free Cuba.

The report has been sent to numerous organizations and entities dedicated to documenting drug trafficking and illegal activities, including the UN International Narcotics Control Board; the Global Initiative against Transnational Organized Crime; the OAS Inter-American Drug Abuse Control Commission; the International Crisis Group; the United Nations Office on Drugs and Crime (UNODC); the United States Southern Command (SOUTHCOM); among other institutions.

“The Cuban regime’s connection to drug trafficking is well documented. There is an abundance of evidence gathered from court proceedings, defector testimonies, investigations, and historical records that detail the involvement of high-ranking officials and Cuban institutions—particularly the Armed Forces—in drug trafficking.the report states:

“Drugs have served Castroism as a lethal weapon to damage American capitalist society, as corroborated by the testimony of retired Romanian general Ion Mihai Pacepa, who documented Fidel Castro and Ceaușescu’s plans during their visit to Havana in 1972 to flood the West with drugs to weaken capitalism. According to Pacepa, Castro told Ceaușescu that “drugs could do more damage to imperialism than atomic bombs.

From that date to the present, evidence of the Havana regime’s involvement in drug trafficking linked to the Colombian guerrillas, the control of Venezuela’s ports of entry and exit by Cuban military personnel to counter Plan Colombia, and the coordination of drug trafficking efforts in the region with other states such as Nicaragua with the Sandinistas under Ortega’s command and Panama during the Noriega regime, are based on direct testimony from former military personnel, former guerrillas, and drug traffickers prosecuted by the U.S. justice system, which directly implicates Cuba as a contact and support center for these illegal operations.”

“We support the international community taking direct measures to stem the flow of drugs into their respective countries and to curb the growing number of young people dying from drug overdoses. We must remember that Venezuela and Maduro bear significant responsibility for these criminal acts, but the driving force is in Havana, and the facts prove it,” said John Suárez, executive director of the Center for a Free Cuba.”

PDF version of the report downloadable here: https://www.scribd.com/document/923479521/Cuba-Precursor-of-the-Cartel-of-the-Suns

SOURCE:  Submitted by drug-watch-international@googlegroups.com On Behalf Of mlp3@starpower.net –   30 September 2025 01:04

Statement by Marcos Neto, UN Assistant Secretary-General, and Director of UNDP’s Bureau for Policy and Programme Support, at the launch of the third UNDP Discussion Paper on drug policy and development, ‘Development Dimensions of Drug Policy: New Challenges, Opportunities, and Emerging Issues’. September 17, 2025

Welcome to the side event Development Dimensions of Drug Policy: Exploring New Challenges, Opportunities, and Emerging Issues.

This is an important conversation. Drug policy remains one of the least represented issues in the 2030 Agenda and the Sustainable Development Goals. The SDGs mention drugs only in the context of substance abuse – a narrow framing.

In reality, the global illicit drug economy, estimated at more than 600 billion dollars, has profound implications for health, human rights, livelihoods, security, the environment, and development. For decades, punitive responses associated with the so-called “war on drugs” have dominated, often with devastating consequences for individuals, families, communities, and entire economies.

Today, we benefit from a growing body of evidence that demonstrates the far-reaching impacts of drug policies. We know that both production and control measures carry serious environmental costs. We know that the proliferation of new substances poses complex public health challenges. And we know that punitive approaches have led to severe human rights violations.

Since the adoption of the 2030 Agenda, UNDP has worked to broaden the understanding of drug policy, extending beyond the security frame, to a development frame with significant human and health impacts. UNDP works on rights and access to services for key HIV populations, including people who use drugs, in 97 countries. Through its partnership with the Global Fund, UNDP has supported HIV programmes in 57 countries, reaching 86,245 people who use drugs with essential services. We work to deliver the UN System Common Position on Drugs, that calls on us to work through partnerships grounded in human rights, health, and science.

And I am pleased that today we launch the third paper in UNDP’s series on the development dimensions of drug policy.

This new paper addresses today’s increasingly complex landscape:

  • the rise of synthetic drugs,
  • the diversification of drug markets,
  • the emergence of regulated cannabis and psychedelics frameworks and the risks of their “corporate capture,”
  • as well as the growing effects of drug production and control on climate and biodiversity.

The paper also proposes a way forward, highlighting innovative, pragmatic, and people-centered approaches that are evidence- and rights-based.

These approaches prioritize health, human rights, and sustainable development. They ensure meaningful community participation and remove legal barriers to prevention, treatment, care, and support services, making sure that we leave no one behind.

While there is still a lot of work to be done, around the world Member States – including my home country, Brazil – are showing that it is possible to safeguard human rights, respect minorities and Indigenous peoples, address the disproportionate impacts on women and youth, and deliver better health and development outcomes for people who use drugs.

We hope today’s conversation will inspire many more.

It is now my great honour to introduce His Excellency Ernesto Zedillo, Commissioner of the Global Commission on Drug Policy, distinguished scholar, and former President of Mexico.

 

Presentation by Commissioner Zedillo:

Development Dimensions of Drug Policy: Assessing New Challenges, Uncovering Opportunities, and Addressing Emerging Issues – September 16, 2025

This discussion paper examines how drug policy affects sustainable development, human rights, governance, health, and the environment. It underscores that punitive enforcement has largely failed, fueling violence, corruption, incarceration, and health crises, while doing little to reduce harm. In response, many countries are shifting toward evidence- and rights-based reforms such as decriminalization and harm reduction. Yet, organized crime continues to dominate markets, and debates over legal regulation are expanding.

The paper highlights both the opportunities and risks of regulation. It shows how reforms could redirect resources into health and social programmes, strengthen governance, and support sustainable livelihoods, particularly for marginalized communities. At the same time, it warns of inequities in emerging legal markets, “corporate capture”, and insufficient attention to gender, Indigenous rights, and environmental impacts.

Aimed at decision- and policy-makers, multilateral organizations, scholars, and civil society, the paper calls for a development-oriented, rights-based approach that ensures no one is left behind and aligns drug policy with the Sustainable Development Goals. It is the third paper of the series on drug policy and development produced by UNDP.

Opening Comment by DrugWatch member Maggie Petito:

It is often stated that comprehensive plans are most effective. Andean media often reports on crime profits from the transport of drugs, weapons and humans.  Additional factual reporting is needed.Few understand the profiteering by the Albanian mafia, Chinese Triads and Russian mobs. South American media does claim that Colombia [and Peru] see soaring cocaine production.Transportation and distribution yields higher profits than the actual production. Nonetheless, common sense reminds that without product, there is nothing to transport.

ARTICLE:

by    Steve Fisher, José de Córdoba and Santiago Pérez  – Wall Street Journal  – Sept. 16, 2025

From a heavily guarded mountain hideout in the heart of the Sierra Madre, 59-year-old Nemesio “Mencho” Oseguera reigns as the new drug king of Mexico, aided in his ascendance by America’s resurging love of cocaine and the Trump administration’s escalating war on fentanyl.

Oseguera spent decades building his Jalisco New Generation Cartel into a transnational criminal organization fierce enough to forge a new underworld order in Mexico, displacing the Sinaloa cartel, torn by warring factions, as the world’s biggest drug pusher.

The Sinaloans, Mexico’s top fentanyl traffickers, got caught in the crosshairs of the Trump administration, which promised to eradicate the synthetic opioid. The crackdown has left an open field for Jalisco and its lucrative cocaine trade, elevating Oseguera to No. 1.

“‘Mencho’ is the most powerful drug trafficker operating in the world,” said Derek Maltz, who served this year as interim chief of the Drug Enforcement Administration. “What is happening now is a pivot to much more cocaine distribution in America.”

Cocaine sold in the U.S. is cheaper and as pure as ever for retail buyers. Consumption in the western U.S. has increased 154% since 2019 and is up 19% during the same period in the eastern part of the country, according to the drug-testing company Millennium Health. In contrast, Fentanyl use in the U.S. began to drop in mid-2023 and has been declining since, according to data from the Centers for Disease Control and Prevention.  

For new users, cocaine doesn’t carry the stigma of fentanyl addiction. Middle-class addicts and the tragic spectacle of homeless crack-cocaine users in the 1990s helped put a lid on America’s last cocaine epidemic.

Oseguera, who grew up poor selling avocados, is making a killing from cocaine buyers in the U.S. His cartel transports the addictive powder by the ton from Colombia to Ecuador and then north to Mexico’s Pacific coast via speedboats and so-called narco subs.

U.S. forces in the Caribbean recently blew up two speedboats, including one this week, that President Trump alleged were ferrying cocaine and fentanyl from Venezuela to the U.S. Fentanyl is largely produced in Mexico, and most cocaine ships through the Pacific. All those aboard the two vessels were killed. The president also has threatened military action against Mexican drug cartels.

A video released and edited by the Mexican military showing the apprehension of a drug-laden speedboat on Mexico’s Pacific coast this year.

The U.S. has a $15 million bounty on Oseguera, but he rarely leaves his mountain compound, according to authorities. Few photos of him circulate. The cadre of men protecting Oseguera, known as the Special Force of the High Command, carry RPG 7 heat-seeking, shoulder-fired rocket launchers capable of piercing a tank, people familiar with cartel operations said.

Visitors to the drug lord’s stronghold are hooded before they embark on the six-hour car trip through terrain sown with land mines, those people said. Locations of the pressure-activated explosives are known only by members of Oseguera’s inner circle.

Oseguera’s fortunes rose after the U.S. pressured Mexico to crack down on the Sinaloa cartel, where Oseguera got his start in the trade. The Sinaloans pioneered the manufacturing and smuggling of fentanyl, an industry breakthrough that sent cartel revenue soaring and drove up the number of fatal overdoses in the U.S. For the Sinaloans, landing in the administration’s spotlight couldn’t come at a worse time.

The capture of Sinaloa cartel leader Joaquín “El Chapo” Guzmán in January 2016 and his extradition to the U.S. a year later, set in motion a precipitous decline. Guzmán’s four sons inherited their father’s empire, highly valued for its network of smuggling tunnels beneath the U.S.-Mexico border, used for moving cocaine, fentanyl and other contraband.

The sons, known collectively as the little Chapos, or “Chapitos,” shifted production resources to fentanyl, which compared with the heroin their father had brought into the U.S. by the ton is easier to smuggle and costs just a fraction to produce.

The Chapitos triggered an internecine war last year as a result of a plot against Ismael “El Mayo” Zambada, the 70-something co-founder of the Sinaloa Cartel. Zambada was forced aboard a private plane bound for the U.S. by Joaquin Guzmán, one of El Chapo’s sons, who hoped for leniency from U.S. prosecutors.

Both men were taken into U.S. custody when they landed outside of El Paso, Texas. Zambada pleaded guilty to drug-trafficking charges last month and faces a possible life sentence. Guzmán, still in custody, pleaded not guilty to trafficking charges.

Zambada’s capture led to a violent split between men loyal to Zambada’s son, Ismael “Mayito Flaco” Zambada, and those allied with the Chapitos. An estimated 5,000 people from both camps have been killed or gone missing in the conflict, along with bystanders caught in the crossfire. Mexico has sent 10,000 federal troops in the past year to the state of Sinaloa, where the federal government has been largely helpless to end the fighting.

Hemmed in by U.S. and Mexican authorities on one front, and Zambada’s men on the other, the Chapitos swallowed their pride and sought the help of Oseguera, once a sworn enemy.

Each side had something the other wanted. Oseguera agreed to meet, looking to a future where he and his Jalisco cartel would rule as Mexico’s dominant criminal enterprise.

Landmark drug deal

In December, Oseguera sat down with a top lieutenant of Iván Archivaldo Guzmán, who leads Sinaloa’s Chapito faction. At the meeting in Mexico’s western state of Nayarit, Oseguera, who was operating from a position of strength, agreed to supply the Chapitos with weapons, cash and fighters.

In exchange, the Sinaloans opened their smuggling routes and border tunnels into the U.S., said people familiar with the meeting. The Jalisco cartel previously paid hefty fees to use the tunnels to move drugs beneath the U.S.-Mexico border, people familiar with its operations said.

The agreement also divvied up the U.S. trafficking trade, these people said: The Chapitos would keep their focus on serving American fentanyl addicts. Oseguera would concentrate on cocaine and its down-market cousin, methamphetamine. The Jalisco cartel now ferries tons of cocaine and record amounts of methamphetamine into the U.S. through Sinaloan-built tunnels, as well as fentanyl, the people familiar with cartel operations said.

The Sinaloa-Jalisco agreement was “an unprecedented event in the balance of organized crime,” Mexico’s attorney general’s office said in a July report. The Jalisco cartel compares with the Sinaloa cartel at the height of its power before El Chapo’s arrest, according to the DEA’s latest drug-threat assessment.

Oseguera caught another break from the Trump administration. The president’s campaign to deport immigrants in the U.S. illegally has taken federal agents away from drug-traffic interdiction. In Arizona, two Customs and Border Protection checkpoints along a main fentanyl-smuggling corridor from Mexico have been left unstaffed. Officers stationed there were sent to process detained migrants. A senior administration official said the U.S. border is more secure than it has ever been.

Colombia is producing records amounts of cocaine, and the volume of the drug arriving in the U.S. is driving down prices, the people familiar with cartel operations said.

Cocaine prices have fallen by nearly half to around $60 to $75 a gram compared with five years ago, said Morgan Godvin, a researcher with the community organization Drug Checking Los Angeles. “The price of pure cocaine has plummeted,” Godvin said.

Tons of cocaine manufactured in Colombia are shipped from Ecuador by small crews of fishermen on a three-week voyage to Mexico.

After refueling near the Galapagos, speed-boats and so-called narco subs continue north. The Mexican navy has deployed special forces to block shipments.

The Jalisco cartel, which controls ports on Mexico’s Pacific coast, now uses routes and tunnels into the U.S. that are controlled by the sons of imprisoned drug kingpin Joaquín “El Chapo” Guzmán.

The Jalisco cartel also draws steady revenue from diverse sources outside narcotics.

The cartel acts as a parallel government in the southwestern state of Jalisco and other parts of Mexico, taxing such goods as tortillas, chicken, cigarettes and beer, security experts said. It controls construction companies that build roads, schools and sewers for the municipal governments under cartel control. 

A booming black market for fuel is another cash cow. Gasoline and diesel stolen from Mexican refineries and pipelines—or smuggled into Mexico from the U.S. without paying taxes—is sold at below market prices to small and large businesses. U.S. officials estimate as much as a third of the fuel sold in Mexico is illicit. The head of the Jalisco cartel’s fuel division is nicknamed “Tank” for his prowess at stealing and storing millions of gallons of fuel. 

The cartel profited from the passage of migrants bound for the U.S., charging them thousands of dollars each to pass through territory it controls. And in recent years, the cartel has operated more than two dozen call centers to scam senior citizens out of hundreds of millions of dollars in a vacation-timeshare fraud, according to the Treasury Department.

Family ties

Oseguera, celebrated as “El Señor Mencho” in narco-ballads, is viewed as an altruistic patriarch by some poor Mexicans living in areas controlled by the cartel, which organizes town fiestas and hands out food, medicine and toys.

In 1994, Oseguera was convicted of dealing heroin and served nearly three years in a California prison. He was deported to Mexico, where he married the daughter of the boss of a Sinaloa-affiliated gang. By 2011, he was leading his own organization based in Jalisco state.

Jalisco gunmen stormed a Puerto Vallarta restaurant in 2016 and kidnapped two Chapitos—Iván Archivaldo and Jesús Alfredo—who were celebrating Iván’s birthday. Oseguera released them after an intervention by “El Mayo” Zambada, who later became a target of the Chapitos. 

Like many of Mexico’s cartels, Jalisco is largely a family business. One of Oseguera’s brothers, Antonio, known as Tony Montana after the Al Pacino character in the movie “Scarface,” was in charge of acquiring heavy weapons, the attorney general’s report said. The brother was arrested in 2022, and in February he was among 29 drug bosses Mexico expelled to the U.S., hoping to address Trump’s demands.

Oseguera’s son, who served as a top leader in the cartel, was sentenced in Washington, D.C., this year to life in prison for drug trafficking.

Hundreds of gunmen trained by former Colombian special forces work for Oseguera, according to Mexican officials. He travels through his territory in a small convoy of armored vehicles with a team equipped to fight off aggressors until reinforcements arrive. He had a specialized medical unit built near his mountain hideout to care for his advanced kidney disease, according to people familiar with the matter.

Photos from the Mexican navy showing packaged cocaine, in a 3.5-ton seizure from a semi-submersible vessel, a so-called narco sub, caught off the Pacific coast and brought to port in Acapulco, Mexico, in June.

Two cartel accountants arrested by Mexican authorities said they were required to leave behind smartphones, Apple Watches and any device with GPS signal before traveling to meet with Oseguera, a precaution against electronic surveillance or tracking, according to the people familiar with the cartel’s operations. Oseguera has a team that manages more than 50 phones of top cartel lieutenants, people familiar with the operations said. Every week, cartel operatives gather and review phone call logs to ensure the men haven’t been speaking with enemies, security experts said. Afterward, the men get new phones. 

In 2020, more than two dozen gunmen fired more than 400 rounds at the armored car ferrying Omar García Harfuch, then Mexico City’s security chief, on the capital’s Paseo de la Reforma. García Harfuch was hit three times but survived. Two of his bodyguards and a woman headed to work were killed. García Harfuch now serves as security minister for Mexico President Claudia Sheinbaum. He is overseeing the law-enforcement offensive, backed by U.S. intelligence, that has crippled the Chapitos. 

Oseguera’s subsequent rise to Mexico’s top drug trafficker puts him in a very dangerous spot, according to a senior Trump administration official.

Source: www.drugwatch.org
drug-watch-international@googlegroups.com

 

NIH – National Library of Medicine – National Center for Biotechnology Information

2025 Oct;178(10):1429-1440.

doi: 10.7326/ANNALS-24-03819. Epub 2025 Aug 26.

by Thanitsara Rittiphairoj1Louis Leslie2Jean-Pierre Oberste2Tsz Wing Yim2Gregory Tung3Lisa Bero4Paula Riggs5Kent Hutchison6Jonathan Samet7Tianjing Li8

Abstract

Background: Rapid changes in the legalized cannabis market have led to the predominance of high-concentration delta-9-tetrahydrocannabinol (THC) cannabis products.

Purpose: To systematically review associations of high-concentration THC cannabis products with mental health outcomes.

Data sources: Ovid MEDLINE through May 2025; EMBASE, Allied and Complementary Medicine Database, Cochrane Library, Database of Abstracts of Reviews of Effects, CINAHL, and Toxicology Literature Online through August 2024.

Study selection: Two reviewers independently selected studies with high-concentration THC defined as greater than 5 mg or greater than 10% THC per serving or labeled as “high-potency concentrate,” “shatter,” or “dab.”

Data extraction: Outcomes included anxiety, depression, psychosis or schizophrenia, and cannabis use disorder (CUD). Results were categorized by association direction and by study characteristics. Therapeutic studies were defined by use of cannabis to treat medical conditions or symptoms.

Data synthesis: Ninety-nine studies (221 097 participants) were included: randomized trials (42%), observational studies (47%), and other interventional study designs (11%); more than 95% had moderate or high risk of bias. In studies not testing for therapeutic effects, high-concentration THC products showed consistent unfavorable associations with psychosis or schizophrenia (70%) and CUD (75%). No therapeutic studies reported favorable results for psychosis or schizophrenia. For anxiety and depression, 53% and 41% of nontherapeutic studies, respectively, reported unfavorable associations, especially among healthy populations. Among therapeutic studies, nearly half found benefits for anxiety (47%) and depression (48%), although some also found unfavorable associations (24% and 30%, respectively).

Limitation: Moderate and high risk of bias of individual studies and limited evaluation of contemporary products.

Conclusion: High-concentration THC products are associated with unfavorable mental health outcomes, particularly for psychosis or schizophrenia and CUD. There was some low-quality evidence, inconsistent by population, for therapeutic benefits for anxiety and depression.

Primary funding source: Colorado General Assembly, House Bill 21-1317

Source: https://pubmed.ncbi.nlm.nih.gov/40854216/

 

By Scott Wolchek –FOX 2 Detroit –  September 9, 2025 

As students return to classes, the DEA is on a mission to help prevent drug abuse on college campuses. 

Big picture view:

The Drug Enforcement Administration (DEA) emphasized that prevention is key to ensuring the health and safety of the nation’s college students, and they are actively spreading that message. The DEA is teaming up with universities across Michigan and Ohio, reaching out to let them know that resources are available.

The focus is on drug awareness because many people between the ages of 18 and 25 are increasingly becoming statistics due to unfortunate overdoses. The DEA is particularly concerned about counterfeit pills, such as ecstasy, which may be laced with fentanyl. 

What they’re saying:

They report that 50% of the counterfeit pills they seize contain a lethal dose of fentanyl. The warning is clear: stop experimenting and stay safe.

“That behavior can lead a student to go online or social media or a weird part of town to obtain what they think is a study aid which might not contain anything but filler and caffeine or worse, fentanyl. We’re just letting our campuses know these pills are out there, and they’re readily available and dangerous,” said Brian McNeal. 

“Is this an age where you see people doing, like more drugs? Uh yeah, certainly. I think more and more this era of humanity is seeing an uptick in drug usage, but I mean it’s been used throughout time and memorium,” said college student Merrick.

Merrick mentioned that he himself had not encountered any of the counterfeit pill issues that the DEA is warning about. He expressed more concern about alcohol use on campus. 

The DEA representative told FOX 2 that while some people may not listen, it’s crucial to heed this advice: don’t take any pills unless you know where they came from, or they are prescribed to you.

With the fentanyl threats all around us, it’s vital to follow the advice being discussed.

Source: https://www.fox2detroit.com/news/dea-launches-drug-abuse-prevention-campaign-college-campuses-across-metro-detroit

Press Office, Media Relations – press-office@brunel.ac.uk

The UK’s science minister, Sir Patrick Vallance, has sounded the alarm over the country’s declining investment in medicines. He warned that the NHS risks losing out on important treatments and the country could lose its place at the cutting edge of medical research if spending does not recover. It comes at a sensitive time – this year drug-makers including Merck and AstraZeneca have backtracked on plans to invest in the UK.

Vallance is correct that there is a need to encourage pharmaceutical firms to keep investing and launching new medicines in the UK. On the other side, there is a need to protect public funds from being wasted on treatments that do not offer enough benefit for their cost.

At the moment, just 9% of NHS healthcare spending goes on medicines. This is less than Spain (18%), Germany (17%) and France (15%). At a time when some experts believe the UK is getting sicker, this might come as a surprise.

But the UK is unusual among major health systems in how carefully it regulates drug spending. The National Institute for Health and Care Excellence (Nice) has, since its creation, judged new treatments not only on clinical evidence but on cost-effectiveness.

That means asking whether a drug’s health benefits – measured in quality-adjusted life years (QALYs) – justify its price compared with existing care. For most treatments the threshold is about £20,000 to £30,000 per QALY. This is not a perfect measure, but it gives the NHS a consistent way of deciding whether the health gained is worth the money spent.

The value of this approach is clear. Nice’s record shows that medicines that pass its tests have added millions of QALYs to patients in England, while also preventing waste on drugs that bring only marginal improvements at high cost.

A study published earlier this year in medical journal The Lancet found that many of the new medicines recommended by Nice between 2000-2020 brought substantial benefit to patients. But it also noted that some high-cost drugs deliver much less health gain than investments in prevention or early diagnosis could.

The study emphasises that maintaining rigorous thresholds around cost-effectiveness ensures that public funds go to treatments that really improve lives. In other words, the discipline of cost-effectiveness has protected the public purse while ensuring access to genuine innovations.

This regulatory strength is reinforced by national pricing schemes for branded medicines. These cap overall growth in the NHS drugs bill and require companies to pay rebates if spending rises too fast. In practice, this means that if total spending on branded medicines exceeds an agreed annual limit, pharmaceutical companies must pay back a percentage of their sales revenue to the Department of Health.

In recent years that rebate rate has been as high as 20–26% of sales, effectively lowering the price the NHS pays. This is made possible by the buying power of the health service.

Together with Nice’s appraisals, these measures have helped the NHS maintain relatively low medicines spending compared with many countries. At the same time, it still secures access to major advances in cancer therapy, immunology and rare disease treatment.

For a publicly funded service under constant financial strain, these protections are vital. Despite the pressure on its budget, the NHS has secured meaningful access to new therapies. For example, by March 2024, nearly 100,000 patients in England – many of whom would otherwise face long delays or rejection – had benefited from early access via the Cancer Drugs Fund to more than 100 drugs across 250 conditions.

The balance with Big Pharma

However, strict controls on price and access can have unintended consequences. If companies see the UK as a low-return market, they may choose to launch new drugs elsewhere first, or to limit investment in research and early trials here.

There is a danger that patients could face delays in receiving new treatments. Or the scientific ecosystem, which relies on steady collaboration with industry, could weaken.

Still, the answer is not to abandon cost-effectiveness. Without it, the NHS would risk paying high prices for small gains. This would divert money from staff, diagnostics or prevention – areas that often bring more health benefit per pound spent.

In such cases, raising thresholds or relaxing scrutiny would do more harm than good. Cost-effectiveness is not just about saving money. It is about fairness, ensuring that treatments funded genuinely improve lives relative to their cost.

The challenge, then, is balance. The UK should continue to hold firm on value for money, while finding ways to encourage investment. That might mean improving the speed and clarity of Nice processes, so that companies know where they stand earlier and patients can access good drugs more quickly.

It could involve reviewing thresholds periodically to account for inflation and medical progress, without undermining the principle that treatments must show sufficient benefit. And it certainly means supporting research and development through stable partnerships with universities, tax incentives and grants.

What should not be underestimated is the UK’s scientific strength. The country remains home to world-class universities, skilled researchers and an innovative biotech sector. The rapid development of the Oxford–AstraZeneca COVID vaccine showed what UK science can deliver at scale and speed.

Pharmaceutical companies know this, and many – including AstraZeneca, GSK, Novo Nordisk, Pfizer, Johnson & Johnson and most recently Moderna – continue to invest in British labs and trials because of the talent and infrastructure. Danish firm Novo Nordisk has strengthened its ties with the University of Oxford, committing £18.5 million to fund 20 postdoctoral fellowships as part of its flagship research partnership.

The UK’s approach to assessing value has won respect internationally. That discipline must be preserved. Reversing the decline in investment means creating a predictable, transparent environment for industry while maintaining the protections that safeguard patients and taxpayers alike. If done well, the UK can continue to be both a responsible buyer of medicines and a world leader in science.

Source: https://www.brunel.ac.uk/news-and-events/news/articles/The-UK-must-invest-in-medicines

From open communication to community involvement, strategies help families tackle teenage substance abuse head-on

Teenage drug use remains one of the most pressing concerns for parents across America, with recent studies showing that experimentation often begins in middle school. While the challenge can feel overwhelming, experts agree that proactive parenting and strategic interventions make a significant difference in keeping teens away from harmful substances.

Establish open and judgment-free communication early

The foundation of drug prevention starts with creating an environment where teenagers feel comfortable discussing difficult topics. Parents who begin conversations about substances before experimentation occurs give their children the tools to make informed decisions when peer pressure arises.

Rather than waiting for a crisis, families should integrate these discussions into everyday life. Talking about news stories, television shows or situations involving drugs provides natural opportunities to explore consequences and share values without making teens feel interrogated or lectured.

Research consistently shows that adolescents who believe their parents would be extremely upset by drug use are less likely to experiment. However, this doesn’t mean ruling through fear. The key lies in expressing genuine concern while maintaining an open door for honest conversations, even when mistakes happen.

Creating this safe space means responding thoughtfully rather than reactively. When teens share information about their peers or express curiosity about substances, parents who listen first and lecture less build trust that pays long-term dividends.

Monitor activities while respecting growing independence

Effective supervision doesn’t mean helicopter parenting or invading privacy at every turn. Instead, it involves knowing where teenagers spend their time, who their friends are and what activities fill their schedules.

Parents should maintain relationships with other families in their teen’s social circle. This network provides valuable perspective on group dynamics and allows adults to coordinate supervision during gatherings and events. When multiple families share expectations about substance-free environments, teens receive consistent messages across their social sphere.

Setting clear boundaries about unsupervised time, particularly during high-risk periods like after school and late evenings, helps reduce opportunities for experimentation. Studies indicate that teens with structured activities and parental awareness of their whereabouts show lower rates of drug use compared to those with minimal oversight.

Technology offers both challenges and solutions in this arena. While social media can expose teens to drug culture, monitoring apps and parental controls provide tools for staying informed without constant confrontation. The balance lies in being present and aware without becoming invasive or controlling.

Build strong connections with schools and communities

Prevention extends far beyond the home. Partnering with schools, coaches, religious organizations and community programs creates a comprehensive support system that reinforces anti-drug messages.

Parents should actively engage with school counselors and administrators to understand prevention programs and warning signs staff might observe. Many schools offer parent education nights focused on substance abuse, providing current information about trends and available resources.

Encouraging participation in extracurricular activities gives teenagers positive outlets for stress and belonging. Whether through sports, arts, volunteering or clubs, structured programs fill time productively while connecting teens with positive role models and peer groups.

Community-based prevention programs often provide peer support groups where teens can discuss challenges with others facing similar pressures. These programs normalize the choice to remain substance-free and demonstrate that saying no doesn’t mean social isolation.

Recognize warning signs and seek professional help early

Even with strong prevention efforts, some teenagers experiment with drugs. Early intervention dramatically improves outcomes, making it essential for parents to recognize warning signs without dismissing concerning changes as typical adolescent behavior.

Significant shifts in friend groups, declining academic performance, changes in sleep patterns, unexplained money issues or loss of interest in previously enjoyed activities warrant attention. Physical signs like bloodshot eyes, unusual smells or coordination problems shouldn’t be ignored.

When concerns arise, parents should consult with pediatricians, school counselors or addiction specialists promptly. These professionals can assess whether experimentation has progressed to problematic use and recommend appropriate interventions.

Many families hesitate to seek help due to stigma or hoping issues will resolve independently. However, substance abuse disorders respond better to early treatment, and waiting often allows problems to deepen. Professional support provides families with strategies tailored to their specific situation while offering teenagers therapeutic tools for addressing underlying issues driving substance use.

Source: https://rollingout.com/2025/10/13/ways-parents-protect-teens-from-drugs/

guardin-logo

 By : Ijeoma Nwanosike –  16 Oct 2025

Experts and policymakers have called on Nigeria to harness technology not only as a tool for innovation but also as a means of combating drug and substance abuse, particularly among young people increasingly exposed to both digital and chemical dependencies.

The call was made at the seventh National Conference and yearly General Meeting of the International Society of Substance Use Professionals (ISSUP) Nigeria, held at the Lagos Chamber of Commerce and Industry (LCCI), Lagos, with the theme: “Impact of Technology on Addiction: Innovations in Prevention, Treatment, Advocacy, and Research.”

Delivering the keynote address, Director of Research, Training and Head of the Drug Abuse Unit at the Neuropsychiatric Hospital, Aro, Dr Sunday Amosu, described technology as a paradox, a force for progress and, simultaneously, a trigger for new forms of addiction.

He observed that while digital tools have expanded access to healthcare and prevention resources, they have also intensified compulsive behaviours, particularly among youth navigating the pressures of modern life.

“Technology can be a double-edged sword. The same innovation that helps us track recovery and connect patients to help can also fuel gaming, gambling, and social media addictions. Our task is to strike a balance, leveraging tech for good while mitigating its harms,” Amosu said.

Representing the Minister of Youth Development, Ayodele Olawande, the Senior Technical Adviser on Youth Health and Policy Research, Dr Obinna Chinonso, commended ISSUP Nigeria for sustaining national dialogue on addiction and mental health.

He reaffirmed the government’s commitment to addressing drug and substance use among the youth, who constitute nearly 70 per cent of Nigeria’s population.

“When a young person falls into addiction, whether to drugs, alcohol, or technology, they are robbed of the clarity and creativity needed to seize available opportunities,” he said.

Chinonso outlined several initiatives, including the YoHealth Initiative, a youth-focused programme that prioritises mental health and substance abuse prevention.

He also announced the establishment of a technical working group bringing together government agencies, development partners, and civil society to strengthen preventive interventions.

He added that the ministry would collaborate with ISSUP Nigeria and other stakeholders on national sensitisation campaigns, including the forthcoming Sensitisation Against Drug Abuse, Crime, and HIV Parliament Course, in partnership with the United Nations Office on Drugs and Crime (UNODC), the National Drug Law Enforcement Agency (NDLEA), and the National Agency for the Control of AIDS (NACA).

In his remarks, President of ISSUP Nigeria, Dr Martin Agwogie, reaffirmed the organisation’s commitment to building professional capacity and promoting cross-sector collaboration to reduce drug demand.

According to him, sustainable prevention “goes beyond rhetoric” and requires systems that integrate community participation, youth engagement, and mental health support at all levels.

Chairman of ISSUP’s Board of Trustees and chief host of the event, Prof. Musa Wakil, commended the collaborative spirit of the conference, describing it as “a critical moment for aligning Africa’s response to addiction with global trends in digital health and behavioural science.”

As Nigeria faces the growing challenge of both drug and technology-related addictions, participants agreed that the future of prevention lies not only in policy but in rethinking how technology itself can be repurposed as part of the solution.

Source: https://guardian.ng/features/health/experts-policymakers-seek-tech-driven-solutions-to-combat-drug-abuse/

 

Kateena Haynes’s smile warms the room as she weaves through playing children at her feet to get to the computer room, chatting with staff as she goes. There, the walls are lined with desktop computers for kids to do their homework. A few minutes later, walking around back under the hot Appalachian sun, she notes the outstanding construction tasks for the new Boys & Girls Club gymnasium, which would officially open later that year, and beams at the progress. Haynes runs the youth development center in Harlan, Kentucky, but even if you didn’t know her official title, you’d quickly figure out that she’s the heart of this place.

During the winter of 2010, 13 of the approximately 60 kids in the Boys & Girls Club of Appalachia had a parent die of a drug overdose. One was a young girl whose father had just returned from prison and asked her to inject opioids into his arm. She said no, knowing he had already had too much.

“He wound up getting out and coming back home and overdosing in the bed with his daughter in the bed with him,” Haynes said in a 2024 interview with Encyclopaedia Britannica.

From opium to Oxy: How history set the stage for the opioid epidemic

According to the U.S. Centers for Disease Control and Prevention (CDC), more than 800,000 Americans died of opioid overdoses between 1999 and 2023. The drug that drove the initial phase of the epidemic was OxyContin, or oxycodone hydrochloride, a narcotic painkiller that can produce a euphoria similar to that of heroin. For its part in producing and distributing OxyContin, pharmaceutical giant Purdue Pharma agreed in 2025 to pay $7.4 billion to all 50 U.S. states, Washington, D.C., and four federal territories. Harlan is expected to receive at least $10 million over 18 years to establish treatment, recovery, and prevention efforts throughout the community.

In the complex evolution from the opium plant to widespread synthetic opioids, the 19th century was a critical turning point. American dental surgeon William Thomas Green Morton first demonstrated opioids’ use for anesthetic purposes when combined with ether in 1846, not long after the popular and wildly powerful pain medications morphine and codeine were isolated from opium. These drugs were widely available and could be used without a prescription. Then in the latter half of the century, heroin was synthesized; it also didn’t require a prescription until 1914.

Before 1874 all opium-related drugs were considered natural opioids. Heroin, synthesized via chemical manipulation of natural opium, was the first in a class of semisynthetic opioids. It is much more powerful than natural opioids—and much more addictive. Though heroin would be a scourge for the second half of the 20th century, the perilous power of morphine dominated the first half.

Learn more about the difference between opioids and opiates.

In 1929 the National Research Council’s Committee on Drug Addiction was created with a very specific first target: morphine. While their researchers were at work on understanding addiction and regulating the use of morphine, meperidine, the first entirely synthetic opioid, was created, ushering in a new era of increasingly potent drugs that carry massive overdose risks. At the same time access to other addictive opioids became more common. While the early-to-mid-20th century brought the use of hydromorphone and hydrocodone for pre- and postoperative pain, the distribution of opioids entered a new era in World War II.

The U.S. gave members of its military medical kits that each included single-use morphine injections to provide pain relief to injured troops waiting for advanced medical personnel. Though they had labels that read “Warning: May be habit-forming,” those labels far understated the drug’s addictive potential. After the war some medical kits were sold or stolen by those seeking morphine doses, and others who’d become addicted turned to heroin when morphine wasn’t available.

In 1947 the Committee on Drug Addiction and Narcotics was established, revamping the effort begun in the 1920s. This renewed focus on controlling the manufacture and distribution of drugs was, in part, spurred by the creation by German researchers of methadone. Methadone had shown potential to mitigate symptoms of opioid withdrawal, a potential that had yet to be fully realized. Though research funding began to trickle in, progress stalled as no stream of financial support was established until the 1960s.

That decade was known for massive societal shifts in the United States driven by the civil rights movement, feminist advocacy, and the rise of a distinct counterculture grounded in the questioning of long-held beliefs. For some, this attitude of rebellion led them to try—and in some cases become dependent on—illicit drugs. The increased use of marijuana, LSD, and eventually cocaine, heroin, and amphetamines led to crackdowns on pharmacies that distributed these drugs as well as a greater focus on prevention and treatment.

In 1962 the White House Conference on Narcotic and Drug Abuse was convened with the goal of determining how to better collect data about drug use, how to manage the use of both narcotic and nonnarcotic drugs, and what treatments could help those facing addiction. That year federally funded mental health centers were established nationally.

The next major move, the Controlled Narcotics Act of 1970, sorted drugs into five schedules, or categories, based on addictive potential and harmfulness, as well as their medical utility. Heroin, which had a spike in use in the late 1960s and early ’70s, was classified as a Schedule I drug, meaning it had a high potential for addiction and no accepted medical use. Cocaine was labeled a Schedule II drug, meaning it had some medical utility. Despite growing attention throughout the presidencies of John F. Kennedy and Lyndon B. Johnson, the official War on Drugs was not launched until 1971, when Pres. Richard Nixon declared “drug abuse” to be “public enemy number one.” The Drug Abuse Council was founded the same year, as the result of the Ford Foundation’s research, and helped to provide funding for research through 1978.

Initially the War on Drugs was praised as a long-awaited intervention for a serious public safety issue, but in hindsight many have called the effort a failure, both ethically and politically. Even with increased attention on the country’s drug problem, the use of crack cocaine soared throughout the 1980s. It was affordable and provided quick access to euphoria, and its ability to be smoked allowed people to receive smaller portions—all of which made it more cost-effective than powder cocaine, which has historically been seen as a symbol of wealth.

Instead of going after large dealers or manufacturers, Nixon’s War on Drugs led to mass incarceration because it targeted people selling relatively small quantities of drugs, which often meant prison time for young Black men in urban areas who were charged with low-level drug offenses. The War on Drugs also brought the use of mandatory minimum sentences, which disproportionately affected Black communities. Those found with five grams of crack cocaine received a mandatory five-year prison sentence. It took 100 times that amount of powder cocaine to earn the same sentence, meaning that a high-level powder dealer could receive a lesser punishment than a low-level crack dealer. Though statistics show that overall drug use is similar between white and Black communities, four in five crack cocaine users were Black. Nixon’s former White House counsel, John Ehrlichman, gave an interview in 1994 in which he explained the intentional targeting of these communities:

The Nixon campaign in 1968, and the Nixon White House after that, had two enemies: the antiwar left and black people.… We knew we couldn’t make it illegal to be either against the war or black, but by getting the public to associate the hippies with marijuana and blacks with heroin, and then criminalizing both heavily, we could disrupt those communities. We could arrest their leaders, raid their homes, break up their meetings, and vilify them night after night on the evening news. Did we know we were lying about the drugs? Of course we did.

Today many see the War on Drugs as having meted out the disproportionate impact of incarceration on historically underserved communities—a pattern that the quickly emerging opioid epidemic would only exacerbate. While the War on Drugs perpetuated stereotypes about Black communities, public response to the opioid epidemic capitalized on and furthered derogatory caricatures of rural white communities before the epidemic spread to all corners of the country.

As cocaine use grew across the United States, so did addiction. The number of cocaine users increased by approximately 1.6 million people between 1982 and 1985 alone. So when Purdue Pharma’s OxyContin (its brand name for oxycodone) was approved by the U.S. Food and Drug Administration (FDA) in December 1995, concerns about drug addiction were prevalent—which made Purdue Pharma’s marketing of OxyContin as less addictive all the more appealing, even if it wasn’t true.

The epidemic

The major problem with OxyContin extended beyond the drug itself. In fact, studies at the time of its release showed that it wasn’t more effective than other opioid analgesics on the market. What set OxyContin apart and led to the opioid epidemic was the marketing and publicity around it.

In the five years after the FDA approved OxyContin, Purdue Pharma trained more than 5,000 medical professionals at all-expenses-paid conferences, often in resort locations, to aggressively promote the drug. While there, these clinicians were trained and recruited for a Purdue Pharma speaker’s bureau that encouraged promoting OxyContin use to colleagues in environments such as grand round presentations in hospitals. The company studied physicians’ prescribing patterns in order to better tailor their sales pitch to individual doctors—especially those with the highest rates of opioid prescriptions. Though this strategy was not unique, the amount of money spent on incentives and aggressive, misleading marketing campaigns were distinctive. The company spent $200 million in 2001 alone marketing OxyContin. Sales representatives also earned bonuses that sometimes outweighed their annually salary, incentivizing them to find physicians who would overprescribe the medication.

Before this period opioids had traditionally been reserved for severe acute pain, used in the palliative care of cancer patients, for example. But Purdue Pharma’s marketing focused on expanding the conditions for which doctors would prescribe OxyContin, leading to a tenfold increase in prescriptions for pain unrelated to cancer in just five years.

This gave rise to the targeting of rural areas such as Harlan. Mining and logging in these regions often led to workplace injuries, making them hotbeds for marketing of pain relief medications. Still, that wasn’t all that made Appalachian communities vulnerable. Since the 1990s Harlan had struggled with addiction and unemployment as the coal industry declined, with more than 25 percent of Harlan county’s population of about 25,000 falling below the poverty line as of 2025. As feelings of hopelessness spread, so did the drug epidemic.

Tom Vicini, president and CEO of Kentucky drug prevention and recovery organization Operation UNITE, explained in a 2024 interview with Encyclopaedia Britannica how this can happen. In early drug roundups law enforcement discovered that people selling opioids in the area needed money to feed their addiction, he said. If they were able to buy and resell others’ prescriptions, both parties could potentially make a profit off the drug.

Why is OxyContin called “hillbilly heroin”?

As the opioid epidemic spread, it quickly became associated with Appalachian communities. Hillbilly is a pejorative term used to describe those living in often low-income rural communities in the Appalachian Mountains. Given that OxyContin had overtaken both heroin and cocaine in becoming the new face of the drug crisis, it was often referred to as “hillbilly heroin” by national media outlets.

Though there is evidence that marketing of OxyContin may have been less aggressive in cities, they were far from immune. Doctors in New York City and other large metropolitan areas received funding from opioid giants and in turn promoted their products as a gold standard for pain relief. And with TV and other advertisements repeating claims of a 1 percent addiction rate, OxyContin advertising appealed to both new patients and longtime chronic pain sufferers. As the country would learn, the actual rate of addiction is much, much higher, with some researchers reporting it as high as 26 percent.

According to the National Institute on Drug Abuse, prescriptions were the most common entry to opioid addiction throughout the 1990s and 2000s—up to 75 percent of all addictions began this way. And prescriptions became more prevalent: Annual opioid prescriptions grew from between 2 and 3 million in 1990 to 11 million by 1999. Even as the addictive potential of OxyContin was publicized, other pharmaceutical companies followed suit in manufacturing generic or brand name pills, including the firms Johnson & Johnson, Endo, Teva, and Allergan. By the 21st century, Purdue Pharma alone had made $1.1 billion in OxyContin sales, more than 20 times the sales of 1996.

With the War on Drugs rhetoric weighing heavily on people’s minds, there is intense stigma associated with drug use and dependency. Through the 1990s and 2000s, the public began to shift from viewing addiction as a moral failing to seeing it as a disease—but this change has been gradual. For some the spread of addiction to all corners of the country, including to cities’ most “elite” residents, prompted this change. Highly publicized deaths involving opioid overdoses—including that of Australian actor Heath Ledger, which was caused by an accidental overdose of a mix of oxycodone and other drugs—further influenced public perception, leading to a renewed awareness of the addictive potential of prescription drugs. Although drug overdoses have long plagued Hollywood, Ledger’s death hit the public differently in light of the rising opioid crisis, especially given OxyContin’s role in his death.

Despite shifting attitudes on the subject, a 2017 study by researchers from Johns Hopkins University found that nearly four in five people think that those struggling with addiction are themselves at fault. Stigma and feelings of shame not only incentivize individuas to hide their addiction, but it can also keep many people from getting help by generating of a network of barriers. Structural stigma, for example, includes negative views held by society that influence the creation of policies that discriminate against those struggling with addiction, such as limiting the development of local treatment centers and the availability of medication for opioid use disorder (MOUD), reducing access to quality care. Self-stigma is internalized shame that can prevent someone from seeking treatment, either because they do not feel they deserve help, are embarrassed about their addiction, or because they lack systems of support.

Long after the opioid epidemic was widely recognized in the early 2000s, rates of opioid overdoses continued an unbridled rise across the country, reaching a peak during the COVID-19 pandemic and its aftermath. In 2022 more than 81,000 Americans lost their lives to opioid overdose, likely because of interruptions in treatment and psychological hardships caused by isolation, boredom, illness, or loss of work. This was especially prominent in people 20 to 39 years old, with opioid overdoses causing more than 20 percent of overall deaths in this age group in 2022, according to a study in The Lancet. Overdoses were the largest accidental cause of death for this cohort.

The physical withdrawal symptoms associated with quitting opioids make it hard to recover from opioid use disorder. Withdrawal can range from extreme physical symptoms such as vomiting and muscle spasms to emotional symptoms such as anxiety and depression. To help people recover, there has been a growing movement to make MOUD accessible.

MOUD includes methadone, buprenorphine, and naltrexone—with the former two considered by the World Health Organization to be “essential medicines” to treat opioid use disorder. MOUD normalizes neural chemistry and blocks the euphoria of opioids and is often paired with behavioral therapy to provide a comprehensive treatment plan that addresses both the physical and psychological effects of addiction and withdrawal.

That doesn’t mean these two approaches are mutually exclusive—in fact, many people rely on multipronged approaches to treatment and community support to recover from drug addiction. In Harlan numerous peer support specialists come from their day jobs to support AA or NA group meetings, which are held every evening in a building just down the alleyway bordering a bank.

Though significant gaps still remain, the shift in understanding opioid use as a public health epidemic rather than a personal moral failing has ultimately advanced the accessibility of recovery care across the country. But meeting the urgent need for support also requires funding—and there were companies that made a lot of money as a result of mass addiction and suffering.

Lawsuits and repairing communities

Large-scale lawsuits, often initiated by state attorneys general, began in the early 2000s, when West Virginia claimed that Purdue Pharma had misled medical professionals about the addictive potential of OxyContin in their aggressive marketing of the drug. The company admitted no fault but chose to settle, paying $10 million to the state over four years, to be used for drug recovery and prevention services.

That was just the beginning. In 2007 Purdue Pharma and three of the company’s top executives were fined a total of $634 million for lying to the public about OxyContin’s risk of addiction. Later that year Kentucky sued the company, and they eventually settled, with Purdue agreeing to pay $24 million to the state. But there was a pivotal clause in that agreement: The judge granted a request to unseal the court documents, making Purdue Pharma’s strategies public and unveiling the marketing strategies that propelled the spread of addiction.

Over the next decade a series of other high-profile cases involving Purdue Pharma were settled. They were brought by state and federal governments alike, including one suit brought by Canada that took more than a decade to settle, with the company ultimately agreeing to pay $20 million to individuals and health providers. Purdue Pharma declared bankruptcy in 2019.

No single settlement was as large as the $7.4 billion agreement Purdue Pharma reached with all 50 states, Washington D.C., and four U.S. territories in June 2025, to be paid out over 15 years to support prevention, treatment, and recovery programs. This resolution to pending lawsuits came just a year after the U.S. Supreme Court overturned what would have been a $6 billion settlement paid out to state and local governments. A large portion of the $7.4 billion is to come from the Sackler family, the former owners of Purdue Pharma.

Although the bell can’t be unrung, there is a breadth of research about how best to invest these abatement funds—and early evidence shows the funding may be helping to change the future of the opioid crisis. In the United States deaths from drug overdoses decreased approximately 27 percent in 2024 from the year prior, with opioid-related overdose deaths dropping by 30,365 cases. One of the states most exemplary of this change is Kentucky, where overdose deaths decreased more than 30 percent the same year.

In Harlan these abatement funds have been used to establish a position for a case manager and advocate for Casey’s Law, which allows family or friends to commit to treatment a loved one struggling with addiction. Van Ingram, executive director for the Kentucky Office of Drug Control Policy, told Encyclopaedia Britannica that there are more mental health resources now than ever, but that there’s never enough—not just in Harlan County, but in rural America as a whole.

What is Casey’s Law?

Officially known as the Matthew Casey Wethington Act for Substance Abuse Intervention, Casey’s Law was passed by Kentucky legislators in 2004 to allow relatives or friends of someone struggling with drug addiction to petition the court for that person to be involuntarily entered into a treatment program. The decision to admit someone to treatment without their consent remains a controversial subject, and many in the recovery space believe that someone must choose to enter recovery and cannot be forced into it. Before Casey’s Law was enacted, there was no way to force an adult to get help unless they committed a crime and were required by the court to enter treatment. The law is named for 23-year-old Casey Wethington, who died of a heroin overdose in 2002. His family believed his death could have been prevented if there had been another route to court-mandated treatment.

As Haynes, CEO of the Boys & Girls Club of Appalachia, and others work to provide mental health resources for their community, Ingram said he is impressed by the growth of Harlan’s recovery community.

Said Haynes: “We started a counseling program, grief counseling, before it actually became a program of Boys and Girls Clubs of America. We were doing it first because the need was there, and we couldn’t wait for them to develop a curriculum.”

Haynes and her colleagues developed a protocol for the kids if a relative died, taking them out to dinner and keeping them occupied while the family managed funeral arrangements.

She tries to mentor these children and give them opportunities that level the playing field, Haynes told Encyclopaedia Britannica: “It’s hard for some people to see beyond these mountains…especially these kids, who are seeing their parents use drugs, and they’re just hopeless.”

Simultaneously, other Harlan organizations have been working on prevention. Both Vicini and Haynes go into schools to provide education about drugs and addiction, as well as opportunities such as field trips and mentoring partnerships to keep kids engaged in their own futures.

The city’s small size enabled the opioid epidemic to spread quickly, but the intimate, close-knit relationships that the community provides have also allowed it to be a safe haven for many, including some who came there for recovery and never left.

With a combination of local efforts led by the city’s drug court and various recovery programs, including some focused on job reentry, Harlan has become an example of what an engaged recovery community can look like—and advocates believe that overdose rates are declining because of it.

Overdoses are decreasing on the national level, as well. According to a study published in the Journal of the American Medical Association, 2023 marked the beginning of “a new wave of sustained deceleration [in overdose rates]…after 2 decades of increase.”

The new wave: Dangers of fentanyl

The epidemic entered a new—and perhaps even deadlier—phase with the introduction of fentanyl. Though it has been around since 1959 as a pain reliever, illicitly manufactured fentanyl has grown increasingly popular since it became a major part of the U. S. illegal drug market in 2013. Drugs such as methamphetamines or cocaine are increasingly laced with fentanyl. In 2022, 6 out of every 10 of the millions of fentanyl-laced fake prescription pills collected by the U.S. Drug Enforcement Administration (DEA) contained a potentially lethal amount of the opioid, up 50 percent from the year before. Though a small segment of people who use drugs seek out fentanyl, many of those buying laced pills are unaware of its presence until it is too late.

Fentanyl is the one of the most potent pharmaceutical opioids and is 100 times more powerful than morphine. A dose of the drug equivalent to just five to seven grains of salt can be lethal, which is partially why it’s responsible for 70 percent of overdose-related deaths. And growing numbers of illegally obtained drugs are laced with fentanyl because its potency allows smaller doses of the pure drug to be sold while providing the same level of euphoria and even higher addictive potential, increasing both profits and demand. Even if it puts customers in danger, the money outweighs the risk for some sellers.

In a February 2025 U.S. Senate hearing, Sen. Dick Durbin of Illinois spoke about the growing risk of fentanyl:

In just a decade this synthetic opioid [fentanyl] has emerged as the deadliest drug in American history. All it takes is two milligrams—that’s a fraction of the size of a penny—to cause an overdose. It is so cheap that dealers are lacing lethal amounts into street drugs like cocaine and heroin, and their buyers are none the wiser.

Yet if communities can harness the growing concern about fentanyl for change, it may give a second chance to those struggling with substance use disorder. Since 2022 Harlan county has held an annual drug summit to bring together more than two dozen exhibitors with a focus on continuing to bring down overdose rates, even in the face of fentanyl.

Along with increased efforts to provide those struggling with addiction transitional housing, reemployment, and improved treatment accessibility, Harlan and other communities hit hard by opioids have another key tool: love.

“There’s people that came here for treatment and never left, because they were loved,” said Dan Mosley, Harlan county judge executive. “That’s truly what makes our place special.”

Source: https://www.britannica.com/topic/How-the-Opioid-Crisis-Devasted-Families-Communities-and-Ultimately-a-Country

 

United Nations

United Nations – Office on Drugs and Crime

07 October 2025

Practical, Digital and Tailored to Help You Grow

The United Nations Office on Drugs and Crime (UNODC) has officially launched its dynamic new Learning and Innovation Programme and with it, the new powerful digital training platform called SPARK.

SPARK brings flexible, high-impact learning to professionals worldwide – from bustling capitals to remote field stations.

In many low-resource or remote settings, criminal justice institutions face significant challenges, such as fragmented access to training, language barriers and geographical isolation. As a result, many practitioners lack training altogether, while those who do receive it often rely on sporadic training or outdated courses, leaving them underprepared for rapidly evolving threats.

UNODC, through the eLearning platform SPARK, addresses these challenges by providing multilingual online and offline courses and fostering a global community of practice. This approach bridges gaps and makes knowledge on justice more accessible worldwide.

Meet SPARK: Learn Anytime, Anywhere

This new Programme reflects a growing institutional shift toward digitalization and innovation not just as tools, but as essential strategies for building safer, more secure societies.

The Learning and Innovation Programme now focuses on three core areas:

  1. Digital training delivery across all UNODC thematic areas, i.e. the world drug problem, transnational organized crime; terrorism; corruption; and criminal justice.
  2. Pedagogical support to enhance the quality and impact of training provided by partners;
  3. Digital transformation for the internal operations and processes of criminal justice institutions and academies.

“This Programme introduces a new approach to capacity-building,” said Aimée Comrie, Chief of UNODC’s Crime Prevention and Criminal Justice Section. “It is practical, digital and tailored to help institutions grow stronger through innovation.”

At the heart of the Programme is SPARK – a powerful, modern digital learning platform that offers cost-effective, flexible interactive and accessible training tools for professionals across the criminal justice system. It includes self-paced eLearning courses, with interactive scenarios and simulations, as well as eClasses, which support both in-person and virtual training formats. Knowledge hubs, including webinars, online libraries, forums and podcasts are also featured. Moreover, content is localized, tailored to regional, national or local needs. 

Digital Transformation: From the Ground Up

Many criminal justice institutions, particularly in remote or underserved regions, continue to face serious barriers to modernization: limited internet access, power outages, outdated administration systems and low levels of digital literacy. These challenges not only hinder operational efficiency but also limit the ability of institutions to adapt to rapidly changing criminal justice threats.

The Programme directly addresses these obstacles by helping institutions digitalize core operations such as data management, administration, communication and training coordination. The Programme also providers basic digital literacy training, from device operation and email use to safe web navigation and online collaboration.

“Digital transformation is not just about technology – it is about empowering institutions to function more effectively, securely and inclusively,” said Nicolas Caruso, Head of the Learning and Innovation Programme. “By addressing infrastructure and skill gaps, we are helping justice institutions become more resilient and better equipped to meet the need of their communities.”

To ensure learning reaches even the most remote locations, the Programme has introduced  Mobile Training Units (MTUs) – portable kits containing a server, laptops and a router that can run for five hours without external power and be deployed in just 20 minutes. The MTUs have been deployed in 30 locations across West, Central and Eastern Africa, Latin America, South Asia and Southeast Asia, and North Africa and the Middle East.

Moreover, over 60 eLearning Centres have already been established globally, blending in-person instruction and creating local hubs for outgoing training.

Source: https://www.unodc.org/unodc/en/news/2025/October/unodc-ignites-innovation-with-new-learning-programme-and-spark-elearning-platform.html

by Ryan Hesketh – Talking Drugs – Posted on September 15, 2025

In November, the World Health Organisation (WHO) will issue its long-awaited recommendation on whether the coca leaf should remain listed under the UN’s most restrictive drug controls.

For decades, the coca leaf has been treated in international law as little more than raw material for cocaine. The 1961 Single Convention on Narcotic Drugs, following the advice of a deeply flawed 1950 WHO report, placed coca in Schedule I, equating its potential harm from use with that of heroin. This decision criminalised traditional use by Indigenous peoples in the Andes, despite millennia of practice, ignoring both its cultural and medical significance. 

Now, with WHO experts due to report their findings in September, attention is turning to whether the organisation can finally correct the record.

Critical timeline

Bolivia’s government initiated the review in 2023, arguing that coca’s scheduling was based on flawed information and infringed on indigenous rights. Since then, the WHO has tasked independent experts with conducting research on coca, its harms, and the potential impacts of change. Those experts are due to report their findings to the Executive Committee in late September, a crucial step on the pathway to potential change.

From there, the Expert Committee will meet in late October, finalising its report and recommendation in time for member states to consider ahead of the UN Commission on Narcotic Drugs’ (CND) reconvened session in December. The formal vote on coca’s scheduling, however, won’t take place until March 2026 in Vienna.

Luis Arce, the former president of Bolivia, holding coca leaves in 2022. Author: Vice Ministry of Communication of Bolivia

Uncertain outcomes

There are essentially three potential outcomes from the review. First, no action. Either the WHO makes no recommendation, which would result in no possibility of a vote, or states vote to maintain coca’s current Schedule I classification. Few expect the WHO to recommend keeping coca in its current schedule. “It’s hard to imagine they’d come to the conclusion that coca belongs where it is,” according to John Walsh, Director for Drug Policy and the Andes at the Washington Office on Latin America (WOLA).

If the review recommends a change in Coca’s scheduling, it would likely move down to either a Schedule II or III – still keeping its classification as a ‘narcotic drug’ subject to most treaty provisions. However, such a move would allow for certain traditional uses of coca and could be seen as a political compromise between those favouring full rescheduling and those favouring prohibition. This would create a clear difference in the scheduling for Coca and cocaine, similar to how opium products and the opium poppy are scheduled. Opium poppies are in Schedule II, while heroin is in Schedule I, reflecting the differing harms of the plant and its derivatives. Though rescheduling might be the most politically expedient outcome, and may align more closely with the UN’s Declaration on the Rights of Indigenous Peoples, it would still be very short of full removal, according to Walsh.

Finally, the result hoped for by many states and drug policy reform advocates: coca could be completely removed from the drug control treaties. This would mean that coca “would no longer be considered a controlled substance. It would open the way to legal natural commerce,” according to Walsh. 

While the size of such a market is hard to estimate, its significance would be massive. Coca teas, flours, and medicinal extracts already circulate domestically in the Andes – only legally within Bolivia as the country had left and re-joined the UN drug control conventions in 2013 – but international markets remain blocked by treaty restrictions. 

Yet there are also risks. Walsh cautions: “There’s a concern, even among those who want coca removed, that those who have guarded the tradition could be undermined.” Comparisons to the cannabis market loom large, where capital from the Global North has quickly moved into spaces originally meant by marginalised communities. The vision of a future un-criminalised market for coca opens future concerns, such as control mechanisms that avoid biopiracy and endorse fair benefit-sharing, particularly with communities that have been destroyed by the plant’s prohibition. The Nagoya Protocol, which addresses protections against the exploitation of genetic resources and Indigenous knowledge, is often cited as a model for future control.

Even in the case of full removal, coca wouldn’t be completely free of international prohibition. “Coca destined to become cocaine would still be illegal; that wouldn’t be optional,” according to Walsh. Better controls to determine the end use of coca would have to be developed.

Politics and removal

In theory, removing coca from Schedule I requires only a simple majority of CND member states. In practice, however, bloc politics loom large. “As a formal matter, there’s no veto. But in a practical matter, the EU looms large,” Walsh explains, given the bloc’s significant role in driving global demand for cocaine. If European states vote together against rescheduling, the motion would be unlikely to pass. However, if the EU allows states to vote individually, the change is much more likely to happen.

The United States’ position is also critical. As Walsh puts it, “It would be difficult to imagine if the US would be supportive of removing coca entirely.” But, though the US was once the world’s biggest supporter of draconian drug laws, its international influence may be waning. The current administration’s defunding of global aid, much of which supported harm reduction and drug prevention programmes, have reduced the US’ ability to enact soft power internationally. President Trump’s “transactional” politics, according to Walsh, may be a signal to countries that they can go their own way on policy while the US is pursuing a more isolationist approach to international relations.

Russia, too, will be notably absent. Having not achieved sufficient votes to remain part of the CND in April 2025, Russia will not be voting on UN drug-related matters from 2026 onwards. Walsh said that “Russia has taken the mantle from the US as ‘drug warrior’” and could’ve stood staunchly against coca’s reclassification. Their absence, therefore, may open new horizons.

The coca review is primarily supported by Bolivia and Colombia, with Canada, Czechia, Malta, Mexico, and Switzerland publicly supporting their position. Some coca-producing nations, notably Peru, are not in favour of reclassification. The country’s drug control agency, DEVIDA, recently argued that reclassifying coca “could become a perverse incentive to increase its diversion to the production of cocaine,” as well as increasing deforestation and food insecurity, especially for indigenous people.

But for some, Peru’s lack of support for the review has more to do with its political priorities than any attempt at harm reduction. “Peru’s denial to support this is indeed very odd, but is a reflection of the kind of political regime it is living under,” says Pien Metaal of the Transnational Institute (TNI). “The Boluarte government is the typical white Lima elite that has ruled Peru over the past decades, with no connection to the hearts and minds of the Peruvian people.”

Indigenous resistance

The roots of the current review go back to decades of Indigenous advocacy. The UN Declaration on the Rights of Indigenous Peoples recognises the right to maintain and protect traditional medicines and cultural practices. Yet international drug treaties continue to criminalise coca chewing and related practices in many countries. 

“There has never been a credible medical or scientific basis for the prohibition of coca leaf,” according to Metaal. “Its inclusion in the 1961 Convention was a political act, not a scientific one.”

Underlying the review is a reckoning with the colonial assumptions that shape global drug control to this day. The 1950 WHO study that underpinned coca’s prohibition dismissed Indigenous practices as harmful and regressive, ignoring evidence of its benign cultural role. For many advocates, the current review is an overdue opportunity to correct that record. As Metaal argues, “This is not just about drug policy. It is about dignity, cultural survival, and Indigenous rights.”

Impending Change

For coca-using and growing communities, the implications are immediate. Continued criminalisation undermines cultural practices, justifies militarised eradication, and fuels human rights abuses. Removing the plant from international control could finally legitimise its traditional use, defund eradication policies, and unlock new economic opportunities grounded in heritage rather than prohibition.

As Walsh reflects: “In five years, I hope that we’re able to see a genuinely growing understanding of how natural coca products can really bring a lot of help to people around the world. I hope those markets can open up and can be beneficial to those communities that are most identified with coca.”

With the WHO’s deadlines fast approaching, the question is whether the international drug control system can rise to meet the moment—or whether it will once again fall back on outdated prejudices, leaving another generation of Indigenous peoples to fight for recognition of what they already know: that prohibition, not the coca leaf, is the problem.

===============================

Source:  https://www.talkingdrugs.org/upcoming-who-coca-review-a-turning-point-for-global-drug-policy/

by Jack Fenwick – BBC Political correspondent – 16 September 2025

Hilary’s son Ben died from a heroin overdose in 2018, but his death was never included on official opioid death statistics

More than 13,000 heroin and opioid deaths have been missed off official statistics in England and Wales, raising concerns about the impact on the government’s approach to tackling addiction.

Research from King’s College London, shared exclusively with BBC News, found that there were 39,232 opioid-related deaths between 2011 and 2022, more than 50% higher than previously known.

The error has been blamed on the government’s official statistics body not having access to correct data and it is understood ministers are now working with coroners to improve the reporting of deaths.

A former senior civil servant said fewer people might have died if drug policies had been based on accurate statistics.

The number of opioid deaths per million people in England and Wales has almost doubled since 2012, but this new study means the scale of the problem is likely to be even greater.

Researchers from the National Programme on Substance Use Mortality at King’s used data from coroners’ reports to calculate a more accurate estimate of opioid-related deaths.

Opioids include drugs such as heroin that come from the opium poppy plant, as well as synthetically-made substances like fentanyl.

The Liberal Democrats have said the government needs to “urgently investigate” how the error was made.

The reliability of the Office for National Statistics (ONS) data relies on coroners naming specific substances on death certificates, something which often does not happen.

Specific substances such as heroin are instead sometimes only included on more detailed post-mortem reports or toxicology results, which the ONS does not have access to.

Government data on overall drug deaths, which does not name specific substances, is not affected by the error, but ministers’ decision-making is generally influenced by the more granular statistics.

The body that oversees police commissioners says correct data on opioid deaths could have led to more funding and better treatment for front-line services such as police forces and public health.

Sir Philip Rutnam, who was the most senior civil servant at the Home Office between 2017 and 2020, told the BBC it was “quite possible” that fewer people would have died, if the government’s drug policies had been based on accurate statistics.

He told BBC Radio 4’s PM programme: “It really does matter, first of all the level of attention given to these issues, but then specifically it will affect decisions on how much funding to put into health-related programmes, treatment programmes, or into different bits of the criminal justice system.”

“My son’s death is one of thousands missed from official stats”

Ben was 27 when he died from a heroin overdose in 2018, but his death was ruled as “misadventure” and was never included on the official opioid death statistics.

His addiction began with cannabis when he was a teenager and progressed to using aerosols and eventually heroin.

“Ben was just a very kind person. We miss him, we all miss him every day,” said his mother Hilary.

At one point, she said Ben appeared to “turn a corner”.

He was awarded a place in a rehab facility, but shortly before he was set to move in, Hilary got the phone call she had always dreaded.

“I think what happened is, he wasn’t using,” she said. “They think probably about three months and his tolerance had gone down.”

Ben’s family believe that different treatment and support for drug addicts could have helped him.

Dr Caroline Copeland, who led the new research, said drug policies “will not have the desired impact unless the true scale of the problem is known”.

She added: “We need to alert coroners to the impact that not naming specific drugs as the cause of death has on the planning and funding of public health policies.”

The research, which has been peer-reviewed and published in the International Journal of Drug Policy, focused specifically on opioid deaths, but similar undercounts are thought to exist in data about deaths from other drugs too.

Further work by King’s College London has found that 2,482 cocaine-related deaths have also been missed off ONS statistics over the last 10 years.

David Sidwick, the drugs lead for the National Association of Police and Crime Commissioners, told the BBC the organisation would “be pushing hard” for more treatment funding, in light of the faulty statistics.

Mr Sidwick, who is also a Conservative police and crime commissioner, said more accurate data would lead to “better decisions about the amount of funding required for treatment” and suggested “new treatment methods” such as buprenorphine, a monthly injection that can help heroin users overcome addiction.

Helen Morgan, the Liberal Democrat health spokesperson, said: “I dread to think of the lives that may have been lost due to damaging policies based on faulty stats.”

She added: “The government now needs to step up, launch an investigation and ensure that the ONS is given access to the data it needs so that it can never make this error again.”

The ONS, which helped with the research, said it had warned that “the information provided by coroners on death registrations can lack detail” on the specific drugs involved.

A spokesperson added: “The more detail coroners can provide about specific drugs relevant to a death will help further improve these statistics to inform the UK government’s drug strategy.”

The flaw in the ONS system is not present in Scotland, where there are no coroners and where National Records Scotland (NRS) is responsible for collating official statistics.

Unlike the ONS, the NRS does receive more detailed pathology reports, but differences in how deaths are reported across the UK make it difficult to compare.

The opioid undercounting raises further questions about the under-fire ONS, which has been accused of failing on several statistical fronts recently.

Data sets on job markets and immigration have been criticised and earlier this year a government review said the ONS had “deep-seated” issues which needed tackling.

A spokesperson for the Department of Health and Social Care said: “We continue to work with partners across health, policing and wider public services to drive down drug use, ensure more people receive timely treatment and support, and make our streets and communities safer.”

 

Source:  https://www.bbc.co.uk/news/articles/cg7dzmyjrjzo

 

by Boston Herald editorial staff – September 17, 2025

There’s a renewed push to legalize overdose prevention centers  on Beacon Hill, with advocates touting supervised drug use as harm prevention.

That depends on how one defines harm.

At these centers, trained health care workers would supervise individuals who use pre-obtained illicit drugs — and they could intervene and prevent fatal overdoses.

Yes, addicts could avoid overdosing and live another day — another day in which they’d steal or prostitute themselves to buy drugs, another day in which opioids could further damage their mind and body, and another day to stumble through the degradation of a life ruled by drugs.

The real winners? Drug dealers and traffickers. Their clientele may have access to rehabilitative services through these centers, but that cry for help may not come for a long time. Meanwhile, they are willing customers for those “pre-obtained” drugs.

In these progressive parts, the law is to be followed except if you don’t like it. Therefore, these proposals would provide legal protections for workers, drug users accessing the facilities, government officials and other stakeholders. Because the drugs being injected are, of course, illegal.

Rep. Mindy Domb, co-chair of the Joint Committee on Mental Health, Substance Use and Recovery, said Massachusetts last year recorded fewer than 2,000 fatal overdoses, breaking a grim years-long trend.

Yes, naloxone is an amazing thing, and distribution of Narcan has saved many lives from overdoses. But making drug addiction safer with the added net of Narcan is like putting a bandage on a deep wound.

One can’t fight the opioid crisis by prolonging addiction. Keeping up the demand for drugs fuels the supply and the crime that comes with trafficking. And the drug market only gets worse.

Nitazenes have entered the chat.

Last year, a state-funded drug checking program in Massachusetts has found opioids up to 25 times stronger than fentanyl, according to WBUR. In a bulletin, public health officials say the number of drug samples testing positive for nitazenes is small — but growing quickly.

“The more that we crack down on things like fentanyl and heroin, that’s going to lead to the rise of other things that are infiltrating the drug supply,” said Sarah Mackin, director of harm reduction at the Boston Public Health Commission.

“Nitazenes is just the newest thing to come through,” after xylazine, the animal tranquilizer found in 9% of overdose deaths in 2023.

However, an investigation of records from hospital emergency departments published by the JAMA Network found it often takes more doses of naloxone to reverse an overdose when nitazene is involved than it would take to reverse a fentanyl overdose. Further study is needed.

Keeping the drug cycle going, however “safely,” isn’t a step in the right direction, it’s just another foot forward on the addiction treadmill.

We need addiction reduction, stat. We need to fund programs such as Boston Medical Center’s Faster Paths to Treatment, its substance use disorder urgent care program. And we need more of them.

True harm reduction comes from helping addicts get clean so they can live full, productive lives.

Source: https://www.bostonherald.com/2025/09/17/editorial-rehab-is-the-best-harm-prevention-for-addicts/?

 

ABU DHABI, 3rd August 2025 (WAM) — The International Society of Addiction Medicine (ISAM) has praised the federal decree-law issued by President His Highness Sheikh Mohamed bin Zayed Al Nahyan establishing the National Anti-Narcotics Authority, describing it as a vital and effective tool that enhances the UAE’s quality of efforts in combating narcotic drugs and psychotropic substances and eliminating their sources.

In a statement, ISAM affirmed that the decree issued by the UAE President reinforces the country’s comprehensive and precise approach in tackling the global threat of drug abuse.

It stated that the UAE has continually updated its legislation to combat narcotics, while simultaneously advancing its security, prevention, treatment and awareness efforts, which have significantly contributed to curbing this menace.

Dr. Hamad Al Ghafri, President of ISAM and Board member of the American Society of Addiction Medicine (ASMA), stated that the establishment of the National Anti-Narcotics Authority provides a holistic framework for developing policies and strategies to combat drug abuse, including mechanisms for prevention, treatment and rehabilitation.

He added that the legal powers granted to the authority would play a key role in enhancing the UAE’s national efforts and institutions, which work relentlessly to eliminate drug sources and confront those who target the country’s youth.

Dr. Al Ghafri explained that the authority’s mandate is built around several core pillars, including reducing both the supply and demand for drugs by tracking and dismantling trafficking networks, bolstering treatment and rehabilitation systems to reintegrate recovered individuals into their families and communities, and advancing legislative frameworks alongside dedicated research.

“These efforts will support community-based prevention initiatives, establish a unified national monitoring system, and promote international collaboration in training and capacity-building. These pillars are central to achieving an integrated approach that combines preventive, security and therapeutic dimensions to effectively tackle all facets of the drug issue,” he added.

Dr. Al Ghafri reaffirmed ISAM’s commitment to supporting all initiatives and programmes related to combating narcotics and psychotropic substances, while enhancing cooperation and coordination and adopting efforts that contribute to building safe and drug-free societies.

Source: https://www.wam.ae/en/article/bl0dfij-isam-praises-uae-presidents-decree-law

new study from researchers at the Johns Hopkins Bloomberg School of Public Health sheds light on how people who inject drugs (PWID) are responding to the growing instability and danger in the U.S. illicit drug supply. Despite facing structural vulnerabilities, participants in the study demonstrated a keen awareness of changes in drug quality and content, and many are taking proactive steps to reduce their risk of overdose, injury, and other harms.

Published July 24, 2025, in the journal Health Promotion International, the qualitative study explores the experiences of 23 PWID in Baltimore City, where a growing number of opioid-related deaths and the emergence of new, harmful adulterants like xylazine have made drug use increasingly perilous. Participants reported encountering potent and unpredictable drug combinations and described cognitive, behavioral, and social strategies they use to navigate this new reality. Notably, the paper’s publication comes just two weeks after a mass overdose in Baltimore’s Penn North neighborhood sent dozens of people to the hospital in the span of a few hours and tests revealed unfamiliar ingredients.

“We found that people who inject drugs are not indifferent to the risks they face,” said lead author Abigail Winiker, PhD, MSPH, an assistant scientist in Health Policy and Management and program director for the Bloomberg Overdose Prevention Initiative. “They are making conscious decisions every day to protect their health, whether that’s testing a small dose, avoiding injecting alone, switching to less risky methods of use, or sharing safety information with peers. These are intentional harm reduction strategies grounded in knowledge and a desire to stay safe.”

The U.S. continues to grapple with a historic overdose crisis, with over 107,000 deaths reported in 2022 alone. Fentanyl and its analogs now dominate the opioid supply, but new substances, often unknown to users, are increasingly present. Participants in the study described a “wildcard” market where real heroin has been replaced by unpredictable blends, sometimes laced with benzodiazepines, dissociative agents, or tranquilizers like xylazine, which are not meant for human consumption.

The uncertainty has led to intense fear and physical harm among PWID, with many recounting a range of adverse reactions from illicit substance use, including blackouts, seizures, severe wounds, and overdose. Despite the increasing risk associated with these drug market changes, most participants reported having no access to a reliable source of information about the composition of the drug supply, making it challenging to adapt in the face of new additives. Most knowledge about specific risks or harmful batches was passed on through word of mouth, which could perpetuate rumors and the spread of misinformation.

Individual and Collective Adaptations 

The study highlights the wide array of harm reduction strategies participants use to mitigate risk. Cognitively, many indicated thinking about their drug use in terms of personal health and family responsibilities, with some expressing a motivation to seek treatment or abstain from use entirely in the face of an increasingly risky drug supply.

Behaviorally, PWID described strategies such as taking smaller test doses, sniffing instead of injecting, and having someone present who could administer naloxone if needed. Socially, trust played a critical role; participants emphasized returning to known sellers who warned them about potent batches and relying on peer networks to spread information about adverse events or dangerous batches in circulation. 

“These strategies reflect a deep sense of agency and adaptability,” said Winiker. “Our findings debunk the dangerous myth that individuals who use drugs are reckless or disconnected from their health. This false narrative perpetuates stigma and limits our ability as a society to recognize the incredible resilience and strength of people who use drugs.” 

Policy and Programmatic Implications 

The authors argue that these findings should inform more responsive public health policies and harm reduction programming. While fentanyl test strips can be an effective intervention, many participants noted that fentanyl’s presence is now expected, but what they fear are the unknown additives they cannot identify or test for, such as those that were found in the case of the mass overdose two weeks ago. Universal drug checking services, real-time supply surveillance, and mobile harm reduction outreach are critical next steps, the study concludes.

The research also points to the urgent need to remove structural barriers to harm reduction. In many states, drug checking equipment is still considered illegal paraphernalia. Criminalization and stigma continue to limit access to lifesaving services, especially among those who are unhoused or medically underserved. 

“People who inject drugs are doing their part to reduce harm,” said Winiker. “It’s time to reform our systems so they stop making it harder for them to do so, by legalizing drug checking, ensuring individuals with lived experience have leadership roles in overdose prevention and response efforts, investing in safer supply programs, and ensuring that stigma and punitive laws don’t block access to care.”

The study was conducted as part of the SCOPE Study, a project led by Susan Sherman, PhD, MPH, to design an integrated drug checking and HIV prevention intervention. It was supported by the National Institute on Drug Abuse and reflects growing interest in how PWID are adapting to the post-fentanyl era.

Source:  https://publichealth.jhu.edu/2025/in-the-face-of-a-volatile-drug-supply-people-take-harm-reduction-into-their-own-hands

by Shane Varcoe – Executive Director for the Dalgarno Institute, Australia – Jul 23, 2025

Alcohol affects 15 of the 17 United Nations Sustainable Development Goals, yet remains one of the most overlooked barriers to global progress. Behind the marketing messages and cultural acceptance lies a stark reality: alcohol is a Group 1 carcinogen causing seven types of cancer, with no safe level of consumption.

This week on the Unnecessary Harm Podcast,  we welcomed Kristina Sperkova , President of Movendi International , a global network of over 170 organizations across 63 countries working to reduce alcohol-related harm. Kristina shared powerful insights from her decade of leadership at the forefront of international alcohol policy advocacy, including her recent work at the World Health Assembly.

Kristina reveals how alcohol undermines everything from poverty reduction to gender equality, the predatory tactics of Big Alcohol at UN meetings, and the groundbreaking policy wins that are reshaping how the world views alcohol taxation and regulation.

 Key Takeaways From This Episode 

  • Massive Global Impact: Alcohol directly affects 15 of 17 UN Sustainable Development Goals, from perpetuating poverty cycles to fueling intimate partner violence (50-80% of violent acts are alcohol-related).
  • Environmental Devastation: Producing one liter of beer requires 270 liters of water, highlighting alcohol’s massive environmental footprint through water depletion and agricultural monocultures.
  • Cancer Connection: Since 1988, alcohol has been classified as a Group 1 carcinogen alongside tobacco and asbestos, yet public awareness remains dangerously low.
  • Industry Deception: Big Alcohol uses front groups, creates dependency through corporate partnerships, and spreads lies about employment impacts and illegal production to derail effective policies.
  • Policy Solutions Work: WHO’s “best buys” – availability restrictions, marketing bans, and public health taxation – are proven, fast-acting interventions that reduce consumption and generate revenue.

Recent Victory: After 10 years of advocacy, alcohol taxation was officially recognised as a source of domestic resource mobilisation at the Financing for Development conference – a major breakthrough for global policy.

Source: https://www.linkedin.com/pulse/alcohols-global-impact-fight-evidence-based-policy-shane-varcoe-fmc8c

 

OPENING REMARK BY NDPA:

Dianova presents itself as a “Swiss NGO recognized as a Public Utility organization, committed to social progress”. Examination of their publications places them as an organisation which is less committed to primary prevention than to reactive approaches, such as harm reduction. A telling quote in this context comes in their publication entitledBetween Music and Substances: a Look at Drug Use at Festivals” they introduce this by saying Drug use is a common occurrence at most music festivals: how can we promote self-care and harm reduction among participants?”there is no mention of prevention as a policy option.

In their ‘history’ Dianova take a position found not infrequently in some other other critics of prevention i.e. any prevention program which does not achieve 100% success is deemed a failure … but no such assessment is made of reactive or accepting policies.

In this publication they dismiss the ‘Just Say No’ program as “…focusing mainly on white, middle-class children, it simply pointed the finger at others, particularly black communities, who were held responsible for the problem.” And yet immediately below this statement they include a photo of a White House ‘Just Say No’ rally, with Nancy Regan surrounded by black youngsters.

Dianova make judgemental remarks – without supporting evidence – in several places, and NDPA take would issue with several of these, but we have elected to retain this paper complete with their judgemental remarks, to illustrate their position on the ‘history’ as they see it.

by the Dianova.org team – 

From the early 20th century to the present day, an overview of the origins of drug use prevention, past mistakes and the current situation in this field

By the Dianova team – Over the past 40 years, prevention has become a key focus of public intervention in many areas, including responses to social issues such as alcohol and other drug use. Prevention strategies are now most often part of a comprehensive approach combining prevention, treatment and harm reduction, and taking into account the needs of people who use drugs and those of society as a whole.

These initiatives are developed on the basis of applied research in the humanities and social sciences, and their implementation and evaluation are based on scientifically validated strategies designed to answer one key question: do they work?

Understanding risk factors is crucial in modern drug prevention interventions, as it enables us to address the root causes of substance use and promote protective factors such as strong family bonds, engagement with school, and community support – Image by stokpic from pixabay, via Canva

Rather than raising awareness of the ‘dangers of drugs’, most initiatives today prefer to target risk factors and protective factors at the individual, family, community and environmental levels. These interventions are designed to be person-centred, while taking into account the many complex interactions between personal and environmental factors that may make certain populations more vulnerable to substance use or addiction. However, this has not always been the case. So what was prevention like before? Is prevention today so different from what it was in the past?

The origins of prevention: combating the ravages of alcohol

All forms of prevention stem from the 19th-century school of thought influenced by Pasteur’s work on the spread of disease: hygienism. This developed in a society plagued by diseases such as tuberculosis and cholera, which were widespread in most European countries, as well as in India, the United States and Canada.

With regard to substance use, it was alcohol that initially became the focus of efforts in Western countries. . In the countries concerned, the Industrial Revolution caused a profound change in drinking habits and exacerbated related problems. The advent of industrialization precipitated a period of exponential growth in the production, transportation and commercialization of alcohol. In urban areas, which experienced a significant increase in population following the rural exodus, millions of workers, reliant on their employers and lacking in social rights, found solace in alcohol, which had become readily available and inexpensive. Alcohol consumption increased significantly, as did the associated problems.

The temperance movement, a group of religious associations and leagues committed to combating the social ills of alcoholism, fought against the consumption of alcohol in the name of morality, good manners and the protection of the family unit. The influence of this movement grew until it reached its zenith in the early 20th century with the advent of alcohol prohibition laws, not only in the United States, but also in Canada, Finland and Russia – with the results we all know.

“The voluntary slave” – press illustration published in “La Fraternité” (France) for the Popular Anti-alcoholic league, author Adolphe Willette – circa 1875 – Adapted from screenshot from L’histoire par l’image

What about illegal drugs?

At the dawn of the 20th century, the concept of ‘illegal’ drugs had yet to be established. Europe and America had recently discovered a ‘remarkable substance’ – cocaine – lauded for its medicinal properties, touted as a panacea for all maladies. Initially imported in small quantities for medical research, its use grew rapidly, particularly within the medical community, and it was prescribed to treat a wide range of ailments, from toothache to morphine addiction. Sigmund Freud himself considered at the time cocaine to be a highly effective medicine for depression and stomach problems without causing addiction or side effects. With regard to cannabis and hashish, these were still available for purchase in all reputable pharmacies, while heroin, a registered trademark of the Bayer pharmaceutical company, was regarded as a sovereign remedy for… coughs.

It should be noted that the issue of substance addiction had not yet manifested itself in the context of affluent, colonizing nations. Elsewhere, the perspective was somewhat different: in a distant country – China – opium had already been wreaking havoc for several decades.

Introduced and marketed by Europeans, it had become a pervasive national scourge affecting millions of Chinese people. Opium  addiction is a prime example of the impact of colonialism on local societies: not only did it trigger two wars against Western powers concerned solely with their economic interests (profits from the opium trade), but it also had profound social and political consequences that are still felt today.

The Western countries’ ‘honeymoon’ with drugs was not to last. The problems they posed became apparent rapidly and, under the influence of American temperance leagues, they swiftly transitioned from being regarded as a universal remedy to being perceived as a threat to society and moral values. This marked the beginning of American policies predicated on drug control (or the war on drugs, depending on one’s perspective), which would shape global policies in this domain for over a century.

The demonization of ‘drugs’

The demonisation of drugs, the effects of which were felt from the beginning of the 20th century, is closely associated with a set of social, racial, political and economic dynamics that resulted in the stigmatization of both the substances themselves and the people who consumed them. As early as 1906, the United States initiated the legislative process, and the phenomenon grew until it culminated in a particularly restrictive and repressive international drug control policy – but that is another matter.

In the 1930s, the American government initiated a media offensive involving the use of racist stereotypes, sensationalist media, and political propaganda to portray cannabis as a dangerous substance that led to violence, insanity, and moral decay.

The process of demonizing drugs was gradual yet unstoppable. The discourse surrounding narcotics such as morphine, opium and heroin was initially shaped by their association with specific demographic groups, namely minorities, the economically disadvantaged, and migrants. This demonization continued over the following decades, fuelled by media sensationalism and public panic, particularly around the use of cocaine and cannabis – substances that were claimed to be the root cause of criminal behaviour and moral corruption.

The criminalization and stigmatization of substances and those who use them have had a profound impact. Not only have they perpetuated and reinforced racist prejudices against Afro-descendant, Latin American and other historically marginalized communities, but they have also completely distorted the approaches and prevention efforts implemented subsequently.

Early drug prevention initiatives

Before the 1960s, the ‘drug phenomenon’ was virtually non-existent in industrialised countries. Apart from a few opium enthusiasts, alcohol and tobacco reigned supreme in the field of substance addiction.

From the 1960s onwards, there was a rapid increase in the use of illegal drugs in the United States, particularly among the counterculture movement. The use of LSD and cannabis – and, to a lesser extent, amphetamines and heroin – spread and became a symbol of rebellion against authority, as part of a broader movement focused on social change.

Within the collective imagination, the 1960s are often regarded as the golden age of illegal drug use. This period was characterised by widespread use of cannabis, as well as the significant distribution of heroin among children in impoverished neighbourhoods. Notable figures such as Timothy Leary, a prominent Harvard professor, popularised the effects of LSD. However, an analysis of historical data reveals that the phenomenon was not as widespread as is commonly believed. Conversely, however, there was a marked increase in the perception of risk associated with drugs. For instance, in 1969, a mere 4% of American adults reported having used cannabis at least once. However, 48% of respondents indicated that drug use was a serious problem.

While many current prevention efforts have a solid theoretical basis and evidence of effectiveness, historic prevention strategies were often based on intuition and guesswork, with an emphasis on such scare tactics as the one depicted above (“Your brain on drugs” campaign, initially launched in 1987)

The notion of prevention as a concept was first developed in the early 1960s within the domain of mental health and behavioural disorders. In the context of drug policy, the first initiatives were echoing the pervasive fear of drugs that was prevalent in both America and Europe during that period. Logically, the primary initiatives were consistent with the propaganda campaigns initiated in previous decades with the objective of demonizing cannabis. The objective of these initial prevention initiatives was not to promote education, but rather to instil a sense of fear and intimidation.

Children and young people in the 1960s and 1970s were no more stupid than anyone else and just as observant. They quickly realised that the messages promoted by schools and families did not correspond to reality.

So simple, ‘Just Say No’.

In 1971, Richard Nixon declared drug abuse ‘public enemy number one’ and launched a widespread campaign against drug use, distribution and trafficking. This marked the beginning of a government policy that led to the incarceration of both traffickers and users. The policy would have far-reaching consequences for many countries, whilst in the United States it would have a disproportionately negative impact on the Black community.

The notion that one should ‘Just Say No’ to drugs is predicated on a rudimentary interpretation of the rational choice model, according to which people choose their behaviour in order to maximize rewards and minimize costs (negative consequences).

Nancy Reagan at a “Just Say No” rally at the White House in May 1986 – White House Photographic Collection, public domain

The D.A.R.E. programme: information is not enough

From 1983 onwards, this concept became central to the D.A.R.E. (Drug Abuse Resistance Education) programme. Initially implemented in Los Angeles, this school-based programme aimed to help young people understand that the harmful consequences of drug use far outweigh any perceived benefits. Young people can therefore avoid these consequences by refusing to take drugs.

The D.A.R.E programme’s model was based on three key elements: 1) drugs are bad; 2) when children understand how bad drugs are, they will avoid using them; and 3) the message is more effective when delivered by police officers, who are considered credible.

The programme was subsequently developed in the United Kingdom, and a similar model was adopted elsewhere in Europe during the same period — notably by associations of rehabilitated individuals — which replaced the credibility of police officers with that of former drug users ‘who could speak from experience’.

In response to findings on the ineffectiveness of the DARE programme, a new curriculum was developed (2009) with a stronger focus on interactive activities and decision-making skills, moving away from the traditional lecture-based approach by a police officer – AI-generated image, via Canva

Over the years, the programme has been the subject of extensive study. One study found that people who completed the programme had higher levels of drug use than those who did not. Another study found that teenagers enrolled in the D.A.R.E programme “were just as likely to use drugs as those who received no intervention”.

The impact of popular culture

The aim here is not to portray the D.A.R.E. programme or similar interventions solely in an unfavourable or ridiculous light. Even though it has lost its central position, the programme is still implemented in most US states, and according to its website, it has been developed in 29 countries since its creation. It is true that the programme has since been adapted to incorporate various aspects, such as resistance to peer pressure and the development of social skills.

However, these initiatives face a major difficulty from the outset. As we know, experimentation and risk-taking are part of normal adolescent development, which is why providing young people with detailed information about different substances is likely to arouse their interest in these drugs, especially if the information is not presented in an appropriate manner. Secondly, this type of strategy only has an impact on young people who are susceptible to alarmist messages because of their cognitive patterns, and is not effective for everyone else, as we now know.

Officers in the DARE programme would sometimes arrive in sports cars seized from drug traffickers to exemplify their message on drugs and crime (Crime does not pay) – A Pontiac Firebird in D.A.R.E. livery in Evesham Township, New Jersey – image: Jay Reed – Flickr, licence: CC BY-SA 2.0

Furthermore, when talking about drugs, one must also consider the influence of popular culture, which, without openly glorifying substance use, often portrays alcohol, tobacco, and other drugs in a favourable light, particularly at an age when young people are most receptive.

We now know that providing information about drugs is not enough to make for a good prevention policy. While education and awareness can always play an important role, they are not sufficient, nor even necessary, to prevent addiction.

Should we talk about drugs to prevent drug use?

According to Dr Rebecca Haines-Saah, who spoke at a webinar organised by Dianova last May, the most effective drug prevention strategies do not focus on drugs, but on much broader social issues, such as reducing poverty, combating discrimination and implementing targeted community programmes.

These approaches aim to create conditions that indirectly discourage drug use, particularly by strengthening social skills and improving people’s living conditions. For example, programmes focused on improving the school environment, teaching social skills or promoting healthy lifestyles can have a positive impact on reducing substance use without explicitly targeting drugs.

Similarly, family interventions that strengthen parent-child relationships and improve communication can also help prevent substance misuse by targeting underlying risk factors. These strategies highlight the importance of a holistic approach to prevention that goes far beyond direct drug education.

Prevention is a science

Preventing substance use – i.e. the use of all psychoactive substances regardless of their legal status –  involves helping people, particularly young people, to avoid using substances. If they have already used substances, the objective is to prevent them from developing substance use disorders (problematic use or dependence).

However, the overall objective is much broader, as highlighted by the UNODC in the second edition of the International Standards on Drug Use Prevention. It also involves ensuring that children and adolescents grow up healthy and safe, so they can fulfil their potential and become active and productive members of society.

Drug prevention is now grounded in research and evidence-based practices. This multi-disciplinary field has developed over the last forty years, aiming to improve public health by identifying risk and protective factors, assessing the efficacy of preventive interventions, and identifying optimal means for dissemination and diffusion –  AndreyPopov from Getty Images, via Canva

There is now a vast body of literature on substance use prevention. Its aim is to highlight effective and less effective strategies based on scientific evidence in order to guide decision-makers and practitioners in the field in their choices. Despite this, prevention activities are still sometimes poorly prepared and based primarily on beliefs or ideologies rather than scientific knowledge.

At Dianova, we believe that addiction prevention, particularly among young people, must take into account societal changes (new drugs, new patterns of use, changes in legislation, etc.) using scientifically validated strategies based on standards and methodological guidelines.

These strategies are based in particular on:

  • The acquisition of psychosocial skills (problem solving, decision-making, interpersonal skills, stress management, etc.),
  • Interventions aimed at developing parenting skills (e.g. communication skills, conflict management, setting boundaries, etc.),
  • Prevention strategies tailored to young people with vulnerability factors (e.g. those whose parents suffer from substance use disorders) and taking into account gender perspectives, abandoning androcentric strategies that obscure the situation of girls and LGBTQI+ communities.

In conclusion, we must bear in mind the mistakes of the past so as not to repeat them and, above all, understand that no prevention system is sufficient on its own. Whatever approach is chosen, effective prevention systems must be evidence-based and integrated into broader, balanced systems that focus on health promotion, the treatment of substance use disorders, risk and harm reduction, and countering drug trafficking.

Effective, science-based programmes that can make a real difference to people’s lives can only be developed by integrating all these elements.

Source: https://www.dianova.org/publications/a-brief-history-of-drug-prevention/

 

Report to Congressional Committees – July 2025  / GAO-25-107845 – United States GAO – (Government Accountability Office)

Highlights

A report to congressional committees.

For more information, contact: Triana McNeil – United States Government Accountability Office

What GAO Found

The 12 experts in a forum which GAO convened said that to develop effective media campaigns and evaluate media campaigns, whether on drug misuse prevention or other topics, campaigns need to consider the following: 

Graphical user interface, text, application AI-generated content may be incorrect.

·         Identify and understand intended audience. Once a campaign has identified who it wants to reach, it needs to understand the intended audience—including by identifying the underlying causes of the behavior the campaign wants to change. For example, experts noted that campaigns may decide to target the underlying reasons why people misuse drugs rather than developing campaigns to target specific drugs.

·         Create content, select messengers, and decide on delivery methods. Campaigns need to create content to deliver their messages, which need to be credible and relevant for the intended audience. Campaigns also need to select messengers to deliver their messages, such as community leaders. Additionally, campaigns need to decide how to deliver their messages. For example, campaigns may use print and social media, among other options.

·         Test messages. Campaigns need to test their messages with the intended audience to ensure that the messages are relevant and resonate with the intended audience. This testing can include using focus groups, interviews, or surveys, among other methods.

·         Define the intended outcome. Campaigns need to have a clear understanding of what they are trying to achieve. Then, evaluators can decide what data are needed to determine whether a campaign is meeting its goals.

·         Select qualified evaluators. Campaigns need independent evaluators who can speak to campaign managers about a campaign’s effectiveness using evidence from evaluations. Evaluators need expertise in research methods, evaluation, and other disciplines and need to understand the campaign substance.

·         Decide when and how to measure effectiveness. Campaigns need to decide if they will evaluate the campaign while it is ongoing or after the campaign has concluded. They also need to decide what they want to measure and what data collection methods they will use.

To access the full document:

  1. Click on the ‘Source’ link below.
  2. An image  – the front page of the full document will appear.
  3. Click on the image to open the full document.

Source: https://files.gao.gov/reports/GAO-25-107845/index.html?

New allegations have emerged about China’s role in the global fentanyl supply chain, highlighting the complex nature of international drug trafficking and the urgent need for comprehensive prevention strategies.

What We Know About Project Zero

According to Yuan Hongbing, a former Chinese academic now living in Australia, sources within Beijing’s political circles have described a coordinated effort called “Project Zero.” This alleged initiative represents one aspect of the broader China fentanyl crisis that has contributed to America’s ongoing opioid epidemic.

Yuan’s claims suggest that some Chinese officials view the current drug crisis through the lens of historical grievances, particularly the 19th-century Opium Wars. Whether accurate or not, these allegations underscore the complexity of the Chinese fentanyl trade and its impact on communities worldwide.

The Evolution of Supply Routes

The China fentanyl crisis has evolved significantly since 2019, when Beijing officially banned fentanyl production under international pressure. Rather than ending the problem, this led to a shift in tactics within the Chinese fentanyl trade.

Companies began focusing on precursor chemicals instead of finished products. These substances travel from manufacturing facilities to Mexico, where they’re processed into fentanyl before reaching American markets. This indirect approach complicates efforts to address the China fentanyl crisis at its source.

Impact on Communities

The human cost of the ongoing crisis is staggering. More than 107,000 Americans died from drug overdoses in 2023, with synthetic opioids like fentanyl being the primary cause. These deaths represent families torn apart and communities struggling with the consequences of widespread addiction.

The China fentanyl crisis affects people from all backgrounds. Parents lose children, children lose parents, and entire neighbourhoods face increased crime and social instability. Understanding these impacts is crucial for developing effective Chinese fentanyl trade prevention strategies.

Government Responses and Investigations

Congressional investigations have revealed concerning patterns in how some aspects of the Chinese fentanyl trade operate. The House Select Committee found evidence that certain companies receive government benefits for exporting precursor chemicals, raising questions about official oversight.

These findings suggest that addressing the China fentanyl crisis requires diplomatic engagement alongside enforcement measures. The complexity of international trade makes it challenging to distinguish between legitimate chemical exports and those intended for illicit use.

Economic Measures and Trade Relations

The current trade tensions between the US and China reflect broader concerns about the Chinese fentanyl trade. Recent tariffs include specific measures targeting fentanyl-related commerce, with most Chinese goods facing increased duties.

These economic responses acknowledge that the China fentanyl crisis extends beyond traditional criminal justice approaches. However, trade measures alone cannot solve the underlying issues that drive demand for these substances in affected communities.

International Cooperation Challenges

Addressing the Chinese fentanyl trade requires unprecedented international cooperation. Different legal systems, varying enforcement capabilities, and complex diplomatic relationships all complicate efforts to tackle the China fentanyl crisis effectively.

Success depends on finding common ground between nations with different perspectives on regulation, enforcement, and prevention. This includes sharing intelligence, coordinating investigations, and developing consistent approaches to precursor chemical controls.

The Role of Prevention

Prevention remains the most effective long-term response to the China fentanyl crisis. Community-based programmes that educate young people about the dangers of substance use can reduce demand for these deadly drugs.

Effective prevention strategies address the root causes that make individuals vulnerable to addiction. This includes mental health support, educational opportunities, and strong community connections that provide alternatives to substance use.

When communities invest in prevention, they create protective factors that help people resist the appeal of drugs, regardless of their source. The Chinese fentanyl trade thrives where demand exists, making prevention efforts crucial for breaking this cycle.

Treatment and Recovery

For those already affected by the China fentanyl crisis, accessible treatment services provide hope for recovery. Evidence-based approaches that combine medical treatment with psychological support offer the best outcomes for people struggling with addiction.

Recovery programmes that involve families and communities tend to be more successful than those focusing solely on individual treatment. This holistic approach recognises that addiction affects entire social networks, not just individual users.

The Path to Prevention and Recovery

The allegations about Chinese involvement in fentanyl trafficking highlight the need for sustained international cooperation on drug prevention. Whether through diplomatic channels, trade measures, or community-based initiatives, addressing this crisis requires coordinated action.

Prevention must remain at the centre of any effective response to the China fentanyl crisis. By reducing demand through education and community support, we can address the root causes that make these supply chains profitable in the first place.

The Chinese fentanyl trade represents a complex challenge that requires nuanced solutions. Success will depend on combining international cooperation with strong local prevention efforts that protect vulnerable individuals and strengthen community resilience.

Only through sustained commitment to prevention, treatment, and community support can we hope to reduce the devastating impact of the China fentanyl crisis on families and communities worldwide.

Source: https://nobrainer.org.au/index.php/resources/wheelbarrows/1469-china-fentanyl-crisis-a-global-challenge-requiring-prevention?

by Vivek Ramaswamy <news@editor.thepostmillennial.com>  01 July 2025 14:34

THE KIDS WILL BE OK

You will never guess what’s happening with young people.  ‌ Believe it or not, the younger generation is finally rejecting woke and radical leftism. You saw this during Trump’s election – a major shift in the 18-29 year old voters.‌ ‌ And the media hates it! ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Here’s a major reason why this is happening … an organization called Young Americans for Liberty (YAL) is identifying, recruiting, and training college students to Make Liberty Win. YAL is the most active and effective pro-liberty youth organization advancing liberty on campus. …..

YAL is doing this, first and foremost, by reaching students where they’re at. By focusing on the issues important to twenty-year-olds – affordable groceries and gas, healthcare, and guns, YAL is able to show young people that socialism is not the answer to all of their life’s problems.

Here are a few of the articles, supporting  this initiative, published in other publications:

  • “America’s Youngest Voters Turn Right” – Axios;
  • “The Not-So-Woke Generation Z” – The Atlantic;
  • “Are Zoomers Shifting Right?” – Newsweek; and
  • “Analysis: Young and Non-White Voters Have Shifted Right Since 2020” – Washington Post.

Below is a step-by-step layout showing how Young Americans for Liberty is advancing the ideas of freedom with college students.
 

STEP 1: Expand the number of YAL chapters across the country to over 500 nationwide. America’s college campuses are covered with YAL chapters actively recruiting and educating hundreds of thousands of students.
 

STEP 2: Recruit 10,000 NEW YAL members and collect more than 150,000 student sign-ups. YAL is building a massive network and a strong foundation to reach the next generation for years to come.
 

STEP 3: Train an ELITE group of top 1,7000 student leaders on how to WIN ON PRINCIPLE. YAL’s top student leaders receive exclusive training on the strategies and tactics to win and advance the ideas of liberty.

STEP 4: Mobilize YAL-trained activists who have knocked on more than 6,000,000 doors to promote liberty causes and candidates. It’s called OPERATION WIN AT THE DOOR, and through it, YAL-trained students have knocked doors to help nearly 400 pro-liberty legislators win crucial races and push for important pro-liberty legislation.
 

STEP 5: Fight tyrannical campus policies and college administrators through YAL’s Student Rights Campaign. YAL chapters and members have made major policy changes on free speech, self-defense, and defunding woke campus programs, which now impact more than 3,100,000 students every year.

Young Americans for Liberty, 3267 Bee Cave Rd, Ste 107-65, Austin, TX 78746, United States

Source:  Post Millennial, 2515 Waukegan Road #1ABC, Deerfield, IL 60015

Filed under: Strategy and Policy,USA,Youth :
Some hopeful news has come to light in the latest Drug Enforcement Administration (DEA) Annual Report: overdose deaths dropped more than 20% nationwide in 2024, which is the largest yearly decrease in four decades of tracking. Although this decrease in overdose deaths is good news, it does not mean the crisis is over. Changes in drug mixtures, independent regional shifts in overdose patterns, and the alarming rise in new chemical contaminants—many of which users don’t even know they’re taking—makes this ever-evolving issue complex and increasingly more dangerous than ever before.

 

The DEA found that 1 in 8 samples of methamphetamine now contains fentanyl, and 1 in 4 samples of cocaine samples are similarly contaminated. And while deaths from fentanyl may be decreasing, fentanyl is increasingly being mixed into other drugs, often with deadly result.

In a regional assessment of fentanyl-related deaths, stimulants such as cocaine and methamphetamine were found to be contaminated with fentanyl and linked to 1 out of every 2 drug-related deaths in the west and 1 out of every 3 drug-related deaths in the east. Contaminated drug mixtures are especially dangerous given that naloxone, one of the key measures in reducing opioid overdose deaths, is ineffective against non-opioid drugs such as stimulants.

 

Among the surprising findings was that between 2018 and 2022, fentanyl-only overdose among 15-24 year olds increased approximately 168%. This age group, which is one that generally does not seek fentanyl, are suspected to be unknowingly consuming drugs laced with it. The low production cost of fentanyl continues to fuel the shift between already dangerous plant-based drugs to lab-made substances. The emergence of additives that cause prolonged sedation such as xylazine and medetomidine increase the dangers associated with the consumption of these drugs as some these mixtures may also render naloxone ineffective.

 

Despite the drop in overall overdose deaths the U.S. still has the highest drug overdose rate in the world, with 324 deaths per million people. Most states are showing promising progress with decreases in drug-related deaths. However, Nevada is an exception, experiencing an increase largely driven by methamphetamines, which have now surpassed fentanyl as the leading cause of drug-related deaths in the state.

 

Although overall trends seem to show a positive promising future, the drug supply is evolving faster than available tools can manage. And overdose risks are no longer about misuse, but also about unknowing exposure to potent synthetic chemicals hidden in recognizable drugs.

 

 

Source:  Drug Free America Foundation | 333 3rd Ave N Suite 200 | St. Petersburg, FL 33701 US

 

Every year the United Nations Office on Drugs and Crimes releases the World Drug Report (WDR) on World Drug Day, which is observed annually on June 26th. The WDR provides updates on international drug markets, policy changes across the world, and summarizes gathered data on ongoing issues caused by drugs on all fronts.

This year’s report calls for communities around the world to break the cycle and #StopOrganizedCrime, stressing the intricacy and ever-expanding reach of organized crime networks on a global scale currently exacerbated by increased global instability. 

Among this year’s highlights, the World Drug Report finds a 28% increase in people who use drugs over the past 10 years, with marijuana the top used substance with 244 million users, followed by opioids, amphetamines, cocaine, and ecstasy.

The report also highlights a 13% increase in people suffering from drug use disorders over the past 10 years and the disproportionate imbalance among men and women with substance use disorders (SUD) who receive treatment. While 1 in 7 men with a substance use disorder receive treatment, only 1 in 18 women with SUD receive treatment.

But the most sobering reality is that youth continue to show a steady rise in drug use over the past decade. Vulnerable populations are bearing the brunt of illegal exploits and are falling prey to the cycle of poverty and crime created by underfunded systems and increased criminal activity.

Stimulant-related criminal activity is growing at an alarming rate. Between 2013-2023, global cocaine production rose 34%, global cocaine seizures rose 68%, and the number of people who use cocaine jumped from 17 million to 25 million. The steady expansion of cocaine use and rise in production continues to break records year after year. Additionally, the synthetic drug market led by methamphetamines and captagon continues to grow with drug and human trafficking feeding criminal networks that are constantly adapting to new intelligence and technological advances. The influence of this global drug crisis is reflected not only on the financial costs to communities, but on health systems, the environment, public safety, and above all, the loss of life.

Now more than ever, prevention plays a vital role in breaking the harmful cycles created by substance use. While local organizations witness the impact of drugs firsthand in their communities, and governments work to address supply and demand on a global scale, civil society is uniquely positioned to listen, respond, and offer immediate support to local leaders and at-risk populations.

By collaborating with organizations and building a network of support, we can empower individuals with evidence-based resources that strengthen protective factors, promote education, and foster long-term resilience.

Drug Free America Foundation leads the Global Task Force, uniting international non-governmental organizations with this shared mission. If you are interested in joining, please reach out to clincoln@dfaf.org .

If you would like to read the full World Drug Report click here 

Source:  Drug Free America Foundation | 333 3rd Ave N Suite 200 | Saint Petersburg, FL 33701 US

Key points

  • Substance use prevention is not just focused on the absence of a disease or illness but on promoting wellness.
  • Funding cuts from DOJ for substance use and treatment services may have long-term consequences.
  • These cuts represent the latest cycle of punitive sentiments towards substances use.

On April 22, the Department of Justice (DOJ) announced the termination of 365 awards that “no longer effectuate Department priorities.” Among these cuts were $88 million in Office of Justice Programs (OJP) funded programs administering substance use and mental health services. During Preisdent Trump’s first term, we witnessed a shift away from behavioral health models toward scare tactics and increased law enforcement activities — strategies known to be ineffective at preventing substance use. This term appears to be following that same trajectory.

America has a long history of reactively and emotionally addressing substance use in ways inconsistent with research and best practices. Large swings in political views and funding are not new and have detrimental effects on prevention efforts and communities. This latest rollback represents a reversion back to failed, punitive models, which threatens to unravel decades of progress in promoting community health and wellness.

Substance Use Prevention

Today’s substance use prevention activities are not the mass media scare campaigns seen during the 1960s to the 1990s or as simple as “Just Say No.” Substance use prevention takes a public health approach to promoting wellness and preventing substance use problems.

Unlike early iterations of “prevention,” the ultimate goal of prevention activities today is to promote wellness. Promoting wellness is not the same as advocating for the absence of a disease or illness but the presence of purpose in life, involvement in satisfying work and play, having joyful relationships, a healthy body and living environment, as well as general happiness. The Substance Abuse and Mental Health Services Administration (SAMHSA), drawing on Swarbrick’s wellness approach, describes wellness as having eight different dimensions – emotional, spiritual, intellectual, physical, environmental, financial, occupational, and social.

Effective prevention programs work across these dimensions to reduce factors that put people at risk of developing behavioral health disorders (i.e., risk factors) as well as promote or strengthen factors that protect people from these disorders (i.e., protective factors).

The Cycle of Prevention Activities

The way we have responded to substance use has always been reactionary and punitive. Responses to substance use in the U.S. has stretched back over a century and followed a repeating cycle of panic, punishment, and progress. A new drug “hits the streets,” a news article highlights the death of a young, innocent victim, or a new political ringleader will enter the scene spouting “tough on crime” rhetoric that causes a moral panic among the masses and calls for increased punishment. Those sentiments take hold for several years and lead to prison overcrowding and an increase in arrest rates. Eventually, scientific advancements push responses to substance use back into the behavioral health realm. Then, a political campaign or story regresses the U.S. back to failed models of addressing substance use with punishment and the cycle repeats.

The 1950s/1960s are generally seen as the beginning of the modern era of prevention — an era dominated by fear-based approaches. School talks aimed at “scaring kids straight” and media campaigns and movies painted exaggerated horror stories about drug use. But scare-based tactics never work, particularly when youth can see that the lessons don’t reflect their lived experience. By the 1970s, the “War on Drugs” had been launched, and President Nixon had called drugs America’s “public enemy number one” and ushered in a wave of punishment over support. One of the most popular mantras of prevention originated in the 1980s with Nancy Reagan’s famous phrase: ‘Just Say No.’ It was catchy, simple, and widespread, but ultimately ineffective.

In the 1990s, science began to shape prevention and we saw large drops in youth substance use rates ever since. Researchers began to examine risk and protective factors associated with substance use. These studies led to a more structured approach to prevention. New, evidence-based school curricula focused on building life skills, resilience, and relationships were implemented. Community coalitions like the Communities That Care model gained traction. This progress continued in the early 2000s, when prevention finally got a seat at the table in public health. Prevention efforts became evidence-based and multi-layered. Programs began to see substance use as due to a complex interaction between systems and started addressing the risk at the family-, peer-, school-, and individual-level, such as the Seattle Social Development Project.

But this progress is often undermined by political agendas.

The punitive spirit of the War on Drugs remains deeply embedded in U.S. policy. The first Trump administration marked a clear pivot away from behavioral health and back toward criminal justice responses. Law enforcement became the answer while programs focused on research and wellness were deprioritized. Youth substance use trends began to stabilize despite the steady decline they had been on since the 1980s, marking an early sign that prevention was losing its momentum. The Biden-Harris administration brought in a new wave of the War on Drugs by naming a specific adulterated substance, fentanyl combined with xylazine, as an “emerging threat to the United States,” a term traditionally held for matters of homeland security.

Why This Matters Now

This new Trump administration brings new challenges and likely worse consequences as we witness an unprecedented time of widespread cuts to federal funding. Many communities rely heavily on these programs to help their fellow residents promote wellness in their area. Without these programs, improvements in trends in substance use will likely plateau, then potentially worsen. The challenge is that the consequences of cutting prevention are long-term, not immediate. As a result, many will turn to this time period in the next year to point out that there was no visible crisis or dramatic increase in substance use but that is based on a deep misunderstanding in evaluation research. The kids that would have relied on these programs will reach adulthood in the next few years which will be when we see the effects of not having these programs. People who relied on federally funded programs for treatment and support will experience worsening symptoms and rates of fatal overdoses will rise. Our schools will likely witness lower rates of attendance and a higher number of students dropping out or failing. Issues of overcrowding in jails and prisons will continue to worsen as increases in law enforcement activity will lead to greater arrests.

The defunding of mental health and substance use programming is a mistake. When prevention works, it’s invisible — no one sees the overdoses that didn’t happen, hears the fights that were avoided, or reads headlines about the crisis that never occurred. The invisibility of its effects does not mean it is not important.

Mobilizing the Community

We are at risk of repeating history by cutting prevention and returning to failed punitive models. Communities must lead where the federal government is failing. The momentum for prevention has always lain in the power of the community. The earliest substance use prevention movements started with everyday people who cared. Mothers Against Drunk Drivers (MADD) and other grassroots organizations started taking an active role in prevention in the 1980s, and ever since we have seen more communities taking the reins when it comes to promoting wellness in their area. Prevention is not an activity reserved solely for those in power; it is the duty and responsibility of every individual. Prevention is more than a policy or program; it is a promise to keep showing up for each other. If you are not sure where to start, start by telling your story and making space for others to lead. Prevention is strongest when it is shared.

Source:  https://www.psychologytoday.com/us/blog/the-nature-of-substance-use/202505/defunding-prevention-a-setback-for-science-and-public

 

Los Angeles — Inside a bright new building in the heart of Skid Row, homeless people hung out in a canopy-covered courtyard — some waiting to take a shower, do laundry, or get medication for addiction treatment. Others relaxed on shaded grass and charged their phones as an intake line for housing grew more crowded.

The new Skid Row Care Campus offers homeless people health care and a place to rest, charge their phones, grab some

food, or even get connected with housing.Angela Hart / KFF Health News

 

The Skid Row Care Campus officially opened this spring with ample offerings for people living on the streets of this historically downtrodden neighborhood. Pop-up fruit stands and tent encampments lined the sidewalks, as well as dealers peddling meth and fentanyl in open-air drug markets. Some people, sick or strung out, were passed out on sidewalks as pedestrians strolled by on a recent afternoon.

For those working toward sobriety, clinicians are on site to offer mental health and addiction treatment. Skid Row’s first methadone clinic is set to open here this year. For those not ready to quit drugs or alcohol, the campus provides clean syringes to more safely shoot up, glass pipes for smoking drugs, naloxone to prevent overdoses, and drug test strips to detect fentanyl contamination, among other supplies.

As many Americans have grown increasingly intolerant of street homelessness, cities and states have returned to tough-on-crime approaches that penalize people for living outside and for substance use disorders. But the Skid Row facility shows Los Angeles County leaders’ embrace of the principle of harm reduction, a range of more lenient strategies that can include helping people more safely use drugs, as they contend with a homeless population estimated around 75,000 — among the largest of any county in the nation. Evidence shows the approach can help individuals enter treatment, gain sobriety, and end their homelessness, while addiction experts and county health officials note it has the added benefit of improving public health.

“We get a really bad rap for this, but this is the safest way to use drugs,” said Darren Willett, director of the Center for Harm Reduction on the new Skid Row Care Campus. “It’s an overdose prevention strategy, and it prevents the spread of infectious disease.”

Despite a decline in overdose deaths, drug and alcohol use continues to be the leading cause of death among homeless people in the county. Living on the streets or in sordid encampments, homeless people saddle the health care system with high costs from uncompensated care, emergency room trips, inpatient hospitalizations, and, for many of them, their deaths. Harm reduction, its advocates say, allows homeless people the opportunity to obtain jobs, taxpayer-subsidized housing, health care, and other social services without being forced to give up drugs. Yet it’s hotly debated.

Politicians around the country, including Gov. Gavin Newsom in California, are reluctant to adopt harm reduction techniques, such as needle exchanges or supervised places to use drugs, in part because they can be seen by the public as condoning illicit behavior. Although Democrats are more supportive than Republicans, a national poll this year found lukewarm support across the political spectrum for such interventions.

Los Angeles is defying President Trump’s agenda as he advocates for forced mental health and addiction treatment for homeless people — and locking up those who refuse. The city has also been the scene of large protests against Mr. Trump’s immigration crackdown, which the president has fought by deploying National Guard troops and Marines.

Mr. Trump’s most detailed remarks on homelessness and substance use disorder came during his campaign, when he attacked people who use drugs as criminals and said that homeless people “have no right to turn every park and sidewalk into a place for them to squat and do drugs.” Health and Human Services Secretary Robert F. Kennedy Jr. reinforced Mr. Trump’s focus on treatment.

“Secretary Kennedy stands with President Trump in prioritizing recovery-focused solutions to address addiction and homelessness,” said agency spokesperson Vianca Rodriguez Feliciano. “HHS remains focused on helping individuals recover, communities heal, and help make our cities clean, safe, and healthy once again.”

A comprehensive report led by Margot Kushel, a professor of medicine at the University of California-San Francisco, this year found that nearly half of California’s homeless population had a complex behavioral health need, defined as regular drug use, heavy drinking, hallucinations, or a recent psychiatric hospitalization.

The chaos of living outside, she said — marked by violence, sexual assault, sleeplessness, and lack of housing and health care — can make it nearly impossible to get sober.

Skid Row Care Campus

The new care campus is funded by about $26 million a year in local, state, and federal homelessness and health care money, and initial construction was completed by a Skid Row landlord, Matt Lee, who made site improvements on his own, according to Anna Gorman, chief operating officer for community programs at the Los Angeles County Department of Health Services. Operators say the campus should be able to withstand potential federal spending cuts because it is funded through a variety of sources.

Glass front doors lead to an atrium inside the yellow-and-orange complex. It was designed with input from homeless people, who advised the county not just on the layout but also on the services offered on-site. There are 22 recovery beds and 48 additional beds for mostly older homeless people, arts and wellness programs, a food pantry, and pet care. Even bunnies and snakes are allowed.

John Wright, 65, who goes by the nickname Slim, mingled with homeless visitors one afternoon in May, asking them what they needed to be safe and comfortable.

“Everyone thinks we’re criminals, like we’re out robbing everyone, but we aren’t,” said Wright, who is employed as a harm reduction specialist on the campus and is trying, at his own pace, to stop using fentanyl. “I’m homeless and I’m a drug addict, but I’m on methadone now so I’m working on it,” he said.

Nearby on Skid Row, Anthony Willis rested in his wheelchair while taking a toke from a crack pipe. He’d just learned about the new care campus, he said, explaining that he was homeless for roughly 20 years before getting into a taxpayer-subsidized apartment on Skid Row. He spends most of his days and nights on the streets, using drugs and alcohol.

The drugs, he said, help him stay awake so he can provide companionship and sometimes physical protection for homeless friends who don’t have housing. “It’s tough sometimes living down here; it’s pretty much why I keep relapsing,” said Willis, who at age 62 has asthma and arthritic knees. “But it’s also my community.”

Willis said the care campus could be a place to help him kick drugs, but he wasn’t sure he was ready.

Research shows harm reduction helps prevent death and can build long-term recovery for people who use substances, said Brian Hurley, an addiction psychiatrist and the medical director for the Bureau of Substance Abuse Prevention and Control at the Los Angeles County Department of Public Health. The techniques allow health care providers and social service workers to meet people when they’re ready to stop using drugs or enter treatment.

“Recovery is a learning activity, and the reality is relapse is part of recovery,” he said. “People go back and forth and sometimes get triggered or haven’t figured out how to cope with a stressor.”

Swaying public opinion

Under harm reduction principles, officials acknowledge that people will use drugs. Funded by taxpayers, the government provides services to use safely, rather than forcing people to quit or requiring abstinence in exchange for government-subsidized housing and treatment programs.

Los Angeles County is spending hundreds of millions to combat homelessness, while also launching a multiyear “By LA for LA” campaign to build public support, fight stigma, and encourage people to use services and seek treatment. Officials have hired a nonprofit, Vital Strategies, to conduct the campaign including social media advertising and billboards to promote the expansion of both treatment and harm reduction services for people who use drugs.

The organization led a national harm reduction campaign and is working on overdose prevention and public health campaigns in seven states using roughly $70 million donated by Michael Bloomberg, the former mayor of New York.

“We don’t believe people should die just because they use drugs, so we’re going to provide support any way that we can,” said Shoshanna Scholar, director of harm reduction at the Los Angeles County Department of Health Services. “Eventually, some people may come in for treatment but what we really want is to prevent overdose and save lives.”

Los Angeles also finds itself at odds with California’s Democratic governor. Newsom has spearheaded stricter laws targeting homelessness and addiction and has backed treatment requirements for people with mental illness or who use drugs. Last year, California voters approved Proposition 36, which allows felony charges for some drug crimes, requires courts to warn people they could be charged with murder for selling or providing illegal drugs that kill someone, and makes it easier to order treatment for people who use drugs.

Even San Francisco approved a measure last year that requires welfare recipients to participate in treatment to continue receiving cash aid. Mayor Daniel Lurie recently ordered city officials to stop handing out free drug supplies, including pipes and foil, and instead to require participation in drug treatment to receive services. Lurie signed a recovery-first ordinance, which prioritizes “long-term remission” from substance use, and the city is also expanding policing while funding new sober-living sites and treatment centers for people recovering from addiction.

“Harm encouragement”

State Sen. Roger Niello, a Republican who represents conservative suburbs outside Sacramento, says the state needs to improve the lives of homeless people through stricter drug policies. He argues that providing drug supplies or offering housing without a mandate to enter treatment enables homeless people to remain on the streets.

Proposition 36, he said, needs to be implemented forcefully, and homeless people should be required to enter treatment in exchange for housing.

“I think of it as tough love,” Niello said. “What Los Angeles is doing, I would call it harm encouragement. They’re encouraging harm by continuing to feed a habit that is, quite frankly, killing people.”

Keith Humphreys, who worked in the George W. Bush and Barack Obama administrations and pioneered harm reduction practices across the nation, said that communities should find a balance between leniency and law enforcement.

“Parents need to be able to walk their kids to the park without being traumatized. You should be able to own a business without being robbed,” he said. “Harm reduction and treatment both have a place, and we also need prevention and a focus on public safety.”

Just outside the Skid Row Care Campus, Cindy Ashley organized her belongings in a cart after recently leaving a local hospital ER for a deep skin infection on her hand and arm caused by shooting heroin. She also regularly smokes crack, she said.

She was frantically searching for a home so she could heal from two surgeries for the infection. She learned about the new care campus and rushed over to get her name on the waiting list for housing.

“I’m not going to make it out here,” she said, in tears.

Source:  https://www.cbsnews.com/news/los-angeles-harm-reduction-drugs-homelessness/

KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the core operating programs at KFF — the independent source for health policy research, polling, and journalism.

 

by Robyn Oster – Associate Director, Health Law and Policy – July 2025

Reminder: The U.S. Preventive Services Task Force (USPSTF), an expert panel, evaluates preventive services and recommends which should be provided at no cost.

  • Why it’s important: Services currently required to be covered at no cost include certain mental health screenings, drug/alcohol screenings, PrEP for HIV, etc.
  • A group of conservative Christian employers in Texas led a lawsuit challenging the requirement. They argued that having the independent panel determine national health coverage violated the appointments clause of the Constitution and that covering PrEP violated religious freedom (though the Supreme Court only weighed in on the appointments clause argument).

The details:

  • The employers argued that USPSTF members were not appointed as either of two types of executive branch officers that the Constitution allows to make certain national policy decisions. They argued that the task force recommendations requiring them to cover certain preventive services in their employer-sponsored health plans were unconstitutional because task force members are not confirmed by the Senate.
  • The government defended the task force, arguing that it is constitutional because HHS officials appoint USPSTF members, and the HHS secretary can remove members at will and veto recommendations.
  • The Supreme Court agreed with the government and affirmed that the HHS secretary has these powers over USPSTF and its recommendations.

The bigger context:

  • The decision is a win for health advocates, who wanted to maintain the no-cost coverage requirement for preventive services. Providing preventive services at no cost is key to increasing access to and receipt of important screenings and other preventive services. Decreasing access to such services would lead to worse health outcomes.
  • But: The ruling could challenge USPSTF’s independence and credibility. It cements a strong role for the HHS secretary in overseeing the USPSTF, including removing members and modifying its rulings. This paves the way for HHS Secretary Kennedy to reject recommendations he disagrees with, allowing insurers to charge for those services or avoid covering them in some cases. It also opens the door for Kennedy to remove all the task force members and appoint new people, and a new task force could reject previous recommendations.

Source:  https://drugfree.org/drug-and-alcohol-news/supreme-court-upholds-aca-preventive-care/

The Association of Community Pharmacists of Nigeria (ACPN)

has advocated  urgent, coordinated, and sustained actions

to combat drug abuse which has constituted

a major public health menace.

by Onyebuchi Ezigbo in Abuja

In his message to mark the International Day Against Drug, the National Chairman of ACPN,  Ezeh Ambrose Igwekamma, said that focus should now be home prevention, education, early intervention, and rehabilitation.

“As the National Chairman of ACPN, I join millions around the world to reaffirm our commitment to the fight against drug abuse and to call for urgent, coordinated, and sustained actions to combat this public health menace in our dear country,” he said.

 Igwekamma said the theme for this year’s celebration, “The Evidence is Clear: Invest in Prevention,” resonates deeply with our vision at the ACPN.

“It reminds us that we must shift our focus from reaction to prevention. As community pharmacists—trusted, accessible healthcare providers on the frontlines—we witness firsthand the silent crisis of substance abuse in our communities, especially among our youth.” 

He said ACPN for more than  a decade has demonstrated a concerns on massive awareness creation through  the National Anti-Drug abuse competition among students in secondary school nationwide.

According to him, the essence of the annual competition is for prevention and also to dis abused the minds of younger generations against the consequences of drug abuse which Align with the same with the  UNODC Strategic plan for substance Abuse 

He added: “Every tablet sold without prescription, every codeine cough syrup diverted, and every hard drug traded illegally is not just a crime—it is a threat to our collective future. 

“Drug abuse fuels mental health disorders, crime, school dropout, family breakdown, and premature deaths. It cripples dreams and sabotages national development”.

The ACPN president  called on all stakeholders—government, civil society, security agencies, religious and traditional leaders, parents, and educators—to intensify their roles in prevention, education, early intervention, and rehabilitation.

Source:  https://www.thisdaylive.com/2025/06/27/drug-abuse-attention-must-now-shift-to-prevention-says-acpn/

by Sihyun Baek,

Grade 11, (16-17 years old)

Chadwick International School

06.29.2025

 

[AI Generated, Addiction. Photo Credit to Pixabay]

South Korea is grappling with a mounting crisis as incidents of teenage drug use increase exponentially, raising serious concerns about youth safety and failed public education systems.

The latest incident, involving two middle schoolers caught using marijuana in a neighborhood playground in Seoul on April 25, has once again brought the issue to the forefront for concerned parents, teachers, and lawmakers alike. 

The students were seen smoking liquid cannabis in broad daylight, prompting local residents to notify the police. 

Authorities are currently looking into how the teens obtained the drugs.

Nationally, the number of juvenile drug offenders, aged 18 and younger, rose to 450 in 2021, marking a 43.8% increase from the previous year and nearly quadrupling since 2018, according to the Supreme Prosecutors’ Office. 

In Seoul alone, teenage drug offenders surged nearly fivefold in just one year, from 48 in 2022 to 235 in 2023.

South Korea, known for its stringent drug laws and historically low rates of domestic usage, now finds itself fighting against a growing number of youth turning to drugs through online platforms and encrypted messaging services like Telegram. 

The rise of drug transactions using anonymous cryptocurrency transactions such as  Bitcoin has dramatically lowered the barriers to accessing such substances online. 

In one case during the summer of 2022, for instance, a drug cartel run entirely online by an 18-year-old using encrypted apps to distribute methamphetamine and MDMA was exposed by police officers. 

Similarly, in November of 2021, a drug-trading chat room was discovered on Telegram.

Prosecutors revealed that all 180 members of the chat room were members of a criminal drug organization, most of whom were teenagers.  

But marijuana and party drugs aren’t the only substances of concern. 

Illegally obtained prescription psychotropic medications are emerging as the country’s primary gateway drugs. 

An increasing number of teenagers have been caught distributing fentanyl patches and pills like Dietamin, an appetite suppressant.

The pill, however, is also a dangerous psychotropic drug derived from amphetamines that produces hallucinations and has addictive properties.

These prescription drugs, often perceived as “safe” or “medically approved,” are creating a dangerous normalization of drug use among teens and increasing the risk of long-term addiction and overdose.

From 2019 to 2021, prescription psychotropics accounted for 55.4% of youth drug cases, followed by cocaine and heroin at 23.8%, and marijuana at 20.8%. 

In one major investigation in June of 2023, 100 teenagers in South Gyeongsang Province were arrested for selling and abusing Dietamin tablets obtained online.

Experts point to peer pressure and stress as the key triggers, particularly within Telegram chat rooms. 

Pop culture also plays a significant role; for example, fentanyl was commonly used by hip-hop rappers in 2019 and has since grown in popularity among teenagers.

To counter this growing issue, authorities have begun intense cyber investigations. 

In 2023 alone, more than 1,000 online crackdowns led to the shutdown of 78 drug-dealing accounts on platforms like Telegram and Instagram. 

Yet, the increasingly sophisticated methods of drug distribution pose serious challenges for law enforcement.

Dealers frequently change their online handles, communicate in code using emojis, and utilize “dead drop” methods, such as hiding drugs in public spaces for buyers to retrieve using GPS coordinates, making it difficult for someone to trace their tracks. 

Understandably, the consequences of this rise in drug use among teenagers are devastating. 

 Drug abuse has been directly linked to an increase in youth suicide attempts. 

Between 2019 to mid-2023, approximately 46.4% of teen suicide attempts resulting in hospitalization were associated with drug use, according to the National Medical Center. 

In 2021 alone, 1,678 minors were treated for drug abuse, a 41.4% jump from the previous year.

To combat this issue, many suggest implementing strengthened education systems on drugs by collaborating with related institutions.

Likewise, while some lawmakers have recently proposed bills to mandate such education programs, experts say the movement lacks urgency and public support and is failing to garner much attention, with the country having yet to integrate drug prevention into its national school curriculum.

For instance, in May of 2024, Government Representative Lee Tae-kyu proposed a bill to mandate drug education in schools, requiring them to implement age-specific drug education programs in collaboration with public health agencies. 

However, as of now, the bill remains stalled in committee.

Comparatively, in the United States, the implementation of Drug Abuse Resistance Education (DARE) programs nationwide began as early as the 1980s, laying the foundation for more modern prevention strategies. 

Simultaneously, South Korea continues to face a lack of infrastructure for rehabilitation sites, as they still remain largely underdeveloped. 

Experts estimate that around 40% of Korean drug offenders return to prison within three years of their release. 

Such a high rate is often linked to the stigma they face in society, with many struggling to find employment, being rejected by hospitals, and being generally excluded from mainstream social life.

Likewise, the number of rehabilitation facilities for minors is limited.  

KAADA, one of the few rehabilitation centers for teen users, receives about 1,000 patients per year, only 10% of whom are under 19. 

Experts note that this is not reflective of actual use rates, but rather the result of underreporting and such social stigma that keep teens and their families silent.

Data gaps also hinder progress. 

Because many teen users are released as first-time offenders, their cases often fail to reach prosecutors, resulting in underreported figures. 

This makes it harder for lawmakers to assess the full scale of the crisis or design policies that address it adequately.

Parents have taken to online forums to express their fears, demanding school assemblies, national awareness campaigns, and stricter regulations on medical prescriptions.

In an interview with Ms. Cha, a concerned parent, commented, “It worries me even more because I don’t have a way of knowing what my child does online, especially as he gets older. You have to respect their autonomy, but at the same time, they could be accessing websites and chat rooms they shouldn’t be in.” 

Another parent, Mr. Kim, stated, “We need more education programs about drug prevention at school. Our children know that drugs are bad, but they don’t fully understand the long-term consequences or how easily peer pressure can lead them down the wrong path.”

Source:  http://www.heraldinsight.co.kr/news/articleView.html?idxno=5498

From the Editor, thepostmillennial.com 01 July 2025 14:34

(original text  draft by Vivek Ramaswamy)

Something BIG is happening on college campuses across the United States.

Believe it or not, the younger generation is finally rejecting woke and radical leftism. You saw this during Trump’s election – a major shift in the 18-29 year old voters.

And the media hates it!

  • “America’s Youngest Voters Turn Right” – Axios;
  • “The Not-So-Woke Generation Z” – The Atlantic;
  • “Are Zoomers Shifting Right?” – Newsweek; and
  • “Analysis: Young and Non-White Voters Have Shifted Right Since 2020” – Washington Post.

Here’s a major reason why this is happening.

An organization called Young Americans for Liberty (YAL) is identifying, recruiting, and training college students to Make Liberty Win. YAL is the most active and effective pro-liberty youth organization advancing liberty on campus.

YAL is doing this, first and foremost, by reaching students where they’re at. By focusing on the issues important to twenty-year-olds – affordable groceries and gas, healthcare, and guns, YAL is able to show young people that socialism is not the answer to all of their life’s problems.

Below I lay out step-by-step how Young Americans for Liberty is advancing the ideas of freedom with college students.

STEP 1: Expand the number of YAL chapters across the country to over 500 nationwide. America’s college campuses are covered with YAL chapters actively recruiting and educating hundreds of thousands of students.

STEP 2: Recruit 10,000 NEW YAL members and collect more than 150,000 student sign-ups. YAL is building a massive network and a strong foundation to reach the next generation for years to come.

STEP 3: Train an ELITE group of top 1,7000 student leaders on how to WIN ON PRINCIPLE. YAL’s top student leaders receive exclusive training on the strategies and tactics to win and advance the ideas of liberty.

STEP 4: Mobilize YAL-trained activists who have knocked on more than 6,000,000 doors to promote liberty causes and candidates. It’s called OPERATION WIN AT THE DOOR, and through it, YAL-trained students have knocked doors to help nearly 400 pro-liberty legislators win crucial races and push for important pro-liberty legislation.

STEP 5: Fight tyrannical campus policies and college administrators through YAL’s Student Rights Campaign. YAL chapters and members have made major policy changes on free speech, self-defence, and defunding woke campus programs, which now impact more than 3,100,000 students every year.

Young Americans for Liberty, 3267 Bee Cave Rd, Ste 107-65, Austin, TX 78746, United States

Source:  editor.thepostmillennial.com

United Nations – Information Service Vienna – 26 June 2025

The global illicit drug trade continues to exact a devastating toll: claiming lives, ravaging public health services, and fuelling violence and organized crime.

Drug trafficking is tearing through communities with substances that are more potent, more dangerous, and more deadly than ever. Meanwhile, criminal networks prey on the most vulnerable – particularly women and youth – as they rake in hundreds of billions annually through the illicit drug trade.

This year, we shine a light on prevention as the most essential strategy for halting the flow of drugs that fuels organized crime worldwide.

We must reduce demand through investing in education, treatment, harm-reduction measures and care; target the machinery of production by eliminating illicit laboratories and offering farmers viable alternatives; and sever trafficking networks by strengthening global trade routes and choking the financial flows of criminal networks, while always ensuring respect for human rights.

Let us recommit to ending drug abuse and trafficking, uniting to dismantle criminal networks, and breaking the cycle of suffering and destruction once and for all.

Source:  https://unis.unvienna.org/unis/pressrels/2025/unissgsm1507.html

By Joe Rossiter – The Mail on Sunday-  29 June 2025 

More than a quarter of police and crime commissioners have written to the policing minister calling for cannabis to be upgraded to a class A substance, The Mail on Sunday can reveal.

In the stark letter to Dame Diana Johnson MP, seen exclusively by this newspaper, 14 police chiefs claim the effect of the drug in society ‘may be far worse’ than heroin.

They warn that ‘we cannot allow this to become the Britain of the future’. And they also hit out at the recent report by the London Commission – backed by Labour London mayor Sir Sadiq Khan – which suggested decriminalising small amounts of cannabis, which is currently a class B drug.

‘Heroin can kill quickly but the cumulative effect of cannabis in our society may be far worse,’ the letter states. 

It adds that class A status – which comes with potential life sentences for suppliers – was the way forward ‘rather than effective decriminalising’.

And renowned psychiatrist Professor Sir Robin Murray, of King’s College London, told The Mail on Sunday that the UK may now be ‘at the beginnings of an epidemic of cannabis-induced psychosis’ which could overwhelm NHS mental health services.

The commissioners also pointed to other countries where laws are laxer, warning that the US has seen ‘unofficial pharmacies’ selling cannabis and the powerful opiate fentanyl alongside one another, while Portugal has been forced to consider reversing drug decriminalisation after a 30-fold increase in psychosis.

They said cannabis’s effects were so devastating it had ‘more birth defects associated with it than thalidomide’ – the notorious morning sickness drug which caused deformities among thousands of babies in the 1950s and 1960s.

More than a quarter of police and crime commissioners have written to the policing minister calling for cannabis to be upgraded to a class A substance (file pic)

Marcus Monzo, 37, was last week found guilty of 14-year-old Daniel Anjorin’s murder while in a state of cannabis-induced psychosis Monzo attacked the teenager with a samurai sword in Hainault, east London, last May

Their warnings came after Marcus Monzo, 37, was last week found guilty of 14-year-old Daniel Anjorin’s murder after he attacked him with a samurai sword in Hainault, east London, while in a state of cannabis-induced psychosis.

David Sidwick, Police and Crime Commissioner for Dorset, said cannabis legislation was ‘clearly not fit for purpose’ and likened it to ‘using a machete for brain surgery’. 

He added the public wanted to see ‘tougher measures’ for cannabis possession because it was a gateway to harder drugs.

His Devon and Cornwall counterpart Alison Hernandez said: ‘The fact that we’ve been so blase about cannabis in society means that people think it’s legal and normal, and it’s not. 

‘We’ve got to show them that it’s not, and the way you do that is to be quite fierce in your enforcement arrangements.’

Latest figures show three in four people caught with cannabis avoid appearing in court, while 87 per cent of children and young people in alcohol and drug treatment cited cannabis dependency, compared to 39 per cent for alcohol.

In the stark letter to Dame Diana Johnson MP, 14 police chiefs claim the effect of the drug in society ‘may be far worse’ than heroin

David Sidwick, Police and Crime Commissioner for Dorset, said he wanted to see ‘tougher measures’ for cannabis possession because it was a gateway to harder drugs (file pic)

Stuart Reece, an Australian clinician and cannabis researcher quoted in the letter said more than 90 per cent of hard drug addicts he encountered had started with cannabis.

He said pro-cannabis campaigners had the view it was ‘my right to use drugs and destroy my body and you will pay for it through the NHS’.

Dr Karen Randall, a physician in the US state of Colorado where recreational cannabis was legalised in 2012, said healthcare costs linked to the drug are ‘exorbitant’.

A Home Office spokesman said: ‘We work with partners across health, policing and wider public services to drive down drug use, ensure more people receive timely treatment and support, and make our streets and communities safer.’

Source: https://www.dailymail.co.uk/news/article-14857305/Cannabis-worse-society-heroin-police-tsars-upgrade-class.html

General News – Saturday 2025-06-28

Vice President Prof Naana Jane Opoku-Agyemang has emphasised the urgent need for increased investment in drug prevention programs, citing clear evidence of the devastating impact of illicit drugs on Ghanaian society.

Speaking at the 2025 World Drug Day event at the Accra International Conference Centre, Vice President Opoku-Agyemang called for action to prevent illicit drug use in the country, as reported by 3news.com on June 27, 2025.

She highlighted the rising prevalence of drug abuse and its detrimental effects on public health, safety, and economic productivity.

The Vice President stressed the importance of a multi-faceted approach to combating the drug problem, which should include education, awareness campaigns, and rehabilitation services.

She noted that while Ghana has made progress against conventional narcotics, the shift to synthetic opioids requires adaptability.

“The evidence is clear: invest in prevention,” she stated, underscoring the theme of World Drug Day 2025.

She added, “We must recognise the urgency of this issue and rise to the occasion to implement appropriate and pragmatic preventive measures.”

Prof Opoku-Agyemang emphasized that prevention is key to mitigating the long-term consequences of drug abuse and building a healthier, more prosperous nation.

She commended the Narcotics Control Commission for its dedication to combating drug abuse and illicit trafficking.

The government is committed to working with stakeholders to implement effective strategies.

She referenced recent operations by the Commission, which resulted in the seizure of large quantities of illicit substances and the dismantling of criminal syndicates, showcasing Ghana’s commitment to the fight against drugs.

The call for increased investment comes amid growing concerns about the accessibility and use of illicit drugs across the country.

The Vice President urged stakeholders to provide the Commission with the necessary tools, training, and resources to stay ahead of evolving threats.

“We must also address substance use disorders with compassion,” she emphasised.

Her remarks signal a renewed focus on this critical issue and the protection of the well-being of Ghanaian citizens.

“The operationalisation of the Substance Use Disorder Rehabilitation Fund is a commendable move, and we must ensure its effective implementation,” she concluded.

Source:  https://www.ghanaweb.com/GhanaHomePage/NewsArchive/The-evidence-is-clear-invest-in-prevention-Vice-President-1989525

Prime Minister Paetongtarn has declared drug prevention a national priority on the International Day Against Drug Abuse and Illicit Trafficking, urging nationwide support for rehabilitation, education, and community action to tackle Thailand’s drug crisis.

On Thursday (June 26), Paetongtarn delivered a speech in line with the United Nations’ declaration. She highlighted that drug abuse and trafficking continue to be persistent global and regional threats, severely affecting lives, public order, and national security.

She reaffirmed Thailand’s commitment to working with government agencies, the private sector, and civil society to combat this challenge.

The Prime Minister announced that drug prevention and resolution have been declared a national priority requiring urgent and tangible action. This initiative will include legal measures and coordinated efforts across central and regional authorities to curb drug smuggling at border areas and dismantle drug trafficking networks decisively.

In response to these threats, the government has launched the Seal, Stop, Safe strategy, which strengthens border control in 52 districts to prevent transborder drug trafficking and transnational crime. Inspections at both permanent and temporary border checkpoints, including natural crossings, have been intensified.

These efforts have led to a rise in the black-market price of methamphetamine, indicating a reduction in drug accessibility, she said.

She called on administrative leaders, provincial governors, community leaders, and particularly families, to collaborate in monitoring and protecting communities.

Paetongtarn also expressed gratitude to all sectors—public, private, and community—for their united efforts in protecting Thai society and future generations. She extended her words of encouragement to those undergoing rehabilitation, wishing them a successful return to a healthy, normal life.

“We invite all Thai people to unite and participate in the prevention and resolution of drug-related issues under the Stop Drugs, Start Power – Unite Thai Strength to End Drug Threats campaign. Let us work together to protect our society and secure a better future for our children,” the Prime Minister concluded.

Source:  https://www.nationthailand.com/news/general/40051801

by Sarjna Rai – New Delhi –  Jun 26 2025 

World Drug Day 2025 theme, “Break the Cycle. #StopOrganizedCrime,” urges global action against drug abuse and illicit trafficking.(Photo: Adobestock)
Every year on 26 June, the world observes the International Day Against Drug Abuse and Illicit Trafficking—also known as “World Drug Day”—to raise awareness of the global drug crisis and promote multilateral action toward prevention, treatment, and rehabilitation.

History & Theme

On December 7, 1987, the General Assembly of the United Nations set aside the 26th day of June of each year as International Day Against Illicit Trafficking of Drugs and other Substances of Abuse to be observed worldwide. 
The theme for 2025, Break the Cycle. #StopOrganisedCrime, emphasises the significance of focused long-term action to disrupt the link between drug trafficking and organised crime, both of which fuel violence, corruption, and instability across regions. 

Source:  https://www.business-standard.com/health/international-day-against-drug-abuse-2025-theme-history-significance-125062600553_1.html

by Sophie Kilusu, TV47 – Kenya – June 27, 2025

The National Authority for the Campaign Against Alcohol and Drug Abuse (NACADA) has emphasized the critical role of prevention in addressing the growing threat of substance abuse in Kenya.

Speaking at a public forum, NACADA Chairperson Stephen Mairori reiterated that preventive efforts are not only economically prudent but also offer the most sustainable way to protect the country’s future generations.“Prevention is not only cost-effective but also one of the most sustainable strategies in this fight,” Mairori stated.

Mairori has also emphasized that proactive measures such as educating the youth, empowering families, and fostering supportive environments are essential in stopping addiction before it begins. “Every shilling spent on prevention saves countless lives and resources that would otherwise go into treatment and rehabilitation,” he added.

The chairperson pointed out that NACADA’s initiatives are aligned with the government’s Bottom-Up Economic Transformation Agenda (BETA), which focuses on inclusive growth and sustainable development.

According to Mairori, curbing drug and substance abuse is a crucial step in building healthier and more productive communities.“When we prevent drug abuse, we secure our future workforce, reduce crime, and promote national development,” he said.

Mairori’s remarks come at a time when Kenya is grappling with rising cases of drug and substance abuse, especially among the youth.

In response, NACADA has intensified its community outreach programs, school awareness campaigns, and partnerships with various stakeholders to foster a national culture of prevention.

Additionally, he has called on parents, schools, faith-based institutions, and local leaders to join hands in creating an environment where young people can thrive without falling prey to drugs.

With the nation’s future hanging in the balance, NACADA continues to champion the message that prevention is not just a strategy, it is a necessity.

Source:  https://www.tv47.digital/prevention-is-key-to-winning-the-war-on-drug-abuse-107008/

Key Takeaways
NACo submitted recommendations to the White House Office of National Drug Control Policy to ensure the 2026 National Drug Control Strategy reflects the needs and realities of county governments.
Counties are essential intergovernmental partners in addressing illicit substance use through prevention, treatment, recovery and public safety efforts at the local level.

On June 20, NACo submitted formal comments to the White House Office of National Drug Control Policy (ONDCP) to help shape the development of its 2026 National Drug Control Strategy. This strategy serves as the nation’s blueprint for reducing illicit drug use, and the ONDCP plays a central role in coordinating federal drug policy across government agencies. As counties remain on the frontlines of the opioid and broader substance use epidemic, ONDCP invited NACo to share the county government perspectives on federal priorities and polices that support prevention, treatment, recovery and public safety across the country.

Counties invest $107 billion annually in justice and public safety and $163 billion in community health systems, funding and administering services that are directly involved in responding to the substance use crisis. NACo’s comments emphasized the vital role counties play and the importance of federal partnership in delivering life-saving services and building long-term recovery systems.

Key recommendation for the 2026 National Drug Control Strategy

  • Invest in the peer workforce: NACo urged federal investment in peer support through training, certification programs and reimbursement pathways for peer-delivered services. Peer specialists play a critical role in county crisis response teams, treatment navigation and long-term recovery efforts.
  • Expand community-based recovery ecosystems: NACo urged expanded federal investment in community-based services such as crisis care, prevention programs, housing, employment supports and peer-run services. These investments are essential to building accessible, regional systems of care that meet rising behavioral health needs.
  • Promote awareness and reduce stigma: NACo urged support for locally led communication strategies that increase awareness, engage underserved populations and reduce stigma around substance use. County officials often serve as trusted messengers and are well-positioned to promote prevention and recovery through tailored outreach.
  • Remove barriers to services, housing and employment: NACo urged the federal government to remove structural barriers that limit access to care—such as the Medicaid Inmate Exclusion Policy and the Institutions for Mental Diseases (IMD) Exclusion—and to integrate housing and employment supports into recovery frameworks for those with SUDS or who are in recovery. These changes are necessary to foster long-term reintegration and community participation.
  • Continuation of existing federal programs: NACo urged continued investment in critical programs like the Drug-Free Communities (DFC) program and the High Intensity Drug Trafficking Areas (HIDTA) program. These initiatives are foundational to local prevention and enforcement efforts, and proposed cuts in the President’s FY 2026 budget could undermine their effectiveness and coordination under ONDCP.

Impact on counties

Counties are not only implementers of public health and safety strategies, but they are also key innovators and partners in national efforts to address substance use. As stewards of opioid settlement dollars and administrators of behavioral health and justice systems, counties are investing in sustainable, evidence-based solutions. But these efforts depend on strong federal support, including robust funding for ONDCP-aligned programs and active engagement in local implementation challenges.

NACo will continue to advocate for county priorities and collaborate with ONDCP to ensure the 2026 strategy and other federal drug policies and priorities reflect the realities and needs of communities across the country.

Source:  https://www.naco.org/news/naco-submits-recommendations-2026-national-drug-control-strategy

Back to top of page

Powered by WordPress